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ABSTRACT OF THESIS 
The human ovarian surface epithelium (hOSE) is a cell monolayer that covers 
the surface of the ovary. Natural events like incessant ovulation, associated 
reproductive hormone action prior to and post-ovulation, along with the ovulation-
associated inflammation, that result in injury and repair of hOSE, are considered to 
have a role in the development of epithelial ovarian cancer (EOC). Progesterone is 
apoptotic and anti-inflammatory, whereas androgens appear cytoproliferative for 
hOSE. Local generation of these steroid hormones is subject to 3β-hydroxysteroid 
dehydrogenase (3β-HSD) activity. Moreover, action of these hormones is achieved 
through coupling to their cognate receptors, progesterone (PR) and androgen 
receptors (AR). The overall aim of this thesis is to elucidate in vitro the regulation of 
progesterone and androgen biosynthesis and downstream signalling during the injury 
and repair of primary hOSE cells that were collected from pre-menopausal women 
who underwent surgery for benign gynaecological disorders. Injury was mimicked 
by treatment of cells with several pro-inflammatory cytokines, whereas repair was 
mimicked with T-lymphocyte, ‘anti-inflammatory’ cytokines.  
Immunohistochemical studies showed immunodetectable 3β-HSD in the 
human ovarian cell surface of whole ovary and three-week cultured hOSE cells, 
establishing 3β-HSD expression in vivo and in vitro. Cross-reaction of the 3β-HSD 
antibody with both enzyme isoforms did not allow investigation of isoform 
expression pattern. However, mRNA transcriptional studies with isoform specific 
primers and probe sets for semi-quantitative (sq) and quantitative (q) PCR revealed 
expression of both isoforms in hOSE cells; 3β-HSD1 mRNA was expressed at higher 
levels relative to 3β-HSD2 mRNA in accordance with the preference of this isoform 
in peripheral non-steroidogenic tissues.  
Of the cytokines tested, only IL-1α and IL-4 affected 3β-HSD expression. IL-
1α suppressed 3β-HSD1 mRNA, whereas it up-regulated 3β-HSD2 mRNA as 
assessed with qPCR, without though affecting total 3β-HSD protein and activity 




levels as assessed with western immunoblotting and radiometric activity assays, 
respectively. IL-1α did not affect AR or PR mRNA levels, suggesting a balance in 
androgen and progesterone biosynthesis during post-ovulatory wounding. IL-4 
massively induced 3β-HSD1 and 3β-HSD2 mRNA and total 3β-HSD protein and 
activity. It also attenuated AR mRNA and protein, without affecting PR mRNA. 
Collectively, these data demonstrate that IL-4 sustains progesterone rather than 
androgen signalling and this may be part of the anti-inflammatory steroid action that 
protects hOSE from genetic damage. IL-1α effects appear to be mediated by NF-κB 
signalling pathway. PI-3K and p38 MAPK appeared involved in IL-1α-induced 3β-
HSD2. IL-4-induced 3β-HSDs required STAT-6 and PI-3K pathways and also p38 
MAPK at the case of 3β-HSD2. IL-4-attenuated AR was reversed by a p38 MAPK 
inhibitor. These data suggest that steroid signalling by IL-1α and IL-4 involve 
multiple signalling pathways.  
In primary EOC, 3β-HSD1 and 3β-HSD2 transcripts were attenuated relative 
to hOSE cells, suggestive of an acquired feature of neoplastic transformation. 
However, both transcripts could be restored after IL-4 treatment, attesting a 
therapeutic advantage of this cytokine.  
 In conclusion, we have shown that 3β-HSD is under inflammatory control 
during ovarian post-ovulatory wound healing of hOSE. IL-1α- and IL-4-mediated 
3β-HSD1 and 3β-HSD2 are regulated by multiple signalling pathways. Also, IL-4 
was identified as an anti-inflammatory agent in hOSE with putative therapeutic 
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1.1 The Female Reproductive Tract  
 The female reproductive tract is encompassed by the vagina, uterus and the 
ovary. The vagina is attached to the uterus through the cervix, whilst the ovaries are 
linked to the uterus through the oviduct or fallopian tubes (Fig. 1.1). The ovaries and 
the uterus are the most active organs of the female genital tract, since the ovary is the 
source of the release of oocyte in the oviduct, where it can be fertilised, and pass to 
the uterus, the site of blastocyst implantation.  
 
 
Figure 1.1: The female reproductive tract. Major components of female reproductive 
tract. Cervix links uterus with vagina and ovary is attached to uterus through the fallopian 
tube. Downloaded and moderately modified after 
http://www.humanillnesses.com/original/images/hdc_0001_0002_0_img0170.jpg (2008).  
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 The functions of the ovary and uterus are subject to endocrine, paracrine and 
intracrine signals that alter periodically at different stages of the menstrual cycle. 
Orchestration of ovarian and uterine function is a pre-requisite for the homeostasis of 
the female reproductive system. Any deficiency in hormonal coordination that results 
in dysfunction of the female reproductive organs could give rise to reproductive 
disorders such as infertility and more importantly cancer.  
 This thesis is focused on the biology and specifically the intracrinology of the 
human ovarian surface epithelium (hOSE) of the pre-menopausal ovary. This cellular 
compartment is essentially the cover of the ovary and its study  has become 
important when it was realised that it was the origin of more than 85% of ovarian 
carcinomas (Auersperg et al. 2001, Runnebaum & Stickeler 2001). Therefore, 
studies that are described herein aim at a better understanding of the physiologic 
function of hOSE that could potentially improve prognosis rates for ovarian disorders 
with great interest in ovarian cancer.  
 In order to understand further the mechanisms which physiologically regulate 
hOSE along with the mechanisms that can lead to malignancy, an overview of the 
biology of the ovary as a whole organ is essential. As such, this chapter is focused on 
the biology and endocrinology of the different ovarian compartments, including the 
human ovarian surface epithelium.  
1.2 The Human Ovary 
1.2.1 Anatomy and embryology of the human ovary 
 The adult ovaries are paired organs found in the abdominal cavity located at 
either side of the uterus.  They are ovoid in shape with variable size and weight, 
depending on the content of their follicular derivatives. The adult ovary consists of 
follicles of different developmental stages, corpora lutea and corpora albicantia that 
are scattered among three ill-defined zones of stroma: the outer cortex, the inner 
medulla and the hilus. The external layer of the outer cortex is commonly referred to 
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as the tunica albuginea; the latter has a fibrotic appearance, consisting of five to 
seven layers of fibroblast and collagen (Espey 1994). All the structures that organise 
the ovary are surrounded by a single epithelial cell layer, the ovarian surface 
epithelium (OSE), that is separated from the inner ovarian compartments by a well-
structured basal lamina (Clement 1994) (Fig. 1.2).   
 Gonads start to develop on 3rd week of gestation. At this time gonad 
formation is common between the two sexes. The indifferent gonads arise from 
proliferation of the coelomic epithelium into the mesenchyme. Mesonephric 
embryonic cells also invade the mesenchyme. The primordial germ cells migrate 
from the yolk sac to the urogenital ridge where the mesodermal (in origin) coelomic 
epithelium starts to proliferate, givimg rise to the surface epithelium of the gonad, 
while the gonad itself starts to divide. Differentiation of the gonad into the female 
ovary starts on the 8th week of gestation and is subject to the absence of testicular sex 
cords due to the lack of testis determining factor. On the other hand, the primordial 
germ cells along with mesonephric cells are joined together and are incorporated to 
the surface epithelial cells, forming a thick cortex. Proliferating epithelial cortical 
cells of probable mesonephric origin start then to divide into primitive granulosa 
cells that surround the germ cells or oocytes, encompassing the primordial follicles 
that enter meiosis and stop to proliferate until puberty.  Primordial follicles are 
scattered in a fibrous tissue, the stroma, which is probably derived from the 
mesenchyme. All these structures are kept together and lined by an ovarian surface 
epithelium that originates from the laterally underlying coelomic epithelium that 
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1.2.2 Histology of the human ovary 
1.2.2.1 The follicle 
 From birth, primordial follicles stay at the meiotic pro-phase until puberty 
when they start to develop progressively to follicles or die through atresia. Therefore, 
whereas at birth, about 400,000 primordial follicles are scattered within the female 
gonad, this number decreases from puberty until disappearance at the end of 
menopause. The primordial follicles consist of a layer of squamous quiescent 
granulosa cells, the pre-granulosa cells that surround the oocyte.  When reproductive 
life starts, the primordial follicles pass into different maturing stages namely primary 
follicle, pre-antral follicle, antral follicle and pre-ovulatory/Graafian follicle (Fig. 
1.2). In each monthly menstrual cycle, only one follicle normally undergoes full 
maturation and is capable of ovulation and fertilisation, whilst the others become 
atretic at earlier developmental phases. Early follicular maturation starts at the luteal 
phase of the menstrual cycle when around three follicles compete for ovulation; only 
one, however, will be competent to respond to the hormonal events at the follicular 
phase and can undergo ovulation (Clement 1994). 
Primary follicles have approximately the same size as the primordial follicles. 
Transition to the primary follicle involves differentiation of flat granulosa cells to a 
more columnar/cuboidal phenotype that are subsequently proliferate to give 5 cell 
layers, forming the pre-antral follicle. Pre-antral follicles are larger in diameter, they 
migrate in a more vascularised environment within the medulla where the 
surrounding stroma is differentiated in the theca interna and externa. Although they 
become active, they do not enter the reactivation of meiosis yet. Oocyte ribosomal 
and mRNA synthesis which will give rise to proteins essential for later stages of the 
oocyte maturation  also occurs (Johnson & Everitt 2000a). The zona pellucida is now 
completely formed to separate the oocyte from the surrounding granulosa cell layers 
which form gap junctions at the oocyte surface through which oocyte-granulosa cell 
interactions are achieved (Johnson & Everitt 2000a, Sommersberg et al. 2000, van 
Wezel & Rodgers 1996). In essence, gap junctions are believed to protect the cells 
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from death signals (Amsterdam et al. 2003). Further proliferation of granulosa cells 
along with secretion of mucopolysacharide-rich fluid results in the formation of the 
antral cavity that encompasses the antral follicle. This is also accompanied by an 
increase in RNA and protein synthesis within the oocyte. The oocyte, in turn, is 
increased in size and orientates to the one side of the antrum where granulosa cells 
proliferate to form the cumulus oophorus that encloses the oocyte. At that stage, final 
maturation of the oocyte occurs, forming the Graafian follicle that is ready to release 
the fertilisable oocyte (Clement 1994, Fortune 2003, Rodgers et al. 2001). 
Interestingly, at this stage the membrana granulosa is enveloped by a basal lamina 
and comprises granulosa cells that vary in the levels of gene expression, shape and 
age, indicating the dynamic role of this cell population during follicular development 
(Rodgers et al. 2001).  
 
1.2.2.2 The corpus luteum 
 The human corpus luteum is one of the most active steroidogenic tissues of 
the body. It consists of small and large luteal cells that arise from the theca and 
granulosa cells of the ovulatory follicle respectively. Unlike small luteal cells that 
have few mitochondria and lack granules, large luteal cells consist of electron-dense 
granules and are rich in mitochondria and lipid droplets (Cooke 1988). The 
physiological relevance of these two cell types (small and large) is unclear, however, 
studies in animal models have shown that they are differentially regulated and they 
possess distinct steroidogenic properties (Hawkins et al. 1993, Juengel et al. 1994). 
Furthermore, the corpus luteum is rich in fibroblasts, endothelial and immune cells. 
1.2.2.3 The human ovarian surface epithelium (hOSE) 
 As noted earlier, the human ovarian surface epithelium or hOSE is of 
mesodermal origin, arising from the proliferating coelomic epithelium. hOSE 
comprises a cell layer that lines the ovary and separates it from other peritoneal 
epithelial structures (Fig. 1.2). It is distinguished from the underlying cortical stroma 
by a well-formed basal lamina. Intriguingly, OSE is identical to the extraovarian 
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mesothelium, because both share the same origin and experience a similar 
environment (pelvic cavity). However, it can be distinguished from the rest of 
coelomic epithelium derivatives by the presence of 17β-hydroxysteroid 
dehydrogenase activity (17β-HSD) (Blaustein 1984) and the absence of CA125 
glycoprotein (Kabawat 1983). Notably, the presence of the latter in ovarian 
neoplasms is reflective of the epithelial-committed phenotype of ovarian carcinomas 
as opposed to the epithelial-mesenchymal transitions of the ovarian cell surface 
(Auersperg et al. 1984, Kruk et al. 1990). This shows that hOSE keeps the features 
of a pleuripotential coelomic epithelium as opposed to the other derivatives of the 
same embryonic origin that are more committed to their epithelial phenotype 
(Auersperg et al. 2001). 
 Scanning electron microscopy (SEM) has revealed that the hOSE is 
encompassed by a heterogenous cell population ranging from a cuboidal (rounded 
and columnar) to a squamous (flat) appearance in a well-defined and distinct manner 
(Gillett et al. 1991). It has been reported that squamous cells are present at the apex 
of the corpus luteum, suggesting that those cells are probably a result of post-
ovulatory repair (Gillett et al. 1991). Others have noticed those cell-like appearance 
at papillary outgrowths as well, reflecting probably a pre-neoplastic appearance of 
OSE (Auersperg et al. 1984, Nicosia et al. 1984). Moreover, those cells appear to 
have reduced numbers of microvilli relative to cuboidal-like cells (Gillett et al. 1991). 
However, in general, OSE cells are laterally joined the one to the other with tight gap 
junctions. Nuclei are quite large and sometimes possess two or three lobes. In 
squamous flat cells, nuclei are elongated and parallel to the cell surface. Golgi 
apparatus and lipid droplets within the cytoplasm do not differ to a great extent 
between the two cell types, whilst the mitochondria are more dense in cuboidal cells 
(Papadaki & Beilby 1971). 
 
 








Figure 1.2: The human ovary. Follicles of different developmental stage as well as corpus 
luteum and corpus albigans are spread in cortical zone. Arteries and veins are located within 
the medulla. Tunica albuginea surrounds the ovarian stroma and is separated from the 
surface epithelium through a basal lamina. The Graafian follicle is protruded at the rupture 
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1.2.3 Endocrinology of the human ovary-The menstrual cycle 
 It is well-established that the menstrual cycle consists of two phases: the 
follicular phase and the luteal phase. These two phases are separated by ovulation 
after which fertilisation can occur; however, if fertilisation fails to happen, 
menstruation follows the luteal phase of the menstrual cycle and this signifies the 
initiation of a new reproductive cycle (Fig. 1.3). The follicular phase is the stage of 
the menstrual cycle when final follicle and oocyte maturation occur and is oestrogen 
dominant, whereas during the luteal phase, the corpus luteum is formed, secreting 
progestogens and thereby preparing the uterus to host the blastocyst. As noted above, 
during follicle growth, steroidogenically quiescent primordial follicles pass through 
the primary, pre-antral, antral and ovulatory stages where different cell layers are 
recruited. Whereas early follicular development is independent of hormone secretion, 
transitions from the antral follicle to an ovulatory follicle and from the ovulatory 
follicle to the corpus luteum require a coordinated paracrine, autocrine and endocrine 
dialogue among ovarian, pituitary and extrapituitary factors. Importantly, different 
cell layers possess different steroidogenic profiles that alter at each stage and interact 
with each other and with the oocyte, leading to a fertilisable oocyte. Essentially, the 
ovarian surface also contributes to these processes, though its constitution to the 
steroid milieu of the ovary has not been well studied. Notably, the distinct 
steroidogenic status at each stage is the result of differential expression of the 
enzymes that are involved in the steroidogenic pathway. Simultaneously, secretion of 
ovarian sex steroid hormones affect uterine morphology and function that also alter 
between oestrogenic proliferative (follicular) and progestogenic secretory (luteal) 








Figure 1.3: Menstrual cycle. Periodical hormonal secretion during different stages of the 
menstrual cycle. Feedback loop mechanisms among hypothalamus, pituitary, ovary and 
uterus. Follicular phase is oestrogenic-dominant under the control of pituitary FSH and LH, 
whilst luteal phase is progestogen-secreted following LH-induced oestrogen elevation. 
Downloaded from http://www.soc.ucsb.edu/sexinfo/images/05-07-Menstrual.jpg (2008). 
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1.2.3.1 Endocrinology of the follicle and the corpus luteum 
i) The follicular phase of the menstrual cycle 
Sex steroid hormone secretion in the ovary is mainly coordinated by pituitary 
hormones, namely follicular stimulating hormone (FSH) and luteinising hormone 
(LH), that determine the follicular phase of the menstrual cycle. In the antral follicle, 
internal thecal androgen synthesis is stimulated by the action of LH, which binds to 
the LH receptor (LH-R) expressed in the outer theca layer of the follicle. 
Furthermore, FSH binds to the FSH receptor (FSH-R) expressed in granulosa. 
Subsequently, gonadotrophin-receptor binding up-regulates intracellular 3'-5'-cyclic 
adenosine monophosphate (cAMP) levels which, in turn, serves as second messenger 
for the induction of the cytochrome P450 aromatase (P450arom) enzyme in the 
ovarian granulosa (Hillier 1994, Strauss 1999). This enzyme facilitates the 
conversion of androstenedione secreted in theca interna cells to oestrogens. 
Intriguingly, androstenedione generation in theca cells is governed by a 17β-HSD 
enzyme that is constitutively expessed in theca cells and is not under hormonal 
influence (Bogovich & Richards 1984). High FSH-driven aromatase activity within 
the pre-ovulatory follicle leads to the expression of LH-R in granulosa, a critical 
event during the selection of the follicle that will be competent for ovulation and 
fertilisation (pre-ovulatory follicle). Subsequently, following the LH surge, elevation 
of oestradiol secretion in granulosa cells ensues, triggering ovulation and final oocyte 
maturation. In contrast, the rest of the follicles are FSH-deficient and undergo atresia 
(McNatty et al. 1979b, 1979c). Ovulation follows between 36 and 38h after the LH 
surge, 24 and 36h after the oestradiol elevation and around 12h after the LH peak 
(Clement 1994).  During ovulation, the follicle wall is ruptured and is differentiated 
into a highly vasculaturised endocrine gland, the corpus luteum, a procedure referred 
to as luteinisation. As mentioned above, the corpus luteum is characterised by its 
high capacity to secrete progestogens, the hormone that maintains pregnancy. 
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ii)  The luteal phase of the menstrual cycle 
Endocrine activity and survival of the corpus luteum are subject to its 
sensitivity to LH, an effect mediated by small luteal cells (lutein-theca), and its 
subsequent competence for progesterone secretion from the large luteal cells (lutein-
granulosa) (Cooke 1988). Progesterone output is controlled by luteotrophic factors 
which differ between species. LH and chorionic gonadotrophin (CG) are the major 
luteotrophic factors that control human corpora lutea maintenance through binding to 
LH-R expressed in both types of lutein-cells (Johnson & Everitt 2000c, Rice 1966). 
Furthermore, FSH has been shown to promote human corpus luteum survival, by 
suppressing apoptotic signals (Matsubara 2000). Besides progesterone, the corpus 
luteum has the dynamics to synthesise oestrone, oestradiol and androstenedione (Le 
Maire 1968). In addition, several cytokines such as transforming growth factor-β1 
(TGF-β1) and macrophage colony-stimulating factor (M-CSF) have been shown to 
promote luteinisation and protect corpus luteum from senescence (Matsubara 2000). 
In a non-fertile cycle, the life span of the human corpus luteum is between 12 
and 14 days. The corpus luteum then degenerates, enabling new follicles to grow. At 
the beginning of the late luteal phase, progesterone levels fall sharply due to the 
attenuated responsiveness of the lutein-cells to the luteotrophic signals (Bukovsky et 
al. 1995) and lutein-cells undergo atresia and ischaemia, a process known 
collectively as luteolysis. In ruminants and likely in primates, this event is thought to 
be a result of the multiple effects exerted by the prostaglandin PGF2α which is 
secreted by both the uterus and luteal cells and suppresses progesterone biosynthesis 
(Bennegård et al. 1991), probably through down-regulation of the expression of 3β-
hydroxysteroid dehydrogenase (3β-HSD) (Duncan et al. 1998), the steroidogenic 
enzyme responsible for the formation of active progesterone (prog/P4) from its 
precursor pregnenolone (Preg/P5) (Samuels et al. 1951). Importantly, PGF2α 
mediates its effects through binding to the cognate receptor expressed in large luteal 
cells (Cooke 1988). Simultaneously, an increase in immune cell populations that 
secrete cytokines such as interferon-γ (INF-γ), tumour necrosis factor-α (TNF-α) and 
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the chemokines interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) 
occurs (Bornstein et al. 2004, Matsubara 2000). Subsequently, release of matrix 
metalloproteinases (MMPs) ensues, culminating in breakdown of the extracellular 
matrix (ECM) and thus destruction of the corpus luteum (Bornstein et al. 2004, 
Duncan 2000). Intriguingly, the reduced responsiveness of the corpus luteum to 
LH/CG is not due to LH-R attenuation in lutein-cells, because it is well-established 
that LH-R expression in these cells persists, albeit at lower levels, during corpus 
luteum degradation (Duncan et al. 1998). Instead, it has been proposed that 
endothelial cells, in the regressing human corpus luteum, sharply express LH-R 
thereby avoiding the transport of plasma LH/CG to the extravascular space of this 
tissue (Bukovsky et al. 1995). Consequently, steroid secretion by theca- and 
granulosa-lutein cells is further abrogated (Best & Hill 1995), culminating in lutein-
cell senescence. As a result, the corpus luteum regresses and becomes an inactive, 
small, avascular gland before being absorbed into the stromal component of the 
ovary. On the other hand, in case of pregnancy, LH-R expression is absent in 
endothelial cells and therefore LH/CG-responsive lutein-cells maintain their 
progestogenic-producing capacity (Bukovsky et al. 1995), a parameter critical for 
corpus luteum survival and maintenance of pregnancy. 
1.2.3.2 Endocrinology of the human ovarian surface epithelium 
 Whereas the biology and endocrinology of the ovarian follicle and the corpus 
luteum are well-established, little is known about the endocrinology of the human 
ovarian surface epithelium. As stated above, increased interest of this miniscule 
compartment of the ovary rose sharply in the last decade when it was realised that it 
was the main source of ovarian cancer (Auersperg et al. 2001). Experimental data 
have demonstrated that this epithelial cell population has all the machinery for 
hormonal synthesis and reception, suggesting a role of this cell surface in ovarian 
function. However, whether the OSE hormonal milieu undergoes periodical changes 
within the menstrual cycle is not known due to lack of animal models and restrictions 
in human tissue availability on the necessary scale for any profound study. 
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There is evidence that hOSE is positive for gonadotrophin-releasing hormone 
(GnRH) receptor (Kang et al. 2000), FSH-R (Choi et al. 2002) and LH-R (Kuroda et 
al. 2001). Although gonadotrophins have been proved mitogenic and inhibit 
apoptosis (Choi et al. 2002, Kuroda et al. 2001), they do not appear to be involved in 
the secretion of steroids from hOSE as opposed to the other ovarian compartments 
indicated above (Ivarsson et al. 2001a, Okamura et al. 2003). However, intracrine 
steroid generation has been predicted by an oligonucleotide microarray analysis 
showing mRNA expression for all the enzymes that are necessary for local steroid 
biosynthesis (Rae et al. 2004b). In particular, this study showed the presence of 
transcripts for P450 cholesterol side chain cleavage, (P450scc), steroid acute 
regulatory protein (StAR) and 3β-HSD, highlighting that the production of 
progesterone in situ is possible. Moreover, hOSE were positive for the mRNA of 
17β-HSD enzymes that are involved in oestrogen and androgen biosynthesis as well 
as for steroid sulfatase (STS), the enzyme responsible for oestrone formation from 
circulating oestrone sulphate (Rae et al. 2004b). Also, transcripts for 
aldoketoreductases (AKR), the enzymes that inactivate steroids, were also present 
(Rae et al. 2004b). Collectively, these data indicate that the hOSE layer is a site of 
steroid metabolism, possessing all the machinery to control steroid bioavailability 
and therefore hOSE might well contribute to ovarian steroidogenesis.  Therefore, it is 
of interest that hOSE cells can produce de novo steroid precursors from cholesterol 
along with the use of precursors which are produced by extra-ovarian or adjacent 
ovarian cells (Rae et al. 2004b, Rembiszewska & Brynczak 1985). The importance 
of steroid biosynthesis along with the major steroidogenic pathway is discussed in 
more detail in following sections of this Chapter. 
  A growing body of evidence has shown that hOSE is also a site of steroid 
reception as revealed by the presence of androgen receptor (AR), progesterone 
receptor (PR-A, PR-B), oestrogen receptors (ER-α, ER-β) (Edmondson et al. 2002, 
Lau et al. 1999, Li et al. 2003, Mukherjee et al. 2005) and glucocorticoid receptor-α 
(GR-α) (Rae et al. 2004a), all members of the nuclear receptor superfamily of ligand-
dependent transcription factors. Therefore, an understanding of steroid and 
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gonadotrophin signalling in hOSE may prove pivotal for the functionality and 
regulation of this compartment. Additionally, several studies have reported that 
hormonal signalling is directly linked with the aetiology of ovarian cancer. This is 
discussed in more detail in later sections of this Chapter.  
1.2.4 Ovulation  
1.2.4.1 Ovulation as a process 
 Ovulation is defined as the process where the oocyte proficient for 
fertilisation is released. This process is tightly controlled and in humans occurs on a 
monthly basis and lasts between 36 and 40 hours. By the mid-luteal phase of the 
menstrual cycle very few follicles (less than four) reach a 4-5mm diameter to 
compete for ovulation in the next reproductive cycle. By the late follicular phase of 
the menstrual cycle only one will reach a 15-25mm diameter, encompassing the pre-
ovulatory or Graafian follicle. The latter starts to migrate within the ovarian stroma 
and protrudes at the ovarian surface at the so-called follicle rupture point or stigma 
(Fig. 1.4). Following local proteolytic enzyme and prostaglandin secretion and action, 
the ovarian surface epithelium, the tunica albuginea and the theca externa at the apex 
of the ovulation site degenerate and the follicle wall breaks allowing oocyte release 
into the peritoneal cavity. The stigma now becomes ischaemic, being enclosed by 
follicular fluid, granulosa cells, fibrin, connective tissue cells and blood. Eventually, 
the wounded ovary is repaired involving intensive healing processes essential for the 
preparation of the ovary to host the next ovulatory cycle (Clement 1994, Okamura et 
al. 2003).   
1.2.4.2 Ovulation as an acute inflammatory reaction 
It has been almost 30 years since Espey first proposed that ovulation is an 
acute inflammatory reaction (Espey 1980). This hypothesis was generated based on 
similarities in physical and biochemical events occurring during ovulation with those 
occurring during acute inflammatory cascades in typically injured tissues.   
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Inflammation occurs when the homeostasis of a tissue is disrupted causing a 
trauma. During this process, the first line of defence system, the so-called innate 
immune cells such as dendritic cells, natural killer cells, macrophages, basophils, 
eosinophils and mast cells, are activated and induce histamine production that 
subsequently promotes infiltration of leukocytes into the injured tissue. The latter, in 
turn, trigger secretion of soluble immune mediators such as cytokines, chemokines 
and matrix proteases that surround the trauma. Concomitantly, this results in the 
activation of the adaptive immune cells such as B and T lymphocytes that counteract 
inflammation and initiate tissue remodelling and regeneration of the harmed tissue. 
Therefore, controlled cell proliferation and cell death of genetically damaged cells 
ensue, allowing extracellular matrix deposition and re-epithelisation and as such 
tissue homeostasis is restored (de Visser & Coussens 2005).  
In the ovary, the LH surge prior to follicular rupture increases the vascularity 
and capillary permeability. As in inflamed tissues, the latter is partially mediated by 
histamine and prostaglandins, induction of which is achieved by the LH-induced 
cAMP elevation. The primary source of histamine is immune cell populations such 
as leukocytes and macrophages as well as proliferating thecal fibroblasts that 
surround the Graafian follicle. Ovarian follicular wall collapse is achieved by 
proteolytic enzymes such as plasminogen activator (PA) that is mainly released by 
white blood cells and proteases such as trypsin that are mainly secreted by fibroblasts 
(theca externa) (Espey 1980, 1994).  Following wounding-induced inflammatory 
mediator secretion, cell proliferation occurs as part of the healing process 
(Brannstrom & Norman 1993, Buscher et al. 1999). Reconstruction of the wounded 
tissue involves regeneration of the connective tissue, components of which such as 
collagen and gelatine are secreted by fibroblasts.  
 




Figure 1.4: Stigma. The follicle ruptures at the ovulation point or stigma. The follicle wall 
breaks, the OSE sloughs and the cumulus-oophorus complex is released in the peritoneal 
cavity. Luteinisation ensues to form the corpus luteum of the luteal phase of the menstrual 
cycle. Adapted from http://www.endotext.org/female/female1/figures1/figure20.jpg (2008). 
1.2.4.3 Inter-relationships between cytokine system and ovulation 
 Cytokines are polypeptide molecules that are naturally secreted at specific 
stages of the menstrual cycle such as ovulation and menstruation. As aforementioned, 
ovulation is an acute inflammatory event closely associated with tissue damage 
followed by an anti-inflammatory repair process (Brannstrom & Norman 1993, 
Buscher et al. 1999). During this process, the Graafian follicle is surrounded by 
cytokines secreted either by the steroidogenic follicular cells (granulosa and thecal 
cells) themselves or by immune populations such as leukocytes (macrophages, 
lymphocytes and neutrophils) that have migrated to the site of follicle rupture 
(Brannstrom & Norman 1993, Brannstrom et al. 1994, Buscher et al. 1999). Along 
with the cytokines that promote the rupture of the follicle causing the wounded tissue, 
cytokines that induce healing mechanisms are also present in both the Graafian 
follicle and the corpus luteum. For example, the IL-1 system has been demonstrated 
to have a major role in intra-ovarian function. IL-1α secretion in the follicular fluid 
can induce IL-6 secretion that in turn stimulates follicular rupture through 
Chapter 1                                                     General introduction and literature review 
18 
 
stimulation of a prostaglandin-associated proteolytic pathway. This deleterious pro-
inflammatory effect can be counteracted by the IL-1 receptor antagonist (IL-1Ra) 
(Buscher et al. 1999). Granulocyte-macrophage-colony-stimulating factor (GM-CSF), 
TNF-α, IL-8 (Buscher et al. 1999, Zhao et al. 1995) and IL-4 (Hashii et al. 1998) are 
also present in the follicular fluid of the peri-ovulatory follicle.  
Intriguingly, leukocyte-induced cytokines can affect steroidogenesis as well. 
Strikingly, TNF-α and IL-1α have been reported to abolish steroidogenesis and more 
precisely progesterone synthesis at the peri-ovulatory period (Terranova & Rice 
1997), whereas IL-4 has been reported to induce progesterone synthesis (Emi et al. 
1991, Hashii et al. 1998). Another striking example of cytokine-endocrine 
interactions is the stimulation of glucocorticoid synthesis through induction of 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1) in response to IL-1α pro-
inflammatory effects in the granulosa cells of the peri-ovulatory follicle (Tetsuka et 
al. 1999).  Notably, it was proposed that this effect represents an efficient mechanism 
for the ovary to counteract inflammatory-associated damage and promote rapid 
healing (Hillier & Tetsuka 1998). It is therefore clear that cytokines are indispensable 
factors for the fulfilment of ovarian functions such as steroid formation, 
differentiation and proteolysis prior to and through peri- and post-ovulation. 
1.2.4.4 Role of the human ovarian surface epithelium in ovulation: Injury and repair 
 As mentioned earlier, the human ovarian surface epithelium or hOSE is a 
single cell layer that lines the ovary and separates it from the other peritoneal 
structures. OSE facilitates the transportation of materials to and from the peritoneum 
(Anderson et al. 1976). Importantly, it is believed to be an integral part of the 
ovulatory process, since ovulation is abrogated after surgical removal of the ovine 
OSE in vivo (Colgin & Murdoch 1997) and frog OSE in vitro (Schuetz & Lessman 
1982), maybe due to the fact that, besides the follicle and the surrounding leukocytes, 
OSE secretes components such as proteases, extracellular matrix components and 
cytokines that have a critical role in follicular wall breakdown.  
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Following follicular rupture, the OSE at ovulation sloughs (stigma) 
undergoing an injury and repair process that involves cell degradation typical of 
apoptosis and proliferation (Fig. 1.4) (Murdoch 1995, Osterholzer et al. 1985). 
Apoptosis is thought to be induced by prostaglandins that are locally secreted when 
the time of ovulation approaches (Ackerman & Murdoch 1993) followed by 
intensive cell proliferation and remodelling to heal the trauma during the luteal phase 
of the menstrual cycle (Murdoch 1994).  The exact time and stage of the luteal phase 
of the menstrual cycle when cell proliferation and repair (healing) of the stigma take 
place is not clear and further studies in animal and human models are required to 
further investigate that. Also, it is yet to be established whether cell proliferation and 
repair happen at the same phase of the luteal phase of the menstrual cycle. However, 
it is understandable that post-ovulatory wound healing is essential such that the ovary 
can host the next ovulatory cycle (Clement 1994, Okamura et al. 2003). 
As part of the injury, it has been shown that OSE cells produce enzymes such 
as cyclooxygenase type 2 (COX-2) that facilitate prostaglandin secretion which in 
turn trigger collagen breakdown (Rae et al. 2004a). Interestingly, this mechanism is 
probably mediated by elevated sex steroid levels that surround the pre-ovulatory 
follicle (Bjersing & Cajander 1975). OSE cells, at least in sheep, are also positive for 
urokinase plasminogen activator (uPA), expression of which is triggered by the 
elevated gonadotrophin levels in the pre-ovulatory follicle (Colgin & Murdoch 1997). 
Plasminogen activator of the OSE and pre-ovulatory follicle synergise to induce 
TNF-α secretion that in turn potentiates local MMP (MMP-1 and MMP-2) 
expression along with microvascular coagulation, both involved in acute 
inflammation, nuclear DNA damage and cellular necrosis (Larrick & Wright 1990), 
thus leading to stigma formation (Murdoch & McDonnel 2002). Importantly, not 
only does inhibition of TNF-α action suppress ovulation but it also impedes ECM 
degeneration  (Johnson et al. 1999, Murdoch et al. 1997). 
 Besides immune cells and the follicle, OSE itself has been proved capable of 
secreting cytokines. Hence, it has been shown that OSE produces significant amounts 
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of pro-inflammatory GM-CSF, CSF, M-CSF, IL-1α, TNF-α, IL-18 and IL-6 as well 
as T lymphocyte-associated cytokines such as IL-10 (Burke et al. 1996, Lidor et al. 
1993, Wang et al. 2002b, Ziltener et al. 1993). Furthermore, OSE is positive not only 
for chemokines such as MCP-1 and IL-8 but also for growth factors such as 
epidermal growth factor (EGF) and TGF-β1 (Burke et al. 1996, Ziltener et al. 1993). 
They have also the ability to respond to many of these agents. Importantly, OSE is 
positive for IL-4 and INF-γ receptors in the absence of de novo capacity to produce 
their ligands (Burke et al. 1996, Ziltener et al. 1993). Such findings point to 
paracrine, autocrine and intracrine roles of this cellular monolayer in ovulation and 
wound healing cycles. 
Importantly, there are implications from epithelial-mesenchymal transitions 
as well as cell separation, migration and mitotic activity during OSE regeneration 
(Auersperg et al. 1994b, Ziltener et al. 1993). Although OSE has a mesothelial 
phenotype with mesenchymal and epithelial features during a non-ovulatory cycle, it 
acquires either stromal or ectopic epithelial characteristics when it is submitted to a 
regenerative process i.e after follicle rupture. Intriguingly, the latter phenotype also 
seems to occur in cell culture, indicating the plasticity of these cells and their 
responsiveness to environmental factors (Auersperg et al. 2001). During regenerative 
processes, OSE cells are frequently invaginated in the stroma, forming inclusion 
cysts (clefts) (Fathalla 1971, Murdoch 1994, Okamura et al. 2003) (Fig. 1.5). 
Physiologically, these entrapped cells can differentiate into fibroblast-like cells, and 
this could be an efficient mechanism to prevent neoplastic transformation (Auersperg 
et al. 2001). Alternatively, such inclusion cysts are believed to give rise to 
pathological conditions such as benign malignancies and metaplasias (Fathalla 1971). 
Under such circumstances, OSE loses its mesemchymal-stromal character and is 
committed to an epithelial phenotype by developing Müllerian duct derived epithelia 
behaviour. Therefore, it can be transformed to tubal, endometrium or uterine cervix 
epithelia that give rise to serous, endometrioid or mucinous epithelial ovarian cancers 
(EOC) respectively (Kaku et al. 2003, Mittal et al. 1995). 









Figure 1.5: Inclusion cyst. Epithelial cells are entrapped in the ovarian stroma of a pre-
menopausal ovary (a). Epithelial character of these cells was confirmed by staining with 
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1.3 Relevance of the Physiological Function of hOSE in the 
Development of Epithelial Ovarian Cancer 
 Development of ovarian cancer is a multifactorial disease involving a 
complex network of molecular and cellular pathways that all synergise to promote an 
oncogenic phenotype. Depending on the origin of the tumour, ovarian cancer is 
classified as surface epithelial-stromal tumour or epithelial ovarian cancer (EOC) 
when it arises from the OSE, sex cord-stromal ovarian tumour when it is of 
mesonephric or mesenchyme origin (granulosa, theca, stromal cells) and germ cell 
tumour when it derives from primordial germ cells (Fig. 1.6). Over 85% of ovarian 
cancers are of epithelial origin with ovarian sex cord-stromal and germ cell tumours 
being rarer cases (Chen et al. 2003). From now on, further references to ovarian 
cancers will relate to tumours of epithelial origin, because the other two groups of 
ovarian cancers, albeit equally important, are outwith the focus of this thesis. 
 It is widely accepted that EOC arises from the clonal expansion of a single 
transformed cell (Ozols et al. 2004). It is commonly believed that hOSE is the origin 
of EOC, because this tissue is very dynamic and undergoes cyclical hormone 
changes and continuous regeneration during reproductive life. Progression of the 
disease is probably the result of accumulating premenopausal genetic errors that have 
escaped from the surveillance of the molecular repairing mechanisms, involving cell 
cycle-, apoptosis- and differentiation-associated genes (Murdoch 1998, Murdoch et 
al. 2001, Ozols et al. 2004, Zeimet & Marth 2003). Pre-neoplastic transition 
probably takes place later at menopause when the hormonal environment has 











Figure 1.6: Classification of ovarian cancer depending on the origin of the tumour. 
Epithelial ovarian cancer arises from the OSE, germ cell tumours originate in primordial 
germ cells and sex cord-stromal tumours arise from ovarian stromal, granulosa and thecal 
cells. Designed by John A Craig. Kindly provided by Professor Charles H. Blomquist, 
University of Minesota, Mineapolis, USA.  
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1.3.1 Epidemiology of ovarian cancer- Links with natural reproductive events 
Along with positive association of menopause with the development of the 
disease, another risk factor is the family history, albeit it accounts only for 4-5% of 
all cases (La Vecchia 2001). Exposure to cosmetics and chemicals such as talc and 
asbestos are believed to increase the risk although their role in the development of 
the disease is controversial (La Vecchia 2001, Langseth et al. 2008 , Merritt et al. 
2008, Muscat & Huncharek 2008, Ness et al. 2000b, Wong et al. 1999). 
Endometriosis (Merritt et al. 2008, Modugno et al. 2004, Ness et al. 2000b) and 
pelvic inflammatory disease (PID) (Ness & Cottreau 1999, Risch & Howe 1995) are 
considered to be positively associated with the development of ovarian cancer as 
well. Oestrogen replacement therapy for longer than ten years is believed to increase 
the risk of ovarian cancer three-fold (Lacey et al. 2002); however, the Million 
Women Collabotrators study showed that this increased risk falls after termination of 
oestrogen therapy (Beral 2007). Polycystic ovarian syndrome (PCOS) and the 
associated risk of ovarian cancer is controversial (Balen 2001, Schildkraut et al. 
1996). Reproductive and hormonal factors such as multiparity (Adami et al. 1994, 
Gwinn et al. 1990, Hankinson et al. 1995, Riman et al. 2004, Risch et al. 1994), 
lactation (Risch et al. 1994, Siskind et al. 1997), oral contraceptive use 
(Collaborative group on epidemiological studies of ovarian cancer 2008, Franco & 
Duarte-Franco 2008, Gwinn et al. 1990, Hankinson et al. 1995, Ness et al. 2000a), 
tubal ligation and hysterectomy (Green et al. 1997, Kreiger et al. 1997, Ness et al. 
2000b) are thought to decrease the risk. A summary of the factors that are believed to 
play a role in the aetiology of EOC are illustrated in Table 1.1. 
1.3.2 Hypotheses for tumour initiation/progression 
 Based on the epidemiological data referred to above, at least three hypotheses 
have been generated to explain the development of EOC from natural processes the 
hOSE undergoes during fertile life.  It should be mentioned that these hypotheses are 
interrelated and thus not mutually excluded and all jointly are probable contributing 
factors in the development of the disease.  
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1.3.2.1 Incessant ovulation hypothesis  
 Fathalla first proposed that the continuous ovulations that the female 
experiences during reproductive age may have profound implications in the 
development of epithelial ovarian neoplasms. EOC can derive from OSE cells 
entrapped in the ovarian stroma, forming inclusion cysts as a result of the repair of 
the ovulatory stigma. Expansion of a genetically damaged cell can result in 
oncogenesis (Fathalla 1971). Indeed, post-ovulatory healing of the surface epithelium 
involves exposure to cytogenotoxic agents that can harm the cell integrity (Ozols et 
al. 2004). The latter has been extensively shown in several basic research studies 
using both human and animal models. Prolonged in vitro subculture of rat ovarian 
surface cell lines display abnormal karyotypes characterised by clonal aberrations, 
unbalanced rearrangements and numerical losses as a result of malignant 
transformation (Godwin et al. 1992, Testa et al. 1994). In vitro prolonged culture of 
mouse OSE followed by intraperitoneal injection of late passage cells resemble Stage 
III and IV ovarian cancers and yield an aneuploid karyotype (Roby et al. 2000). 
Human OSE cells in in vitro culture display epithelio-mesenchymal transitions 
through subculturing, mimicking in vivo ovulation-associated regeneration. 
However, hOSE cell cultures from patients with family history (i.e. with BRCA-
1/BRCA-2 mutations) appear more committed to an epithelial phenotype after long-
term propagation, showing a susceptibility of those cells to a pre-neoplastic 
phenotype probably developed after continuous ovulations (Dyck et al. 1996). 
Moreover, in vivo injection of the mutagen 7,12-dimethylbenz(a)anthracene to 
induce carcinogenesis combined with gonadotrophins to mimic ovulation-affected 
OSE, results in epithelial lesions in rat ovaries. Intriguingly, the stage of the ovarian 
neoplasia is more severe with increasing doses of the mutagen (Stewart et al. 2004). 
Also, the animals generate point mutations in p53 and ki-Ras genes (Stewart et al. 
2004), approaching what has been observed in  late stage human ovarian 
malignancies (Aunoble et al. 2000, Berchuck et al. 1994, Mayr et al. 2006, Wang et 
al. 2004). Nonetheless, it is worth noting that mutant p53 overexpression in ovarian 
cancer is likely more a cause of general genetic instability due to accumulated 
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genetically harmed cells rather than a direct effect of ovulation, suggesting a role in 
the progression rather than the initiation of the disease (Schildkraut et al. 1997). It 
has also been reported that 8-oxoguanine adducts were more frequent in post-
ovulatory relative to inactive OSE in ewes, ovine, humans and hens (Murdoch & 
Martinchick 2004, Murdoch et al. 2001, Murdoch et al. 2005). Addition of 
indomethacin to suppress ovulation reduced 8-oxoguanines in the OSE cells of 
ovulation (Murdoch et al. 2001). Collectively, these and other studies further support 
the concept that random expansion of irreparable non-committed to death cells 
arising from post-ovulatory repair can lead to an oncogenic phenotype (Fathalla 
1971, Murdoch 2005).  
The incessant ovulation hypothesis is supported by epidemiological studies 
suggesting that ovulatory-inhibitory events such as pregnancy, multiparity, breast-
feeding and oral contraception reduce the risk of EOC (see 1.3.1 for references). 
Moreover, it is of interest that ovarian neoplasms from puberty onwards, when the 
female has experienced repetitious ovulatory cycles, are of epithelial origin as 
opposed to rare germ-cell and stromal-sex cord ovarian tumours that constantly 
appear before the menharge age (Fathalla 1971). Additionally, EOC rates increased 
during the 20th century where it has been estimated that women release about 400 
oocytes in their lifetime as opposed to the previous century when women had more 
children and thus wasteful ovulations were less abundant (Banks et al. 1993). On the 
other hand, anovulatory situations such as PCOS and infertility are thought to 
promote rather than reduce EOC risk, although this has not been confirmed in every 
study (see 1.3.1 for references). Also, another caveat of this hypothesis is that the 
progestin-only pill that does not impede ovulation has been reported more protective 
than the combined (oestrogens with progestogens) ovulation-suppressive pill (Risch 
1998, Rodriguez et al. 1998).   
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1.3.2.2 Gonadotrophin and sex steroid hormone hypothesis 
 As referred to above, ovulation is a controlled reaction tightly driven by 
pituitary gonadotrophins as well as ovarian steroids, androgens and oestrogens, that 
in turn result in progesterone secretion peri- and post-ovulatory. Therefore, ovulation 
could indirectly lead to the development of EOC through the secretion of 
reproductive hormones prior to and after ovulation. As noted, the ovarian cell surface 
at the site of rupture as well as the cells entrapped in the stroma (inclusion cysts) are 
exposed to high levels of gonadotrophins that derive from the peri-ovulatory follicle. 
Subsequently, gonadotrophins trigger oestrogen secretion that in turn signifies 
ovulation. Thus, gonadotrophins and oestrogens equally could give rise to neoplastic 
transformation of OSE (Cramer & Welch 1983) (Fig. 1.7).  
Elevated gonadotrophin levels in follicle-depleted post-menopausal ovaries, 
when the majority of ovarian cancer cases occur suggest that they impact upon OSE 
(Cramer & Welch 1983). Several studies have shown that FSH and LH/hCG signal 
via their cognate receptors in the ovarian cell surface, ovarian pre-neoplastic and 
cancer cell lines  (Choi et al. 2002, Kuroda et al. 2001, Parrott et al. 2001, Syed et al. 
2001, Zheng 1996). All of these studies have shown cytoproliferative effects of 
gonadotrophins in the ovarian cell surface, attesting to a direct link with the 
development of ovarian cancer. Numerous mechanisms have been described to 
explain gonadotrophin cell growth stimulatory effects. It has been shown that FSH 
exerts its effects through rapid activation of the mitogen-activated protein kinase 
(MAPK)-responsive Elk-1 transcription factor (Choi et al. 2002), leading to 
activation of oncogenic pathways (Choi et al. 2004) in ovarian pre-neoplastic and 
neoplastic cells. In particular, overexpression of FSH-R in OSE cell lines resulted in 
extracellular signal-regulated kinase (ERK)1/2 activation and accompanied with 
increased expression of growth factor receptors and oncogenes such as EGF-R, 
Her2/neu receptor, c-myk (Choi et al. 2004), catenin-β1 and cyclin G2 (Ji et al. 
2004). Interestingly, FSH has been established to impact upon EGF-R activity, whilst 
LH impacts upon EGF-R mRNA stability. Moreover, differential FSH- and LH-
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induced EGF-R cytoproliferative effects have been shown to be mediated by ERK1/2 
and phosphatidyl-inositol-3-kinase (PI-3K) pathways (Choi et al. 2005, Gubbay et al. 
2004). Furthermore, recent data are demonstrative that these cytoproliferative effects 
can be successfully blocked by supplementation of ovarian cancer cells with EGF-R 
inhibitors and EGF, thereby sensitising the cells to taxol-associated cell death 
pathways (Cao et al. 2008). The IL-6/signal transducers and activators of the 
transcription protein (STAT)-3 signalling pathway has been also reported to drive 
FSH and LH mitogenic activity in ovarian epithelial immortalised and ovarian cancer 
cell lines (Syed et al. 2002). Another mechanism for gonadotrophin action in ovarian 
cancer development is through suppression of the anti-proliferative GnRH and its 
cognate receptor (Choi et al. 2006, Choi et al. 2001a). A further study showed that 
mitogenic effects of LH on ovarian cancer cell lines are exerted through abrogation 
of the Fas-induced cell death pathway (Slot et al. 2006b). The Fas pathway has been 
shown to be active in the human ovarian surface epithelium as well as in ovarian 
cancer and it is one of the major mechanisms of the ovary to induce cell apoptosis 
(Ghahremani et al. 1998, van Haaften-Day et al. 2003). Consistently in the rat ovary, 
pro-apoptotic associated Fas ligand and bax molecules have been mainly detected in 
OSE at the apex of ovulatory follicles. Active caspase-3 has been also observed in 
post-ovulatory OSE cells (Slot et al. 2006a). Along with cytoproliferative effects, it 
has been suggested that gonadotrophins may promote cell invasion and adhesion 
through stimulation of proteolytic enzymes such as MMP-2 and MMP-9 and 
inhibition of tissue inhibitors of MMPs (TIMPs), TIMP-1 and TIMP-2 (Choi et al. 
2006). An angiogenic effect of FSH on OSE  has been also shown (Wang et al. 
2002a). 
Positive links of increased LH and FSH levels agree with the protective role 
that breast-feeding has against EOC (See 1.3.1 for references). Previous reports have 
suggested that anovulation-related breast-feeding is a result of decreased LH and 
FSH (Chubak et al., 2004; McNeilly 2001).   Moreover, ovarian cancer cysts contain 
more abundant FSH and LH levels relative to benign tumours, suggesting a positive 
link of gonadotrophins with EOC that should not be underestimated (Krämer et al. 
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1998). Nonetheless, whereas the vast majority of studies support that FSH and LH 
mediate cell proliferation and survival, there are conflicting reports. In primary hOSE 
cell cultures from pre-menopausal and post-menopausal women, FSH suppressed 
cell proliferation, especially in the case of confluent cell cultures from post-
menopausal women (Ivarsson et al. 2001b). The reason for this discrepancy is not 
known, though different cell culture systems and treatment concentrations may be 
responsible for these inconsistencies (Choi et al. 2007). Alternatively, this effect 
could also mimic in vivo natural OSE cell death (stigma) occurring as a part of 
oocyte release when gonadotrophin levels are elevated (Choi et al. 2007, Murdoch 
1995). 
Another mechanism through which gonadotrophins can contribute to the 
development of EOC could be indirectly through exposure of the ovulatory OSE to 
gonadotrophin-induced oestrogens. Oestrogenic 17β-HSD5, the enzyme for the 
intracrine formation of oestrogens, as well as ERs (ER-α and ER-β) are expressed in 
both OSE and neoplastic ovarian cells (Blomquist et al. 2002, Cardillo et al. 1998, 
Hillier et al. 1998, Lau et al. 1999, Li et al. 2003, Nagayoshi et al. 2005, Rae et al. 
2004b). Oestrogen levels are 10,000 times higher in the peri-ovulatory OSE than 
their circulating levels (Risch 1998). Moreover, another oestrogen peak occurs at the 
luteal phase of the menstrual cycle when post-ovulatory OSE healing is thought to 
take place (Clement 1987, 1994, Murdoch & Van Kirk 2002). It appears, therefore, 
that ovarian cytoproliferation is associated with a high oestrogenic environment. 
Intriguingly, ER-α appears to be the functional receptor with little responsiveness of 
the ER-β. For example, in primary cancers and cancer cell lines, the ER-α/ER-β ratio 
appeared higher than in normal OSE cells, revealing a positive link of ER-α and 
EOC (Li et al. 2003). In support of this, ER-α but not ER-β has been shown to be 
positively up-regulated by the thyroid hormone, triiodothyronine (T3), an 
inflammatory gene-associated surrogate (Rae et al. 2007). Moreover, a cDNA 
microarray study showed twenty-eight genes to be affected by oestradiol treatment in 
PEO1 ER-positive ovarian cancer cells and these effects were mediated by ER-α and 
not the ER-β isoform and were blocked when the anti-oestrogen tamoxifen was 
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applied (O'Donnell et al. 2005). Oestradiol has been also shown to induce the IL-
6/STAT3 mitogenic signalling pathway in human immortalised and ovarian cancer 
cell lines (Syed et al. 2002) as well as the c-myc oncogene in NIH:OVCAR-3 cancer 
cell line (Chien et al. 1994). Inhibition of apoptosis in response to oestradiol has 
been also demonstated in sheep OSE and notably this effect appeared to be non-
genomic since it was not blocked by tamoxifen (Murdoch & Van Kirk 2002b). Up-
regulation of the extracellular matrix component fibulin-1 has been also shown to be 
triggered by oestradiol in EOC cell lines, attesting to a possible metastatic and 
invasive role of this steroid hormone (Clinton et al. 1996). Establishment of ovarian 
neoplasms after exposure of guinea pigs to diethylstilbestrol and oestradiol has been 
also demonstrated (Silva et al. 1998). Overall, it appears that a rich oestrogen 
environment either in hOSE itself or in the surrounding ovarian components exerts a 
cell growth effect and this is possibly a contributing factor in EOC development 
(Fig.1.7). This agrees with the epidemiology that claims a positive link of oestrogen 
replacement therapy and the development of the disease that can be reversed when 
oestrogen supplementation stops (see 1.3.1 Section for references). 
Along with oestrogens, a series of studies have demonstrated 
cytoproliferative effects of androgens in normal OSE and EOC through their binding 
to the cognate androgen receptor (AR) (Edmondson et al. 2002, Lau et al. 1999, 
Syed et al. 2001). It has been established that androgens may impact upon OSE 
through intracrine and/or paracrine mechanisms (Risch 1998).  Androgenic 17β-HSD 
has been demonstrated in the ovarian surface epithelium, suggesting a capacity of 
this monolayer to form androgens in situ. Moreover, androgens are secreted daily by 
growing follicles suggesting a possible paracrine interaction thereof with the OSE of 
inclusion cysts or of the ovarian surface (McNatty et al. 1979a, Risch 1998) (Fig. 
1.7).  It is also widely established that the post-menopausal ovary, that is at greater 
risk for the development of EOC, retains the steroidogenic capacity to produce 
androgens (Havelock et al. 2006, Laughlin et al. 2000). Previous studies have 
consistently shown increased AR protein (Cardillo et al. 1998, Kühnel et al. 1988) 
and co-activators (Shaw et al. 2001) in ovarian cancer. Another study revealed that 
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5α-dihydrotestosterone (5α-DHT) can reverse the TGF-β1-induced inhibition of cell 
growth (Berchuck et al. 1992, Choi et al. 2001c) not only in primary normal hOSE 
cells but also in several primary cancer cells. Importantly, the same study showed 
that 5α-DHT  positively mediated AR co-activators such as androgen receptor-
associated protein 70 (ARA-70) and steroid receptor co-activator-1 (SRC-1) 
(Evangelou et al. 2000).  Furthermore, guinea pigs displayed benign epithelial cysts, 
small papillary neoplasms and glands in the stroma in response to testosterone 
treatment. Notably, testosterone serum levels were approximately 500 times higher 
than in control animals (Silva et al. 1997).  
It is obvious therefore that androgens may play an indispensable role in the 
aetiology of ovarian cancer and this agrees with epidemiological studies that 
associate androgen-related events such as PCOS, hirsutism and acne with EOC 
(Schildkraut et al. 1996). Moreover, it has been demonstrated that the contraceptive 
pill that protects against development of the disease attenuates testosterone and 
dehydroepiandrosterone sulphate (DHEA-S)  formation (Murphy et al. 1990, van der 
Vange et al. 1990).  
As discussed in Section 1.3.1, pregnancy, multiparity and oral contraception 
are associated with a reduced risk of development of ovarian cancer. All these 
anovulatory events are associated with high levels of progestogens. Notably, it has 
been proved that the progestin-only contraceptive pill that does not impede ovulation 
is more protective than the combined pill (Risch 1998, Rodriguez et al. 1998). 
Moreover menopausally, progesterone secretion appears attenuated (Havelock et al. 
2006). Collectively, progestogens appear to protect from the emergence of the 
disease.  
A sequence of basic and epidemiological studies has been conducted to 
investigate further this hypothesis and identify the mechanisms through which 
progesterone acts upon the surveillance of the ovary and more precisely of OSE.  
Progesterone mainly signals through binding to the nuclear PR, both isoforms of 
which (PR-A, PR-B) have been shown to be expressed in the ovarian cell surface and 
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ovarian cancer cells (Lau et al. 1999, Li et al. 2003, Mau et al. 1999, Mukherjee et al. 
2005). Epidemiological studies have recognised the deletion of PR in a high 
percentage of ovarian cancer specimens and loss of PR is associated with a poor 
prognosis for the disease (Abd-Elaziz et al. 2005, Cardillo et al. 1998, Langdon et al. 
1998, Lau et al. 1999, Li et al. 2003). Also, ovarian cancer development is more 
common in women with progesterone deficiencies and progesterone receptors are 
absent or genetically altered in EOC (Ho et al. 2003). Moreover, in primary hOSE 
and ovarian cancer cell lines, it has been demonstrated that both oestrone and 
oestradiol negatively regulate PR and this effect can be blocked by the ER antagonist 
ICI 182780. Additionally, high doses of progesterone increased caspase-3 activity 
and inhibited cell mitogenesis. This effect was further enhanced in co-treatment with 
ICI 182780 and was abolished in co-treatment with the PR antagonist RU486 
(Mukherjee et al. 2005). In accordance, another study showed an enhancement of 
OSE cell proliferation after addition of another PR antagonist, Org 31710 (Ivarsson 
et al. 2001a). Additionally, oestrogen-induced ovulation in the mouse resulted in a 
stratified appearance of the ovarian epithelium as opposed to a normal appearance of 
the OSE after co-administration with progesterone (Gotfredson & Murdoch 2007). 
Likewise, the apoptotic rates of macaque OSE appeared three-fold higher in 
progestin-induced animals than in those administered with both oestrogens and 
progestogens (Rodriguez et al. 1998). Consistently, oestradiol cytoproliferative 
effects were counteracted by progesterone administration in sheep (Murdoch & Van 
Kirk 2002b). Commonly, progesterone appears to inhibit cell growth and trigger 
apoptosis in the OSE and this might be an efficient mechanism to nullify the clonal 
expansion of genetically spoilt cells.   
The mechanisms through which pro-apoptotic effects of progesterone are 
exerted have been investigated. As mentioned above, the ovary is subject to wound 
healing and repair cycles of the OSE in response to ovulation and this can lead to 
genetic instability of the ovarian cell surface. It has been shown that progesterone 
triggers apoptosis to attenuate potential genetic damage of the post-ovulatory ovarian 
surface. In ewes and sheep, progesterone treatment resulted in a decline of 8-
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oxoguanine adducts through induction of polymerase-β and poly(ADP-ribose) 
polymerase (PARP) increase, both involved in DNA repair. These effects appeared 
to be progesterone-specific and exerted at the transcriptional level as it was revealed 
by supplementation of RU486 and actinomycin D respectively (Murdoch 1998, 
Murdoch et al. 2001). Moreover, reports suggest that progesterone exerts its 
apoptotic and anti-proliferative effects through up-regulation of the tumour 
suppressor p53 protein (Murdoch & Van Kirk 2002b). The latter has been also seen 
in human ovarian cancer cell lines, where the progesterone exerted anti-proliferative 
and apoptotic effects through arrest of cells at the G1 phase of the cell cycle and 
concomitant stimulation of p53 mRNA (Bu et al. 1997). This possibly facilitates the 
DNA repair machinery to restore or remove any genetically instable cells and protect 
against clonal expansion of any transformed cell (Murdoch & Van Kirk 2002).  Also, 
there is evidence that progesterone promotes cell apoptosis through activation of 
caspase-8 and caspase-3 pathways that in turn stimulate the Fas/Fas-ligand apoptotic 
pathway (Syed & Ho 2003).  
In summary, it is obvious that reproductive hormones can be beneficial or 
destructive for the integrity of the ovarian cell surface. Therefore, tightly controlled 
cytoproliferation, cell survival and cell apoptosis are subject to a balanced dialogue 
among reproductive hormones to minimise the chance of any fatal scar occuring on 













Figure 1.7: Impact of reproductive hormones on inclusion cysts and/or hOSE. During 
ovarian post-ovulatory repair of hOSE, sloughed OSE cells are invaginated in the stroma 
forming inclusion cysts. Both cysts and hOSE are exposed to gonadotrophins and steroid 
hormones during the menstrual cycle. As such, cells differentiate and this may lead to 
neoplastic transformation. Designed by John A Craig. Kindly provided by Professor Charles 
H. Blomquist, University of Minesota, Mineapolis, USA.  
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1.3.2.3 Inflammation hypothesis 
 As recalled throughout this chapter, ovulation along with ovulation-
associated hormones impact upon the ovarian cell surface and these are considered 
risk factors for the development of EOC. On the other hand, anovulatory events as 
well as suspension or stimulation of individual reproductive hormone secretion 
appears essential for prevention of EOC. It was aforementioned that ovulation has a 
local inflammatory basis, involving secretion of immune mediators that positively or 
negatively affect local hormonal milieu and vice versa (Espey 1980, 1994, Terranova 
& Rice 1997). Moreover, factors that are associated with development of the disease 
such as asbestos, talc and endometriosis may act in the OSE through induction of 
inflammatory responses. Conversely, a protective role of hysterectomy and tubal 
ligation could be subject to the blockage of inflammatory effects of these factors. 
Jointly, all these led to the idea that inflammatory events triggered either naturally by 
ovulation or environmentally by extraovarian factors may impact upon OSE 
integrity, thereby initiating EOC (Ness et al. 2000b).  
i) Inflammation and cancer 
Links between inflammation and cancer are not a novel concept. The role of 
inflammation in the development of cancer was first hypothesised in 1863 by Rudolf 
Virchow who recognised the infiltration of leukocytes into tumour tissues, 
suggesting initiation of tumour progression at sites of chronic inflammation 
(Balkwill & Mantovani 2001). As a general concept, the development of cancer is 
the result of perturbations of the innate and adaptive immune balance, thus resulting 
in excessive tissue remodelling that in turn places the tissue in a continuous oxidative 
stress, increasing therefore the susceptibility of cells to DNA and protein alterations 
(de Visser & Coussens 2005). For example, breast carcinoma is characterised by 
excessive infiltration of macrophages that lead to increased vasculature and 
angiogenesis of the tumour (Leek et al. 1996, 1999). Pro-inflammatory cytokines 
such as IL-1, IL-6 and TNF-α are part of the tumour milieu and contribute to the 
growth and spread of the tumour (Balkwill & Mantovani 2001, Balkwill et al. 2005). 
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Notably, TNF-α secretion by epithelial or stromal cells can directly and indirectly 
promote carcinogenesis of hepatocytes and skin through induction of the nuclear 
factor kappa B (NF-κB) inflammatory pathway. This effect was not apparent in the 
TNF-α knockout mouse. Besides, tumour progression was attenuated with anti-TNF-
α therapy as well as induction of inhibitor kappa B (IκB) - an intermediate NF-κB 
suppressor - at later stages of hepatitis tumour development (Arnott et al. 2002, 
Pikarsky et al. 2004).  
Another contributing factor to cancer progression is T lymphocyte-associated 
cell dysfunction and this appears to be the case in invasive renal (Das et al. 2008) 
and squamous head and neck cancers (Gastman et al. 2000). Intriguingly, FasL-
induced T-cell apoptosis as well as inhibition of T-lymphocyte anti-inflammatory 
effects by T regulatory (Treg) cells have been proposed as candidate mechanisms for 
the tumour to escape T cell surveillance (Das et al. 2008, Gastman et al. 2000, Hori 
et al. 2003, Woo et al. 2002).   
Furthermore, a classic pathway to spoil immune balance is through mutations 
and polymorphisms of genes that control immune regulation and responses such as 
cell survival, tissue remodelling and angiogenesis, all factors that contribute to the 
development of cancer (Mantovani 2005). For example, gastric cancer is related to 
IL-1 polymorphisms (El-Omar et al. 2000). Strikingly, attenuated skin neoplastic 
development was observed in mast cell-deficient mice, largely due to down-
regulation of MMPs and thus restriction of angiogenic and cytoproliferative effects, 
suggesting that tumour progression may be harnessed by altering harmful innate 
immune cell action (Coussens et al. 1999). Moreover, B and T lymphocyte 
deficiency in skin carcinogenic mouse model (HPV16 mouse) resulted in attenuation 
of blood vascularity, angiogenic vascular endothelial growth factor (VEGF)-A and 
MMP-9 proteins as well as epithelial cytoproliferative responses. However, injection 
of B-lymphocytes in HPV16 mice brought back chronic inflammation-induced 
carcinogenic potential, thereby attesting a dual role of adaptive immunity in cancer 
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progression - T cells eliminating cell invasion, whereas B cells appearing 
perpetrators of cancer promotion (de Visser et al. 2005).  
Another molecule that appears to be up-regulated in neoplasias and mediated 
by pro-inflammatory cytokines is COX-2, a major regulator of cell survival, 
angiogenesis and immune control. Intriguingly, COX-2 inhibitors are considered key 
therapeutic targets in inflammation-related tumours such as mammary cancer (Basu 
et al. 2004, Chang et al. 2005).  
Synoptically, it is obvious that inflammation is a critical factor of initiation, 
progression and invasion of tumours. 
ii) Inflammation and development of epithelial ovarian cancer  
Consistent with the inflammation hypothesis for the development of EOC 
(Ness & Cottreau 1999) along with solid evidence for a role of inflammation in many 
types of cancer described above, a series of studies have been performed to 
investigate the mechanisms through which inflammation can promote the 
development of EOC. Regarding this, two approaches have been used: a) elucidation 
of inflammation-associated events in both malignant and normal ovary and b) 
identification of anti-inflammatory mechanisms that could protect OSE from 
neoplastic transformation.  
  As discussed in section 1.2.4, the immune system has a key role in ovarian 
functions such as ovulation and steroid formation and action. It was also mentioned 
that hOSE is responsive to immune mediators such as cytokines which impact upon 
it in an autocrine and paracrine manner. Fundamentally, cytokine secretion and 
responsiveness to cytokines such as IL-6, IL-1, TNF-α, GM-CSF and IL-8 is retained 
in the ovarian tumour microenvironment, suggestive that the development of EOC is 
a consequence of altered local immune balance (Burke et al. 1996, Merogi et al. 
1997, Nash et al. 1998, Obata et al. 1997, Szlosarek et al. 2006, Ziltener et al. 1993). 
Notably, it has been shown that both normal and malignant ovaries lack ‘anti-
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tumour’ T lymphocyte-associated cytokines such as IL-4 and IL-10, albeit that 
receptors for these cytokines are present (Burke et al. 1996), thereby implicating that 
secretion from adjacent cells is essential for immune homeostasis. In support of this, 
T lymphocyte dysfunction has been shown in ovarian carcinomas. Remarkably, it has 
been reported that T lymphocyte apoptosis is induced by the Fas ligand that is 
secreted by tumour cells. Intriguingly, this effect was reversed when caspase 
inhibitors were present (Rabinowich et al. 1998). Another candidate mechanism to 
eliminate T lymphocyte ‘anti-inflammatory’ action is by T regulatory cells that 
infiltrate the tumour milieu. Importantly, a positive correlation between T regulatory 
cells, spread of the ovarian tumour in the peritoneal cavity and poor prognosis of the 
disease has been demonstrated (Curiel et al. 2004).  
An additional striking paradigm of immune imbalance in ovarian cancer is 
the loss of biologically active pro-inflammatory IL-18. Precisely, it has been shown 
that mature IL-18 which normal OSE expresses is lost in ovarian cancer (Wang et al. 
2002b). Also, heterozygous IL-18 GC genotype was proposed as a marker in ovarian 
cancer invasion and metastasis (Bushley et al. 2004).   
Another pro-inflammatory cytokine that has an indispensable role in natural 
ovarian processes and is a candidate for the development and progression of EOC is 
TNF-α (Murdoch et al. 1997, Murdoch 1999). TNF-α has been shown to have a role 
in extracellular matrix degradation during ovarian rupture, triggering therefore a 
series of inflammatory processes. Its capacity to impact upon OSE by mediating 
genes involved in membrane degradation such as uPA and MMP-9 prior to and post-
ovulation reveals its possible part in OSE neoplastic transformation (Murdoch & 
Lund 1999, Yang et al. 2004).  Expression of TNF-α in the apex of epithelial tumour 
areas and ascites along with its cytoproliferative effects have been also reported 
(Marth et al. 1996, Naylor et al. 1993). A proposed mechanism for TNF-α action in 
tumour progression and invasion is through activation of mitogenic and 
inflammatory signalling pathways such as Jun N-terminal kinase (JNK) and NF-κB 
respectively (Hagemann et al. 2005, Kulbe et al. 2005). Supplementation with 
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factors,  such as infliximab, that suppress tumour-associated TNF-α secretion has 
been proposed as an immunotherapeutic modality in ovarian cancer treatment 
(Szlosarek et al. 2006). Moreover, indomethacin, a non-steroid anti-inflammatory 
agent that suppresses ovulation, abrogated stigma formation in ewes and  reduced the 
cytotoxic effect of TNF-α on OSE in vitro (Murdoch & Lund 1999).  
Further support for the positive association of inflammation with EOC also 
comes from studies with the IL-1α gene family, namely IL-1α, IL-1R and IL-1Ra. 
IL-1α has been shown to be up-regulated in the serum of patients with EOC (Zeisler 
et al. 1998). Also, an autocrine cell growth effect of IL-1α on ovarian cancer cells 
has been reported (Marth et al. 1996). In the normal ovary, IL-1α is secreted prior to 
and during ovulation and signals in hOSE in a paracrine and autocrine manner. A 
sequence of studies has proved that this proxy alters the local inflammatory 
environment of hOSE. IL-1α attenuated GnRH receptor mRNA expression (Rae et 
al. 2004b), through which GnRH mediates its anti-proliferative effects (Kim et al. 
2005). Also, this surrogate reduced 3β-HSD1 mRNA that could in turn decrease 
local progesterone formation that has been shown to exert anti-inflammatory and 
apoptotic effects on OSE (Bu et al. 1997, Murdoch & Van Kirk 2002, Rae et al. 
2004a, Rae et al. 2004b). On the other hand, IL-1α up-regulates COX-2 mRNA 
expression in hOSE, showing that it potentially promotes prostaglandin secretion that 
in turn leads to follicular wall break and rupture, events that are associated with cell 
damage and genotoxicity (Rae et al. 2004a). It also up-regulated IL-6 and IL-8 
mRNAs, both secreted as part of the ovulation-associated inflammation, and also 
lysyl oxidase (LOX) mRNA that is involved in basement membrane deposition and 
this could be relevant to tissue post-ovulatory repair as well as stimulating 
downstream NF-κB inflammatory pathway molecules (Rae et al. 2004b). At the 
same time, IL-1α induced 11β-HSD1 mRNA and activity, the enzyme that is 
responsible for intracrine regeneration of anti-inflammatory cortisol from cortisone, 
attesting to an efficient role of the hOSE to locally alleviate tissue from cell damage 
and promote post-ovulatory wound healing (Rae et al. 2004a, Yong et al. 2002). 
Remarkably, addition of cortisol to IL-1α-treated hOSE cells in vitro further 
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stimulated 11β-HSD1 mRNA levels, revealing a positive feedback loop mechanism 
for cortisol regeneration (Rae et al. 2004a). Concomitantly, cortisol suppressed IL-
1α-induced COX-2 mRNA, highlighting once more its local anti-inflammatory 
action in hOSE (Rae et al. 2004a). On the other hand, 11β-HSD2 that reduces 
cortisol levels by catalysing its conversion to inactive cortisone was undetectable  in 
primary OSE cells (Gubbay et al. 2004, Rae et al. 2004a). However, 11β-HSD2 
mRNA levels are significantly higher in ovarian cancer cell lines. Moreover, cancer 
cell lines are not responsive to IL-1α despite measurable expression of IL-1R 
mRNA. These data imply that 11β-HSD2 expression and lack of 11β-HSD1 
induction by  IL-1α stimulus might be defining features of ovarian neoplastic 
transformation (Gubbay et al. 2005). 
A separate stimulus that has been recently shown to mediate inflammatory-
associated genes in hOSE is the thyroid hormone, T3. In essence, T3 directly impacts 
upon OSE by stimulating expression of COX-2, MMP-9 and 11β-HSD1 all involved 
in promoting or counteracting inflammatory cascades during ovulation (Rae et al. 
2007). These findings have direct clinical relevance, since a positive association 
between hyperthyroidism and EOC has been described (Ness & Cottreau 1999). 
In conclusion, it is widely accepted that inflammation-associated events 
affect the functionality of the ovarian cell surface (i.e steroid production, 
angiogenesis and tissue remodelling) prior to and after ovulation. Immune imbalance 
has been also demonstrated in ovarian carcinomas. Collectively, all these imply an 
early need for the identification of physiological inflammatory and anti-inflammatory 
mechanisms in the ovarian cell surface as well as in ovarian cancer in order to 
develop novel molecular markers for treating or diagnosing ovarian cancer ( Rae et 
al. 2004b,  Rae & Hillier 2005). 
In summary, it is clear that there are obvious inter-relationships among 
the different hypotheses (ovulation-associated inflammation, hormone-mediated 
inflammation and inflammation-mediated hormone signalling), and as such EOC 
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should be considered and investigated as a multifactorial and complex disease. A 
summary of all the contributing factors of the disease is illustrated in Table 1.1. 
 
                  Table 1.1 Summary of factors that are involved in the aetiology of EOC 
Risk factors Role in hOSE/EOC 
Ovulation tissue damage/cytotoxicity/inflammation 
Inflammation wounding/tissue remodelling 
Family history epigenetics/mutations 
PCOS elevated androgens/cytoproliferation 
Endometriosis inflammation-associated 
PID inflammation-associated 
Oestrogen replacement therapy elevated oestrogens/cytoproliferation 
Hyperthyroidism chronic inflammation 






Pro-inflammatory cytokines  inflammation-associated/tissue remodelling 
T regulatory-associated cytokines T lymphocyte apoptosis 
EGF cytoproliferative 
    
Protective factors   
Pregnancy progesterone-associated apoptosis/anovulation 
Lactation anovulation 
Oral Contraception anovulation 
Hysterectomy/Tubal ligation blockage of inflammation-associated factors 
GnRH anti-proliferative 
progesterone apoptotic/anti-inflammatory/anti-proliferative 
T lymphocyte-associated cytokines anti-inflammatory/anti-tumourigenic 
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1.4 Steroid Metabolism 
 As detailed in the previous sections of this chapter, steroid hormones 
including androgens, oestrogens, progestogens and glucocorticoids have an 
indispensable role in the biology of the human ovarian surface epithelium. They may 
be beneficial or destructive for the homeostasis of the ovarian cell surface, they are 
involved in cell apoptosis, cytoproliferation, inflammation and tissue remodelling 
and they appear to be leading candidates for the development of novel strategies to 
diagnose and treat EOC. Given their essential role in ovarian cell surface integrity, it 
is timely to investigate the local mechanisms through which steroid pre-receptor 
formation is regulated in hOSE. It is therefore relevant to take an in-depth look and 
review the major steroid formation mechanisms that occur not only in the human 
ovary but in many if not all tissues of the body and this is the scope of this section. In 
particular, a focus is given to the molecular biology and intracrinology of the 3β-
HSD steroidogenic enzyme, as the regulation of this enzyme in hOSE and EOC will 
be the major focus of the following Chapters. 
1.4.1 Intracrine generation of steroid hormones 
Steroid hormones are small lipid-soluble molecules that derive from 
cholesterol through sequential modifications that are achieved by a panel of 
steroidogenic enzymes (Fig. 1.9). These enzymes locally control the biosynthesis as 
well as inactivation of steroid hormones namely progestogens, synthesised 
principally in the corpus luteum and placenta, oestrogens, secreted in the granulosa 
cell layers of the follicle, androgens that are mainly secreted in the testicular Leydig 
cells but also in theca cells of the developing follicle and glucocorticoids and 
mineralocorticoids that are both produced in the adrenal cortex. The synthesis of 
steroid hormones is subject to the bioavailability of cholesterol in the circulation or 
in the target cell and the induction of the production of StAR protein, the enzyme 
that is responsible to transport free cholesterol from the cytoplasm to the inner 
mitochondrial membrane of the target cell, where the first enzyme, cytochrome 
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P450scc of the steroidogenic pathway is located (Fig.1.9). Typically, as illustrated in 
Fig. 1.8, steroid enzymes principally facilitate the bioavailability of active steroidal 
hormones that can signal in target cells through binding to cognate nuclear steroid 
receptors. This, in turn, leads to the dissociation of the receptor from the chaperone 
complex and its homo- and/or hetero-dimerisation in the nucleus. The ligand-
receptor complex, then, transactivates the transcription of target genes through 
binding to hormone response elements (HRE) located in their promoters (5’-flanking 
sequence). An alternative pathway of transcription of the target genes is the reaction 
of the active ligands with their cognate membrane steroid receptors (whose structure 
resemble G-protein couple receptors or GPCRs), leading to rapid transmission of 
signals through signalling transduction pathways (non-genomic actions). Function 
and controversies about non-genomic steroid effects have been reviewed elsewhere 
(Hammes & Levin 2007, Losel & Wehling 2003) and are beyond the scope of this 
thesis.  
There are two main classes of enzymes that are involved in the gonadal and 
adrenal steroid production: i) the cytochrome P450 haem-containing enzymes and ii) 
the hydroxysteroid dehydrogenases (HSDs). A major difference between the two 
classes is that each P450 enzyme is derived from a single gene, whilst each HSD 
activity exists in multiple forms, each form a product of a distinct gene, making the 














Figure 1.8: Steroid hormone action. Transactivation of nuclear steroid receptors is subject 
to the local availability of active steroid hormones that is determined by the catalytic 
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1.4.1.1 The cytochrome P450 haem-containing enzymes  
 The cytochrome P450 haem-containing enzymes are membrane-bound 
enzymes located either in endoplasmic reticulum (microsomes) or mitochondria. 
These enzymes are responsible for the hydroxylation and cleavage of steroid 
substrates and utilise reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) as co-factor. Electron transfer to steroid substrate is achieved either by a 
mitochondrial microsomal electron transfer system. This family includes P450scc 
that converts cholesterol to pregnenolone and delineates the first reaction of the 
steroidogenic pathway, P450c17 that gives rise to DHEA or androstenedione using 
pregnenolone or 17α-progesterone as substrates; P450arom converts C19 androgens 
to C18 oestrogens, whilst P450c11 yields cortisol. Regulation of expression of 
P450scc and P450c11 requires the steroidogenic nuclear factor-1 (SF-1) (Lala et al. 
1992, Morohashi et al. 1992). The reactions catalysed by these enzymes are 

















Figure 1.9: Major pathways of steroid biosynthesis. Most important steroidogenic 
enzymes of both P450 haem-containing and HSD enzymes. Grey coloured structures reflect 
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1.4.1.2 Hydroxysteroid dehydrogenases (HSDs)  
 The complexity of  HSDs relates to their characteristics of not only catalysing 
bi-directional enzymatic reactions (dehydrogenase and/or reductase) but also to their 
existence as multiple isoforms with specific expression patterns and enzymatic 
activities in tissues and species (Penning 2003).  
Milestones in the isolation of cDNA have revealed at least two distinct 
protein phylogenies; i) the short-chain alcohol dehydrogenase/reductase (SDR) 
family and ii) the aldo-keto reductase (AKR) family. The former encompasses 57 
members, including the 3β-hydroxysteroid dehydrogenase/ketosteroid isomerase (3β-
HSD/KSI), oestrogenic and androgenic 17β-HSDs and 11β-HSD enzymes 
(Krozowski 1994), whilst the latter family includes isoforms that exhibit 3α-HSD 
and 20α-HSD activities (including 17β-HSD5) (Deyashiki et al. 1995, Lacy & 
Dunbar 1993). 
Classification of the enzymes that belong to each distinct protein family 
relates to similarities in protein folding patterns. The SDR family contains 
membrane-bound members that have 25-30% sequence homology and are multimers 
that consist of 25kDa monomers. Despite their low homology, they all share an α-
helix/β-strand arrangement with a common motif (Gly)-xxx-Gly-x-Gly) in the N-
terminus, constituting a so-called Rossman Fold (β-α-β-α-β)2 (Fig. 1.10A) that is the 
NAD(P)(H) cofactor binding domain. Moreover, they all share a common motif 
(Tyr-x-x-Ser-Lys) that seems responsible for the dehydrogenase activity of the 
enzyme (Chen et al. 1993, Ensor & Tai 1991, Obeid & White 1992). Finally, the C-
teminal domain varies among the members of the SDR family and it seems to relate 
to the binding of the different substrates (Kallberg et al. 2002). 
The AKR superfamily includes more than 40 soluble proteins, which are 
monomers of approximately 34kDa. They utilise NAD(P)(H) as cofactor, although 
they do not have a Rossman-fold arrangement; instead a salt-linked safety-belt TIM-
barrel structure (α/β)8 in the N-terminal domain allows the protein-cofactor and 
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protein-steroid specific interactions (Fig. 1.10B) (Penning 1997). The Tyr 55/Lys 84 
pair that belongs to the Asn 50, Tyr 55, Lys 84 and His 117 tetrad appears to lead the 
catalytic activity of the enzyme (Schlegel et al. 1998). Notably, despite their 
differences in three-dimensional structures, site-directed mutation studies have 
revealed that catalytic activity of both families involves the use of Tyr/Lys pair, 
implicating evolution of a similar catalytic mechanism (Bennett et al. 1996). Distinct 




















Figure 1.10: Schematic categorisation of the two major hydroxysteroid dehydrogenase 
families. A) Short-chain dehydrogenase/reductase members along with their basic features 
including Rossman-fold motif, B) Features and members of aldoketoreductase family. TIM-
barrel motif is conserved among members of this HSD family. Adapted after 
http://www.biochem.arizona.edu/classes/bioc462/462a/NOTES/Protein_Structure/alpha_beta
_domain_txt.htm (2006), http://www.med.upenn.edu/akr/akr_graphic.html (2006), Penning 
(2003). 
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1.4.2 Molecular biology and biochemistry of 3β-hydroxysteroid dehydrogenases 
1.4.2.1 Biochemistry and gene structure of 3β-hydroxysteroid dehydrogenase  
 The 3β-HSD/KSI enzyme was first desribed in 1951 (Samuels et al. 1951) 
and catalyses the conversion of the Δ5-3β-hydroxysteroids to the active Δ4-3-
ketosteroids. Notably, 3β-HSD/KSI is the enzyme that catalyses the first step of the 
conversion of steroid precursors to active steroids from cholesterol (Fig. 1.11) and 
therefore it controls the bioavailability of all the classes of steroid hormones, namely 
androgens, progestogens, oestrogens, mineralocorticoids and glucocorticoids not 
only in typical steroidogenic tissues but also in peripheral ones. It metabolises 3β-
hydroxy-5-ene-steroids (DHEA and PREG) to 3-oxo-4-ene-steroids 
(androstenedione and PROG respectively) (Thomas et al. 1988)  (Fig. 1.11).   
 The reaction involves two steps; following dehydrogenation of 3β-equatorial 
hydroxysteroids, Δ5-3-ketosteroids products are isomerised to the α, β-unsaturated 
ketones; the first reaction is triggered by a conformational shift around a single 
steroid-binding site of the protein and requires reduction of  NAD+ to NADH that in 
turn stimulates the isomerase reaction. Although 3β-HSD can convert steroid 
substrates to active steroids with different catalytic efficiency, enzyme activity levels 
are not substrate dependent   (Thomas et al. 1988, Thomas et al. 1989, Thomas et al. 













Figure 1.11: Reactions catalysed by the 3β-HSD/KSI enzyme. The conversion of 
pregnenolone to progesterone and DHEA to androstenedione involves reduction of binding 
co-factor NAD+ to NADH. Adapted after Penning (1997). 
 There are different isoforms of 3β-HSD/KSI with species- and tissue-specific 
expression patterns. The first to be isolated was from the microsomes and 
mitochondria of human placenta and is now called 3β-HSD type 1 (3β-HSD1) 
(Thomas et al. 1989, Thomas et al. 1988). The mRNA of this enzyme encodes a 
protein of 372 amino acids (aa) and has a molecular weight of 42kDa (Lorence et al. 
1990). Besides progesterone and androstenedione, it is also involved in the formation 
and/or degradation of 5α-androstanes such as 5α-DHT. The same isoform was also 
identified in peripheral tissues such as skin and mammary gland. Notably, site-
directed mutagenesis of 3β-HSD1 revealed that His 261 is the key residue for 3β-
HSD activity, whereas Tyr 253 or Tyr 254 are responsible for the isomerase activity 
(Thomas et al. 1998). Two years later, isolation of a cDNA from human adrenal that 
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encodes a 371aa protein followed (Rheaume et al. 1991). This isoform, 3β-HSD type 
2 (3β-HSD2), was also highly expressed in gonads. The HSD3B1 and HSD3B2 genes 
are located in chromosome 1p13.1, are 7.8kb and 7.7kb in length respectively, 
consist of 4 exons that give a 1.7kb transcript, and three introns (Berube et al. 1989) 
and they share 93.5% similarity (Rheaume et al. 1991). The start site of translation of 
both isoforms is located in exon 2 (Clarke et al. 1996). Gene, transcript and proteins 
for 3β-HSD1 and 3β-HSD2 are illustrated in Fig. 1.12. 
 
 
 Figure 1.12: Summary of structures of HSD3B1 and HSD3B2 genes. HSD3B1 and 
HSD3B2 genes encoding for 3β-HSD1 and 3β-HSD2 respectively share at least 93% 
similarity. Adapted after ensemble databases (http://www.ensembl.org/ 2006).  
A unique feature of 3β-HSDs that is absent in the other HSDs is that they 
have two catalytic motifs rather than one (Tyr 154-x-x-x-Lys 158) in their primary 
structures. Importantly, 3β-HSD1 has Tyr, whilst 3β-HSD2 has His at position 156 
of this domain (Thomas et al. 2002a). Subcellular localisation studies revealed that 
3β-HSD is a membrane-associated enzyme and is located in smooth endoplasmic 
reticulum and mitochondria (Thomas et al. 1989). Submitochondrial fractionation of 
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bovine adrenal showed that functional 3β-HSD protein and activity are present in the 
inner mitochondrial membrane and within a particulate fraction between the inner 
and outer membranes. 3β-HSD activity was much higher in this intermediate fraction 
than in the inner mitochondrial membrane and it was suggested that this might well 
serve the transportation of cholesterol to the inner membrane where P450scc is found 
and facilitating conversion of pregnenolone to progesterone (Cherradi et al. 1993). 
Kinetic studies showed that the human type 1 enzyme has 5.9-, 4.5- and 2.8-fold 
higher relative catalytic efficiency (maximal velocity (Vmax)/Michaelis constant 
(Km)) for PREG, DHEA and 5α-DHT, respectively relative to 3β-HSD2 (Rheaume et 
al. 1991). The higher Km of 3β-HSD2 seems to be consistent with the principal 
expression of this isoform in steroidogenic tissues and/or cell types that de novo 
produce high levels of endogenous substrates (Labrie et al. 1994).  
Intriguingly, five and six 3β-HSD isoforms have been identified in rat and 
mouse respectively (Abbaszade et al. 1995, Delaunoit et al. 1992, Lachance et al. 
1991, Lorence et al. 1990, Zhao et al. 1991). Also, three 3β-HSD isoforms have been 
identified in the hamster genome (Rogerson et al. 1995). Single 3β-HSD genes in the 
bovine and canine genome only become apparent with the availability of the 
complete genomes of bovine and canine species (Zhao et al. 1989, Mendoza-
Hernández et al. 1990). The different isoforms are numbered according to the time 
when they were identified and therefore the same numeral in different species does 
not reflect the same functional isoform. For example, mouse 3β-HSD1 is the 
orthologue of human type 2, whilst 3β-HSD6 is the homologue of human type 1. 
Notably, whereas mouse 3β-HSD types 1, 3 and 4 are dehydrogenases/isomerases, 
the types 4 and 5 function as 3-ketosteroid reductases and thereby they deactivate 
steroid biosynthesis (Abbaszade et al. 1995, Clarke et al. 1993). Rat 3β-HSD3 
belongs to the latter functional group as well (Delaunoit et al. 1992). 
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1.4.2.2 Regulation of expression of 3β-HSDs  
 Despite their high homology, the separation of the two human 3β-HSD genes 
by two pseudogenes does not allow their regulation by the same promoter (McBride 
et al. 1999). Therefore, transcription of each isoform is probably regulated by 
different transcription factors. Hence, the most established factor that controls 3β-
HSD2 expression is SF-1 with 3 consensus binding sites in the proximal promoter. 
Importantly, SF-1 elements are associated with cAMP and phorbol ester-induced 3β-
HSD2 expression as revealed by promoter studies in human adrenocortical cells 
(H295R) (Leers Sucheta et al. 1997, Rainey et al. 1994). Another candidate molecule 
that might be involved in 3β-HSD2 transcriptional regulation is the STAT-5 
transcriptional factor (Feltus et al. 1999, 2003). 
 The regulation of the mouse 3β-HSD6 (the orthologue of human 3β-HSD1) is 
not subject to SF-1control but is controlled by the activator protein-2 (AP-2) and the 
distal-less 3 (Dlx 3) that were identified in both placenta and adrenal (Peng & Payne 
2002). Surprisingly, although the human 3β-HSD1 promoter has binding sites for 
AP-2 and Dlx3, it does not seem to be regulated by these two factors, but by the 
transcription enhancer factor-5 (TEF-5) and a GATA-like protein (Peng et al. 2004). 
Interestingly, 3β-HSD1 transcriptional activity is increased by cAMP, at least in 
choriocarcinoma JEG-3 cells (deMoura et al. 1997). Another candidate factor that 
controls human 3β-HSD1 regulation is the STAT-6 transcription factor and two 
STAT-6 elements have been identified in two distal sites of the gene promoter 
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1.4.2.3 Tissue-specific regulation of 3β-HSDs in female reproductive organs 
  As noted above, 3β-HSD1 and 3β-HSD2 arise from two distinct genes of 
high homology that are differentially regulated. Moreover, their catalytic efficiency 
differs and this may be associated with their tissue/cell-specific expression pattern. In 
this section a summary of the regulation of 3β-HSDs expression in distinct tissues is 
presented. The focus will be on the regulation in human with reference to other 
species when considered necessary.  
i) Adrenal 
  The principal isoform expressed in the human adrenal is 3β-HSD2. Notably, 
the expression pattern of the enzyme differs between the different zones of the adult 
adrenal gland, highlighting distinct steroidogenic capacities of each zonal 
compartment (Dickerman et al. 1984). Thus, in the zona fasciculata (ZF) and zona 
reticularis (ZR) adrenocorticotropic hormone (ACTH) principally induces 3β-HSD 
expression, whereas 3β-HSD in the zona glomerulosa (ZG) is mainly dependent on 
angiotensin-II (A-II) stimulation. Intriguingly, 3β-HSD expression is suppressed in 
fetal human adrenal (Byrne et al. 1985); although in vitro it can be induced in 
response to ACTH treatment (Doody et al. 1990). Studies with H295R human 
adrenocortical cells has shown that 3β-HSD stimulation is a result of a cAMP 
increase triggered by ACTH (Bird et al. 1996). Importantly, co-treatment of the 
cAMP activator, forskolin, with AII reduced 3β-HSD activity in the same cells (Bird 
et al. 1996). Interestingly, protein kinase C (PKC) activation appears to also inhibit 
3β-HSD expression as revealed by addition of staurosporine to the ACTH-treated 
mouse Y1 adrenal cell line (Reyland 1993). Notably, several studies in both human 
adrenocortical cells and the H295R cell line have implicated the regulation of 3β-
HSD by growth factors such as TGF-β1, EGF and insulin-growth factor (IGF)-II 
(Doi et al. 2001, Feltus et al. 2003, Lebrethon et al. 1994, Mesiano & Jaffe 1993). 
Also, dexamethasone treatment has been reported to increase 3β-HSD2 mRNA levels 
in H295R cells (Feltus et al. 2002). 
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ii) Ovary   
 The principal isoform expressed in human ovary is 3β-HSD2 (Rheaume et al. 
1991). The steroidogenic activity of this reproductive organ appears in puberty. 
Importantly, ovarian steroidogenic capacity in puberty starts at the pre-antral follicle 
and increases as follicles develop in the pre-ovulatory follicle with a peak 
steroidogenic capacity and abundant 3β-HSD2 expression in the progestogenic 
corpus luteum (Dupont et al. 1992, Sasano et al. 1990). Interestingly, studies have 
shown an early expression of 3β-HSD in the theca of the fetal ovary. From birth until 
puberty, low 3β-HSD immunostaining was observed (Dupont et al. 1992). From 
puberty to menopause, the theca interna was the principal cell compartment positive 
for the enzyme with lower staining in granulosa cells of growing follicles. Induction 
of the enzyme activity in granulosa cells, mainly in membrana granulosa, was 
observed at the pre-ovulatory follicle (Sasano et al. 1990) and this effect appeared to 
be mediated by an intracellular increase of cAMP (McAllister et al. 1989), adenyl 
cyclase and protein kinase A (PKA) as a result of the pituitary FSH and LH hormone 
secretion (Cooke 1999). Interestingly, the absence of 3β-HSD immunoreactivity in 
theca interna cells overlying the membrana granulosa of the pre-ovulatory follicle 
suggested that these cells may reflect fibroblast-like cells that are devoid of 3β-HSD 
activity and are not directly involved in steroidogenesis (Dupont et al. 1992, Sasano 
et al. 1990). In post-menopausal ovaries, 3β-HSD was only immunodetected in 
scattered interstitial cells (Dupont et al. 1992). EGF also appeared to positively 
regulate 3β-HSD as it has been shown in studies with rats (Bendell & Dorrington 
1990). In vitro studies for the regulation of 3β-HSD in human are very challenging 
due to limitations of tissue collection at early stages of folliculogenesis. However, 
more data regarding the intracrinology of the human ovary can be obtained from 
corpus luteum studies because the collection of lutein cells has been facilitated with 
in vitro fertilisation procedures. Thus, studies with lutein-granulosa cells have shown 
up-regulation of 3β-HSD by LH, hCG, forskolin and insulin (McAllister et al. 1990, 
McGee et al. 1995). Moreover, McAllister et al. showed stimulation of cAMP-
enhanced 3β-HSD by growth factors such as fibroblast growth factor (FGF), EGF 
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and TGF-β (McAllister et al. 1994). Oestradiol has been demonstrated to antagonise 
progesterone synthesis, an effect mediated by 3β-HSD abrogation by oestradiol 
(Fisch & Rose 1994, Vega et al. 1994). Finally, luteolytic prostaglandin PGF2α has 
been found to suppress progesterone synthesis in macaques (Bennegård et al. 1991) 
through rapid down-regulation of 3β-HSD (Duncan et al. 1998). 
iii) Placenta  
 The placenta is the organ notable for the production of progestogens and 
oestrogens during the later stages of pregnancy. The human placenta is positive for 
the 3β-HSD1 isoform which is mainly located in synciotrophoblastic cells. No 
evidence of 3β-HSD2 in placenta was reported (Lachance et al. 1991). The 
regulation of the placental enzyme is mainly achieved through activation not only of 
the PKA pathway that increases intracellular cAMP but also with the PKC pathway 
as shown with human choriocarcinoma JEG-3 cells (Tremblay & Beaudoin 1993). 
Importantly, insulin and IGF-I were shown to induce 3β-HSD activity in primary 
human cytotrophoblasts (Nestler 1989). Also, 3β-HSD1 promoter studies in JEG-3 
cells revealed regulation by TEF-5 and a GATA-like factor as noted above (Peng et 
al. 2004). 
iv) Breast 
 Expression of 3β-HSD in mammary gland was first described by Belanger et 
al. who noticed elevated pregnenolone, progesterone, DHEA and androsterone in 
breast cyst fluid (Bélanger et al. 1990). Moreover, the ratio of DHEA and its 
metabolite androstenedione suggested 3β-HSD activity in the mammary gland. 
Further studies also showed immunolocalisation of  3β-HSD in breast carcinomas 
(Sasano et al. 1994). Most information about the regulation of 3β-HSD in breast in 
both health and disease comes from Simard’s group who first showed a positive up-
regulation of 3β-HSD by IL-4 and IL-13 cytokines along with potential signalling 
mechanisms that modulate this effect (Gingras et al. 1999, 2000). According to these 
studies, in ZR-75-1 human breast cancer cells, IL-4 signalled through activation of 
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insulin-receptor substrates (IRS)-1 and IRS-2 which in turn led to transduction of 
downstream factors such as the PI-3K and MAPK signalling pathways. The inability 
of IGF-I, insulin or phorbol-12-myristate-13-acetate (PMA) to stimulate 3β-HSD 
expression in the absence of IL-4 suggested that this response required an IL-4-
specific signalling molecule. Regarding this, the STAT-6 transduction signalling 
pathway was a pre-requisite for IL-4-responsive gene regulation (Shimoda et al. 
1996, Takeda et al. 1996). Thus, the multiple pathways downstream of IRS-1 and 
IRS-2 could cross-talk with the STAT-6 transcription factor to induce 3β-HSD1 
mRNA and protein expression (Gingras et al. 2000) (Fig. 1.13). 
 
Figure 1.13: IL-4/IL-13 action in ZR-75-1 cell line. This figure summarises the signalling 
pathways involved in IL-4/IL-13 action. Downloaded from Gingras et al. (2001).  
1.5 Cytokine Receptor Transactivation and Signalling Networks 
 As referred to earlier, the two cytokines that have been studied and appear to 
influence importantly 3β-HSD are firstly IL-1α that in vitro suppresses 3β-HSD1 
mRNA transcript (Rae et al. 2004b) in the human ovarian surface epithelium and 
also IL-4 that induces 3β-HSD activity in multiple tissues, including breast cancer 
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cell lines (Gingras et al. 1999). These two cytokines exert their effects through 
binding to cell surface receptors, the IL-1 receptor (IL-1R) and the IL-4 receptor (IL-
4R) respectively. Upon their binding to their cognate receptor, transactivation of the 
latter follows, thereby resulting in the initiation of signalling cascades to mediate cell 
responses, from cell survival to gene transcription. As stated earlier, IL-1α in the 
human ovary has been established to be involved in ovulation-associated 
inflammation and the subsequent injury of hOSE. Regarding IL-4, it has been shown 
to be secreted mainly at the peri-ovulatory period with a peak at the luteal phase of 
the menstrual cycle; however, there are no reports of its actions, if any, in the post-
ovulatory injury and repair of hOSE. In this regard, IL-1 and IL-4 action in steroid 
signalling of hOSE at ovulation will be a major focus of this thesis. Therefore, an 
overview of their action and signalling network will be presented in this section.  
1.5.1 The IL-1 system and its signalling networks 
1.5.1.1 The IL-1 system: protein interactions and transactivation  
 The pro-inflammatory cytokine IL-1 has been widely studied due to its 
pleiotropic role in inflammatory responses in almost every cell type of the body, 
including the human ovarian cell surface. In human, the IL-1 gene system is located 
on chromosome 2 and consists of two agonist ligands, IL1-α and IL1-β, two cell 
surface receptors, the IL-1 type 1 (IL-1R1) and type 2 (IL-1R2) receptors and a 
receptor antagonist ligand, IL-1-Ra (Webb et al. 1986). In human, the two agonist 
ligands share a 22% similarity and have comparable biological properties, albeit their 
structure reveals distinct receptor binding sites (Labriola-Tompkins et al. 1993, 
March et al. 1985). IL-1R1 and IL-1R2 belong to the toll-like/IL-1 receptor (TIR) 
superfamily. The feature of these receptors is the presence of the phylogenetically 
conserved Toll/IL-1R (TIR) cytoplasmic domain that consists of a domain of at least 
200aa and is involved in the transduction of innate and inflammatory responses and 
also contributes to the activation of adaptive immunity, key processes for the 
restoration of local and systemic inflammatory reactions (Mantovani et al. 2007, 
O'Neill & Dinarello 2000, Rock et al. 1998). Receptors of this family can be divided 
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into two subgroups: those that have three immunoglobulins (Ig) in their extracellular 
domain, such as the IL-1R, and those whose extracellular segment is composed of 
leucine-rich repeats, as in the case of toll-like receptors (TLRs). The receptors of this 
family have been conserved through evolution and appear to mediate signalling 
pathways associated with pathogen and mechanical injury in insects, plants and 
mammals.  
IL-1α, IL-1β and IL-1Ra responses are exclusively mediated through IL-1R1, 
the first discovered member of the TIR superfamily, whereas IL-1R2 is a decoy 
receptor (Sims et al. 1988, 1993, Stylianou et al. 1992). IL-1R1 is a 80kDa 
glycoprotein that is composed of a 319aa extracellular domain and a 217aa 
cytoplasmic domain (Sims et al. 1988). After the binding of an agonist ligand, IL-
1R1 is phosphorylated by a Ser/Thr kinase, thereby triggering heterodimerisation 
with another member of the TIR family, the IL-1R accessory protein (IL-1RacP) 
(Gallis et al. 1989, Huang et al. 1997). The heterodimer, in turn, interacts with the 
exclusively cytosolic MyD88 through its TIR domain (Wesche et al. 1997). The 
latter also possesses a death domain that interacts with the death domain of the IL-1-
related associated kinase-1 (IRAK-1), a serine-threonine kinase, that is bound to the 
TNF-receptor-associated-factor-6 (TRAF-6). Intriguingly, it has been demonstrated 
that IRAK-1 trafficking to the receptor complex is facilitated by IL-1RAcP (Huang 
et al. 1997, Volpe et al. 1997). Then, IRAK-4 interacts with the death domain of 
IRAK-1 resulting in phosphorylation of the latter on Thr 209 and 237 and 
dissociation of TRAF-6/IRAK-4 complex from MyD88. Following interaction with 
the TGF-β-activated kinase 1 (TAK-1), IRAKs and TRAF-6 are poly-ubiquitinated 
and degraded, thereby activating TAK-1 that induces downstream signalling 
pathways like mitogen-activated protein kinase kinases (MKKs) and inhibitory κB 
kinases (IKKs) that mediate IL-1-responsive gene transcriptional activity (Dower & 
Qwarnstrom 2003, O'Neill & Dinarello 2000, Wesche et al. 1997, Yamaguchi et al. 
1995). A simplification of the network involved in IL-1 signalling is illustrated in 
Figure 1.13.   
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There are two pathways commonly activated by TIR superfamily members. 
First, it is the classic inflammatory NF-κB pathway activated by IKK singlasome 
(Mercurio et al. 1997) and secondly it is MAPK pathways, namely the stress/osmotic 
associated protein kinase/jun N-terminal kinase (SAPK/JNK) and p38 MAPK 
signalling pathways activated by MKKs, (Freshney et al. 1994) (Fig. 1.13). 
Extracellular signal-regulated kinases 1 and 2 (ERK1/2), albeit mostly activated by 
mitogenic factors, are also activated by TIR receptors in selective cases (Bird et al. 
1991, Waterfield et al. 2003).   
The IL-1R2 is a 60kDa protein and first cloned in 1991 from B cells and 
expressed in several cell types such as bone marrow cells, neutrophils, keratinocytes 
and monocytes (McMahan et al. 1991). Similarly to IL-1R1, IL-1R2 is encompassed 
by an extracellular domain, containing three Igs, a transmembrane domain and a 
cytoplasmic domain of 29aa only, much shorter than the IL-1R1 one, lacking TIR 
domain. The total homology of the two receptors is only 28%; however, they can 
both bind the two agonist and antagonist ligands with high affinity, as their 
extracellular domains share high similarity (McMahan et al. 1991). The absence of 
the TIR domain on the IL-1R2 is probably responsible for the inability of this cell 
surface receptor to transduce signals, establishing therefore this receptor as a decoy 
receptor (Colotta et al. 1993, Curtis et al. 1989, Sims et al. 1993, Stylianou et al. 
1992). Intriguingly, IL-1R2 action is widely considered as a mechanism to counteract 
inflammatory responses and maintain tissue homeostasis (Mantovani et al. 2004, 
Mantovani et al. 2007). For example, it was demonstrated that injection of 
keratinocytes transfected with human IL-1R2 into mice resulted in attenuated 
expression of inflammatory cytokines such as IL-6 and it overall decreased the 
severity of collagen-associated rheumatoid arthritis (Bessis et al. 2000). Moreover, 
transfection of U937 cells (a human leukemic monocyte lymphoma cell line) with 
IL-1R2 negatively regulated IL-1 secretion (Penton-Rol et al. 1997). Further support 
for the anti-inflammatory effects of IL-1R2 comes from studies with 
immunosuppressive and anti-inflammatory glucocorticoids and the T helper-2 (Th-2) 
cytokine, IL-4. Dexamethasone has been reported to enhance IL-1R2 mRNA along 
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with membrane IL-1R2 binding domain in human polymorphonuclear (PMN) 
leukocytes (Re et al. 1994). Furthermore, IL-4 has been reported to induce IL-1R2 
mRNA and most importantly to inhibit IL-1β-induced prolongation of the life-span 
of PMN cells (Colotta et al. 1993). Intriguingly, a proposed mechanism for IL-1R2 
negative action is through enhancement of IL-1 ligand affinity for the IL-1R2 by the 
soluble form of IL-1RAcP (Smith et al. 2003). 
 
Figure 1.14: The IL-1 signalling network. This cartoon illustrates the main molecules 
involved in transactivation of IL-1R1 and associated signalling pathways. Binding of IL-1 to 
the IL-1R heterodimer results in sequential phosphorylation of serine/threonine kinases that 
in turn mediate transduction of NF-κB and MAPKs molecules.  
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1.5.1.2 IL-1α-associated signalling transduction pathways 
 As referred to above, IL-1R1 transactivation leads to activation of signalling 
pathways that monitor regulation and transcription of responsive genes communally 
having roles in inflammatory cascades.  
i) The NF-κB signalling pathway 
 NF-κB was first described as a transcription factor that regulated transcription 
of genes possessing immunoglobulin μ and κ sequences in their promoter (Sen & 
Baltimore 1986), but it is now realised that it regulates transcription of multiple 
inflammatory-associated genes. NF-κB is found as a homo- or heterodimer, subunits 
of which contain a conserved rel domain in N-terminus consisting of a dimerisation 
domain, a nuclear transfer signal domain and a DNA-binding region. It is most 
commonly encompassed by a 50kDa DNA-binding protein (p50) truncated from its 
105kDa precursor (Bours et al. 1990) and bound to another DNA-binding 65kDa 
protein, the p65 subunit (Ghosh et al. 1990, Nolan et al. 1991). The p50 subunit 
shares high homology with the proto-oncogene c-rel and the dorsal gene of 
Drosophila. Similarly, p65 appears to share common characteristics with rel gene  
(Ghosh et al. 1990, Kieran et al. 1990, Nolan et al. 1991). As mentioned above, NF-
κB is a downstream activator of the IL-1R1 signalling network. In its inactive form, 
NF-κB is located in the cytoplasm bound to a member of IκB protein family, all 
members encompassed by ankyrin-type repeats in their C-terminus, domains that are 
frequently present in cytoskeleton-associated proteins (Baeuerle & Baltimore 1988a, 
Baeuerle & Baltimore 1988b). This suggests that anchor cytosolic proteins are 
probably responsible for association of p50/p65 complex to IκB (Davis et al. 1991), 
thus masking the nuclear transfer signals of the NF-κB that facilitate its import to the 
nucleus (Beg et al. 1992). It has been suggested that the interaction of IκB is 
achieved through the rel domain of the p65 subunit rather than the rel domain of the 
p50 subunit (Nolan et al. 1991). Transmission of signals signified by IL-1 binding to 
its cell surface receptor leads to activation of IKK singlasome (Fig. 1.13) that in turn 
phosphorylates Ser 32 and Ser 36 of IκB-α, thereby marking IκB for proteolytic 
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degradation and ubiquitination that allows dissociation and activation of NF-κB 
(DiDonato et al. 1995, Ghosh & Baltimore 1990, Henkel et al. 1993, Régnier et al. 
1997). The release of NF-κB by IκB through a proteolytic-independent tyrosine 
phosphorylation of the latter has been also proposed (Imbert et al. 1996). 
Additionally, phosphorylation of p65 by PKA has been demonstrated as a pre-
requisite for full NF-κB activation before its migration to the nucleus (Zhong et al. 
1997). As a result, active NF-κB translocates to the nucleus where it can bind to κB 
DNA sequences of the promoters of target genes and initiate transcription. 
Inactivation, association and re-translocation of NF-κB/IκB complexes in the 
cytoplasm are subject to a feedback loop mechanism. Precisely, NF-κB induces 
transcription of the MAD-3 gene that gives rise to the nuclear regulatory protein IκB-
α. After its synthesis, nuclear IκB-α interacts with nuclear NF-κB dimers terminating 
thereby transcriptional activity of the latter in the absence of a new stimulus. The 
newly-formed IκB/NF-κB complexes migrate to the cytoplasm (Zabel et al. 1993).   
ii) The MAPK signalling pathways 
 MAPKs are protein kinases that commonly drive cellular processes, such as 
gene transcription, proliferation, differentiation, cell survival and cell death (Chang 
& Karin 2001). They are expressed in all cell types and monitor cellular responses 
associated with cell surface receptors e.g IL-1R1 and IL-4R. Mammals commonly 
express at least three families of MAPKs, namely ERK1/2 (Boulton et al. 1990), 
SAPK/JNK (Kyriakis et al. 1994) and p38 MAPK (Han et al. 1994, Rouse et al. 
1994). Their common characteristic is that they are activated by phosphorylation of 
the C-terminus at threonine and/or serine residues located laterally adjacent to 
another residue (x), consistent with the motif Thr-x-Ser. Moreover, all MAPKs 
possess a proline residue near phosphoacceptor sites probably serving as a 
recognition marker for kinase activators and inactivators. Activated ERK1/2 is 
signified by phosphorylation of the 202/185Thr-Glu-Tyr204/187 motif (Butch & Guan 
1996, Payne et al. 1991), activated SAPK/JNK by phosphorylation of 183Thr-Pro-
Tyr185 (Hibi et al. 1993, Lu et al. 1997) and p38 MAPK by phosphorylation of 
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180Thr-Gly-Tyr182 tripeptide (Dérijard et al. 1995). The phosphorylation/activation of 
each MAPK is coordinated by a specific MAPK kinase (MAPKK) such as MEK1/2 
for ERK1/2 (Crews et al. 1992, Zheng & Guan 1993), MKK3/6 for p38 MAPK 
(Dérijard et al. 1995, Stein et al. 1996) and MKK7 for SAPK/JNK (Moriguchi et al. 
1997). ERK1/2 is predominantly induced by growth factors such as EGF and insulin 
(Boulton et al. 1990, Boulton et al. 1991), whilst SAPK/JNK and p38 MAPK are 
commonly induced by cytokines, ultraviolet (UV) light and osmotic stress (Kyriakis 
et al. 1994, Rouse et al. 1994). The action of MAPKs is transient as 
dephosphorylation by MAPK phosphatases (MKPs) ensues in the absence of a new 
signal. MKPs can target more than one substrate, however with different efficiency. 
For example, MKP-1 dephosphorylates  p38 MAPK and JNK, thereby blocking UV 
apoptosis that these MAPKs trigger in U937 leukemic cells (Franklin et al. 1998). 
However, in the same cells, ERK2 inhibition by MPK-1 is less sensitive. Notably, 
MKP-1 can abrogate the PMA-induced c-Jun and AP-1 transcriptional activity (JNK 
and JNK/p38 MAPK targets respectively) to a higher degree relative to c-Myc and 
Elk-1, both transcription factors mediated mainly by ERK1/2. Importantly, MKP-1-
dependent inactivation of stress-associated MAPKs appears to be downstream of 
ERK2 activation, attesting to a cross-talk signalling mechanism among separate 
MAPKs (Franklin & Kraft 1997). Collectively, it is apparent that the proper 
communication of each separate MAPK with interacting signalling molecules and 
substrates is the key for specificity of each member of the MAPK family and 
prevention of impaired signalling that could be detrimental for the cell fate. In 
support of this, it has been recently realised that the successful interaction of MAPKs 
with interacting upstream and downstream molecules is coordinated by amino acid 
residues adjacent to the catalytic domain of the enzymes, the so-called MAPK-
docking sites. Remarkably, all the members of human MAPK family appear to 
interact with cognate activators, inactivators and substrates through a common 
domain near the C-terminus of the protein, the common docking (CD) site (Tanoue 
et al. 2000).  
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Intriguingly, whereas ERK1/2 MAPKs are involved in cell proliferation and 
survival, p38 MAPK and SAPK/JNK signalling pathways appear to promote pro-
apoptotic and cell death procedures. For example, in PC-12 cells (rat adrenal medulla 
tumour cell line) in vitro depletion of neuron growth factor (NGF), a rapid stimulator 
of mitogenic ERK1/2 (Boulton et al. 1991), resulted in activation of p38 MAPK and 
SAPK/JNK signalling pathways that in turn started apoptotic cascades (Xia et al. 
1995). Moreover, supplementation with forskolin, insulin or basic fibroblast growth 
factor, agents that suppress apoptosis through stimulation of ERK1/2 cascades, 
reversed p38 MAPK and JKN induced activity (Xia et al. 1995).  Notably, co-
transfection of the cells with p38 MAPK and its specific activator MKK3 (Fig. 1.13) 
in the presence of NGF notably increased p38 MAPK-dependent cell apoptosis (Xia 
et al. 1995). However, despite the similarities of the p38 MAPK and JNK with 
regard their stimuli and role in cell fate, they significantly differ in upstream (i.e. 
MAPKKs) and downstream molecules (i.e. substrates) they interact with (see below), 
suggesting that these pathways are either complementary or parallel.   
The specificity of separate MAPKs is also subject to their responsiveness to 
distinct stimuli and their activation by separate MAPKKs (see above). Several 
studies have constistently reported induction of JNK and p38 MAPK by IL-1 in 
many cell types. In the case of ERK1/2, it is mainly activated by phorbol esters, EGF, 
insulin and NGF (Boulton et al. 1991). For example, in COS cells, IL-1 activated 
MKK3, but it failed to activate MEK1, the MAPKK of ERK1. Moreover, IL-1 
induction of MKK3 increased p38 MAPK activity, an effect that was not reproduced 
when cells were treated with EGF, a proxy of the MEK-ERK system (Dérijard et al. 
1995). Interestingly, IL-1-induced MKK3 did not affect JNK activity either, proving 
that this MAPKK specifically impacts upon p38 MAPK (Dérijard et al. 1995). On 
the other hand, MKK4 was capable of activating both p38 MAPK and JNK (but not 
ERK1/2), attesting some cross-talk/parallel/common features of stressed-associated 
pathways (Dérijard et al. 1995). However, activation of ERK1/2 by IL-1 has been 
also reported in a number of cell systems such as HepG2, KB and HGF cells (Bird et 
al. 1991).  
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Additionally, all three groups of MAPKs target diverse substrates. ERK 
proteins regulate mitogenic-associated transcription factors such as Elk-1 and c-Myc, 
whilst p38 MAPK phosphorylates small heat-shock proteins (Freshney et al. 1994, 
Rouse et al. 1994) as well as the activating transcription factor-2 (ATF-2) and in 
some cases AP-1 (Raingeaud et al. 1995). Finally, SAPK/JNK activates c-Jun 
(Dérijard et al. 1994, Hibi et al. 1993, Kyriakis et al. 1994) but also, as p38 MAPK, 
AP-1 transcriptional activity (Dérijard et al. 1994, Moriguchi et al. 1997). For 
example, as expected, in HeLa cells, IL-1-induced p38 MAPK regulated ATF-2, but 
it did not affect c-Jun or c-Myc (Raingeaud et al. 1995).  
Numerous studies over the years have been identified the MAPKs that control 
transcriptional or translational regulation of various genes after treatment with IL-1. 
To acknowledge some of them, p38 MAPK has been reported to mediate IL-6 and 
prostaglandin production in human fibroblasts (Funakoshi et al. 2001). Moreover, in 
the same cell type, gelatinase synthesis (ECM component) has been shown to be 
disrupted upon p38 MAPK inhibition (Funakoshi et al. 2001). Furthermore, tissue 
PA (t-PA) activity appeared to involve ERK1/2 and p38 MAPK pathways in the 
osteosarcoma U2OS cell line (Chang et al. 2006). Also, in odogenic keratocyst 
fibroblasts, IL-1α-induced COX-2 mRNA appeared to be regulated by all three 
MAPKs cascades as well as NF-κB pathways (Ogata et al. 2007). 
Collectively, it is widely accepted that cell signalling transduction pathways 
are both distinct and common, depending on the end-point and cell type. A common 
stimulus can result in concomitant signalling cascades not only of all three MAPKs 
but also of other signalling networks such as the NF-κB signalling pathway for the 
regulation of a single gene. This effect is not necessarily reproduced in all cell 
systems. In general, regardless of the specificity that each separate signalling 
molecule can display, all together they encompass a complex and dynamic network 
that needs to cooperate accurately to secure cell homeostasis.   
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1.5.2 The IL-4 system and its signalling networks 
1.5.2.1 The IL-4 system: protein interactions and transactivation  
IL-4 is a T lymphocyte-associated cytokine produced mainly by Th-2 cells 
and thus is involved in several cell immune responses with principal role in 
ameliorating autoimmune and inflammation-associated diseases such as cancer 
through inhibition of Th-1 responses (Godfrey et al. 2000, Nagai & Toi 2000, 
Nakamura et al. 1997, Nelms et al. 1999). As mentioned above, IL-4 action is 
mediated through its coupling to the IL-4R that is expressed in several immune cell 
types as well as in epithelial cells, including the ovarian cell surface (Burke et al. 
1996, Lowenthal et al. 1988).  IL-4R belongs to the family of haematopoietin 
receptors and consists of two polypeptide chains; the IL-4Rα chain through which 
signalling transduction is initiated and the γ common (γc) chain that is responsible 
for the activation of signalling pathways by IL-4Rα (Harada et al. 1990, Mosley et al. 
1989, Russell et al. 1993).  
IL-4Rα is a 140kDa protein that contains type III fibronectin domains in an 
extracellular region rich in cysteine residues as well as two tryptophan, serine 
dipeptides surrounding another amino acid (x) (Trp-Ser-x-Trp-Ser or WSxWS) in the 
proximal membrane region. The latter is believed to maintain the conformation of the 
receptor in such a state where it is recognisable by the ligand (Bazan 1990). The IL-
4Rα chain has also a cytoplasmic domain that is characterised by a conserved 5-Tyr 
peptide and a short sequence with serine residues, termed the ‘box 1 motif’ 
(Murakami et al. 1991, Seldin & Leder 1994). The box 1 motif is located in the 
proximal membrane region and facilitates interaction with the receptor with Src-
related kinases (Minami et al. 1993). 
IL-4 binding to the IL-4Rα chain results in heterodimerisation with the 
70kDa γc chain that is responsible for the activation of downstream signalling 
cascades by IL-4Rα (Kammer et al. 1996, Letzelter et al. 1998). Interestingly, 
neither of the two chains have endogenous kinase activity; this role, however is 
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fulfilled by janous-family tyrosine kinases (Jak) that attach to cytoplasmic domains 
of the two chains upon IL-4 binding to the IL-4Rα (Smerz-Bertling & Duschl 1995). 
Jak-1 is associated with IL-4Rα, whilst Jak-3 with the γc chain (Miyazaki et al. 1994, 
Russell et al. 1994, Witthuhn et al. 1994). As a result, IL-4Rα is activated through 
the phosphorylation of the 4 cytoplasmic tyrosines. Site-directed mutations or 
truncations of the cytoplasmic domain of the IL-4Rα chain have identified that the 
conserved tyrosine (Y) 497 mediates cell proliferation (Keegan et al. 1994), whereas 
Y575, Y603 and Y631 are responsible for transcriptional regulation of IL-4-
responsive genes such as CD23 (Ryan et al. 1996). The general concept is that cell 
proliferation is mediated by the association of IRS1/2 with Y497 after 
phosphorylation and upon IL-4 binding to the receptor, as revealed in the myeloid 
cell line 32D (Keegan et al. 1994). IRS1/2 can then interact with the PI-3K 
regulatory subunit or with the Grb-2 adapter molecule initiating thereby PI-3K or 
ERK1/2 signalling pathways, respectively (Sun et al. 1993). Shc is another molecule 
that can bind to Y497 instead of IRS1/2 and is also capable of transducing ERK1/2 
MAPKs (Rozakis-Adcock et al. 1992). On the other hand, the attachment of STAT-6 
to Y575 and/or Y603 and/or Y631 triggers phosphorylation that in turn induces 
transcriptional activity of target genes (Reichel et al. 1997). Nonetheless, it should be 
noted that this is an oversimplified concept, as it has been shown that PI-3K can also 
be involved in the regulation of IL-4-responsive genes and on the other hand STAT-6 
could mediate cell survival. For example, the IRS1 pathway has been shown to 
participate in the regulation of immunoglobulin ε (Wang et al. 1997). Moreover, 
IRS1/2 molecules have been demonstrated to be members of the IL-4-induced 
machinery that led to stimulation of 3β-HSD1 in human  breast cancer cell lines 
(Gingras et al. 2000). Additionally, site-directed mutagenesis of the IL-4Rα chain at 
residues that function as docking sites for IRS1/2 molecules abolished not only the 
linkage of IRS1/2 to IL-4Rα but also of STAT-6 activation and induction of the 
CD23 IL-4-responsive gene (Wang et al. 1998). Therefore, the IL-4-related 
signalling network and responses may differ among cell types and this is part of the 
complexity hidden behind signalling transduction pathways. A simplification of the 
IL-4 signalling network is illustrated in Figure 1.14. 






Figure 1.15: The IL-4 signalling network. This cartoon gives an overview of the main 
molecules that take part in transactivation of IL-4R and associated signalling pathways. 
Binding of IL-4 in IL-4Rα results in heterodimerisation with γc chain and linkage to tyrosine 
kinases, Jak-1 and Jak-3 that in turn coordinate sequential phosphorylation of 
serine/threonine kinases which mediate transduction of IRS1/2 mitogenic pathway and 
STAT-6 gene regulation pathway. However, participation of IRS1/2 in STAT-6-mediated 
gene transcription and of STAT-6 in IRS1/2-driven cell proliferation cannot be excluded.  
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1.5.2.2 IL-4-associated signalling transduction pathways 
i) The IRS1/2 signalling pathway  
 As aforementioned, IRS1/2 phosphorylation is induced by its attachment to 
Y497 of the IL-4Rα chain and functions as a docking protein for the initiation of 
signalling cascades that may result either in activation of PI-3K or ERK1/2 kinases 
or parallel activation of both (Sun et al. 1993).  
  The PI-3K protein is a heterodimer that consists of two subunits; the 
regulatory p85 (85kDa) subunit (Escobedo et al. 1991) and the catalytic p110 
(110kDa) subunit (Hiles et al. 1992, Otsu et al. 1991). Interactions between p85 and 
p110 subunits are achieved through a 104aa sequence in the C-terminal domain of 
p85 and a 88aa region of the N-terminal domain of p110 subunit (Dhand et al. 1994). 
In essence, a Tyr-Met-x-Met motif of the phosphorylated IRS1/2 signifies the 
linkage of p85 subunit to the IRS1/2 and thus it functions as an intermediate that 
associates tyrosine phosphorylated IRS1/2 with p110 catalytic subunit (Sun et al. 
1993). Once catalytically active, the p110 subunit is capable of triggering 
phosphoinositide production that in turn mediates processes such as cell survival and 
protein synthesis through Ser/Thr phosphorylation of kinases such as PKC and 
PKB/Akt (Dudek et al. 1997, Franke et al. 1997). 
 The ERK1/2 is another downstream activating pathway of the IL-4-induced 
IRS1/2 (Skolnik et al. 1993). In particular, ERK1/2 activation is achieved through 
the adapter molecule Grb-2 that recognises the phosphorylated Tyr-Val-Ile-Asn 
motif of IRS1/2 (Sun et al. 1993). As such, ERK1/2 MAPKs initiate their mitogenic 
effects as described above. However, ERK1/2 is not constantly triggered by IL-4. For 
example, IL-4 does not activate ERK1/2 MAPKs in MC-9, FDC-2 and R6X 
haematopoietic cell lines (Duronio et al. 1992). Also, IL-4-associated cell 
proliferation are not mediated through activation of ERK1/2 in either FDMAC11 and 
CT.4S murine myeloid cell lines or primary T cells and mast cells obtained from 
mice (Welham et al. 1994). 
Chapter 1                                                     General introduction and literature review 
72 
 
 An alternative mechanism for the activation of ERK1/2 by IL-4 is through the 
linkage of the IL-4Rα with Shc, a docking protein that shares similar structural 
characteristics with IRS1/2 docking proteins (Zhou et al. 1995a, Zhou et al. 1995b). 
Precisely, Shc contains one C-terminal and one N-terminal region that can interact 
with tyrosine-phosphorylated molecules such as Jak-3/IL-4Rα and Grb-2 
respectively (Rozakis-Adcock et al. 1992, Songyang et al. 1993, Zhou et al. 1995b). 
Grb-2 adapter recognises phosphorylated Y317 of Shc and thus initiation of ERK1/2 
signalling cascades are fulfilled (Rozakis-Adcock et al. 1992). 
ii) The STAT-6 signalling pathway 
 As referred to above, STAT-6 activation by IL-4-transduction of IL-4Rα is 
implicated in activation of Th-2 responses as well as the transcription of target genes 
such as CD23, immunoglobulins ε and γ (Reichel et al. 1997, Ryan et al. 1996, 
Shimoda et al. 1996). STAT-6 interaction with IL-4Rα is achieved by the binding of 
the N-terminus of one or more STAT-6 molecules to three phosphorylated tyrosines 
(Y575, Y603, Y631) located in a region between 557 and 657 amino acids of the 
cytoplasmic domain of IL-4Rα chain (Fig. 1.14) (Wang et al. 1996). Upon binding of 
STAT-6 to IL-4Rα, the former is phosphorylated in the C-terminal domain resulting 
in its dissociation from the receptor. As such, it triggers homodimerisation with the 
C-terminus of a second STAT-6 molecule through its docking sites in the N-terminus. 
Homodimers then translocate to the nucleus where they bind to STAT-6 response 
elements of target genes (Mikita et al. 1996, Schindler et al. 1995).  
 It appears that STAT-6 is a critical component of IL-4 signalling as STAT-6 -
/- mice display impaired IL-4 activity. For instance, in STAT-6 deficient mice, IL-4 
was unable to induce transcriptional activity of target genes such as CD23 and 
immunoglobulin ε and also could not promote Th-2 responses (Takeda et al. 1996). 
Remarkably, dysfunction of STAT-6 and not of IL-4R was demonstrated to be 
responsible for impaired IL-4 signalling (Takeda et al. 1996) 
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1.6 Summary of Chapter 1 and Scope of Thesis 
 As discussed above, hOSE is a very functional and dynamic tissue that 
physiologically undergoes cyclical tissue remodelling prior to and post-ovulation. It 
is capable of secreting and receiving hormones, cytokines and growth factors and its 
homeostasis is subject to mutually interrelated endocrine, paracrine and intracrine 
signalling of these molecules. 
 As detailed, progesterone and progesterone-associated events are protective 
in the development of ovarian cancer. On the other hand, androgens and androgen-
associated situations are considered as risk factors for the initiation of the disease. 
Moreover, immune mediators appear to impact upon the steroid hormonal milieu of 
the OSE and inflammatory-associated events such as ovulation promote neoplastic 
transformation of the ovarian cell surface. The elucidation of the pro-inflammatory 
and anti-inflammatory steroid mechanisms occurring physiologically in the OSE 
could improve the poor prognosis of EOC and contribute to the diagnosis and 
treatment of this fatal disease (Rae & Hillier 2005, Rae et al. 2004b). Regarding this, 
and as mentioned above, from a screen of inflammatory-associated markers in hOSE 
cells, it was shown that IL-1α suppressed 3β-HSD1 mRNA, one of the 3β-HSD 
isoforms that drives intracrine generation of progestogens and androgens (Rae et al. 
2004b).  This observation suggested that the 3β-HSD enzyme is under inflammatory 
control and as such functionality of this enzyme may be critical for hOSE 
homeostasis. Although, the relevant contribution of 3β-HSD1 and 3β-HSD2 
expression to 3β-HSD enzymatic activity is unknown, total 3β-HSD activity in hOSE 
is expected to determine the availability of progesterone and androgen for signalling 
via nuclear progesterone (PR) and androgen receptors (AR), respectively. Thus, the 
scope of this thesis is to investigate the regulation of pre-receptor metabolism and 
downstream signalling of progesterone and androgens, focusing on 3β-HSD1 and 3β-
HSD2 mRNAs, total protein and activity along with the PR and AR in normal hOSE 
and EOC.  
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To undertake our studies, we used i) primary hOSE cells that were collected 
from pre-menopausal women who undertook surgery for benign gynaecological 
conditions and ii) primary ovarian cancer cells that were obtained from women who 
were diagnosed with EOC. 
 Therefore, our central aim can be divided into the following objectives: 
a) Investigation of expression pattern of functional 3β-HSD in the human 
ovarian surface epithelium in vivo and in vitro. 
b) The study of the regulation of 3β-HSD1 and 3β-HSD2 mRNA and total 
protein and activity by ovarian-associated pro-inflammatory and anti-
inflammatory cytokines in primary hOSE cell cultures. 
c) The elucidation of transduction signalling pathways through which cytokines 
affect 3β-HSD1 and 3β-HSD2 transcriptional function in primary hOSE cell 
cultures. 
d) The evaluation of the regulation and transduction of AR and PR mRNA by 
cytokines that impact upon 3β-HSD1 and/or 3β-HSD2 in primary hOSE cell 
cultures. 
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2.1 Tissue Culture 
2.1.1 Subjects  
2.1.1.1 Physiology (normal ovary) 
hOSE cells for in vitro experimentation or ovarian tissue for histological 
studies were obtained from pre-menopausal women who underwent surgery for 
benign gynaecological disorders, such as fibroids, heavy menstruation and pelvic 
pain. Subjects who had evidence of endometriosis or receiving any medication that 
could affect ovarian physiology were excluded from this study as previous reports 
documented the possibility of lesions in cells collected from endometriotic patients, 
although they probably might possess good growth potential (Auersperg & Maines-
Bandiera 2000).  Formal written consent was submitted by all experimental patients 
and the project was approved by the Lothian Research Ethical Committee (LREC; 
project numbers 1998/6/331, 05/S1103/142, 04/S1103/33). Basic clinical information 
of each patient used for our studies is given in the respective Chapters.  
2.1.1.2 Diseased ovary (ovarian cancer) 
 Cancer material was recruited from patients who were diagnosed with 
ovarian cancer after diagnostic laparotomy. Solid ovarian tumours and freshly 
isolated ascites were either plated for in vitro culture or were fixed and embedded in 
paraffin blocks for histological assays. Histological, staging and grading assessment 
of ovarian cancers was performed by Professor Alistair Williams, Royal Infirmary of 
Edinburgh (RIE) Department of Pathology. Individual details for each patient are 
denoted in Chapter 8. Formal written consent was obtained from all patients tested 
                                                 
1 Principal Investigator Professor Hilary Critchley. 
2 Principal Investigator Professor Hilary Critchley. 
3 Principal Investigator Dr Scott Fegan. 
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and studies were performed according to LREC regulations (project number 
04/S1103/444). 
2.1.2 Establishment of cell monolayers 
 Primary hOSE cells and primary ascites were cultured as previously 
described (Dunfield et al. 2002, Hillier et al. 1998, Kruk et al. 1990). Ovarian 
surface epithelial cells were scraped from the ovary at an early stage of the surgery to 
minimise any contamination with blood and stromal cells. ‘Flakes’ of hOSE cells 
were then inoculated into culture medium (see below) and transferred to the 
laboratory. Epithelial cells were grown in donor calf serum (DCS) pre-coated T75 
flasks (Corning Inc. Glass Works; Corning NY) containing MCDB 105: M199 media 
(1:1 v/v), 15% (v/v) fetal bovine serum (FBS), 2mmole/L L-glutamine, 50μg/mL 
streptomycin and 50IU/mL penicillin (all obtained from Life Technologies, Inc., 
Renfrewshire, UK, Sigma Chemical Co., Poole, UK and Cambrex, Berkshire, UK) in 
a humidified tissue culture incubator gassed with 95% air-5% CO2 at 37oC. Medium 
was refreshed every seven days. This cell culture protocol allowed cells to reach 
confluency between 2 and 4 weeks (Hillier et al. 1998). A further advantage of 4-
week cell culture in FBS-containing medium prior to experimentation was 
neutralisation of any disparity of different hormonal levels among individual patients 
that could be encountered as a result of cell collection at different stages of the 
menstrual cycle (Rae et al. 2004a, Yong et al. 2002). This step appeared essential, 
since the use of multiple patients to produce sufficient replicates for each distinct 
experiment allowed us to overcome restrictions in cell numbers along with 
limitations in long-term culture of cells from the same subject. Moreover, all the 
conclusions we make are based on the reproducibility of data obtained from at least 
three separate patients and therefore are potentially reflective of a broader in vivo 
physiology.      
                                                 
4 Principal Investigator Dr Scott Fegan.  
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The purity of epithelial cultures was confirmed with phase-contrast 
microscopy. Further confirmation that this system gave high purity epithelial 
cultures was checked in selective cases by staining with a mouse monoclonal 
antibody that immunoreacts with cytokeratins 5, 6, 8 and 17 or a mouse monoclonal 
that recognizes cytokeratin 7 (Auersperg et al. 2001, Rae et al. 2004b, van Niekerk 
et al. 1991). After the establishment of confluent cellular monolayers, the culture 
medium was removed and cells were washed with Dulbecco’s phosphate-buffered 
saline (DPBS; Sigma) and enzymatically digested by incubation in 5mL 
trypsin/EDTA (Sigma) in Hank’s balance salt solution (HBSS; 0.05% w/v trypsin, 
0.5 mM EDTA) at 37oC for 5min. The resultant cell suspension was washed with 
10mL DPBS and transferred to universal eppendorf tubes (Sterilin, Birmingham, 
UK). After centrifugation at 800 g for 3min, the supernatant was discarded. This step 
was repeated twice after re-suspension of cells in 5mL DPBS. The cells were then 
re-suspended in 1mL pre-warmed FBS-containing culture medium and the cell 
number counted using a haemocytometer. Cell viability was assessed used trypan 
blue (Sigma) staining exclusion criteria. The viability of both primary hOSE cells 
and ascites ranged between 85 and 95%. Cell suspensions were then taken forward 
for experimentation.  
2.1.3 Experimental treatments 
 Cell suspensions were adjusted to 3.5x105 viable cells per well (35 mm) of 6-
well culture plates for mRNA and protein studies or 105 viable cells per well of 12-
well plates (Corning) for 3β-HSD activity assays. After establishment of a cell 
monolayer (24h), the culture medium was replaced with serum-free medium 
containing 0.01% bovine serum albumin (BSA) instead of FBS for 24h. Cells were 
then exposed to the agents of interest (cytokines and/or signalling pathway 
inhibitors). Incubation times and concentrations applied are denoted in the relevant 
experiments. In all experimental sets, cells receiving no treatment were used as the 
control.  
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2.1.4 Cell harvest 
 For mRNA studies after experimental treatments, the cell monolayers of 6-
well plates were washed twice with 1mL DPBS. Homogenisation of cells was 
achieved by lysis in 0.35mL guanidine thiocyanate-containing buffer (lysis buffer, 
RLT; Qiagen, West Sussex, UK) supplemented with 0.01% β-mercaptoethanol 
(Sigma). The resultant cell lysate was transferred to a 2mL eppendorf tube. To 
maximise lysis and thus RNA recovery, the lysates were vortexed vigorously for 
2min. Lysates were then processed for RNA purification using the RNeasy Mini kit 
(Qiagen) per manufacturer’s guidelines (see below).   
 For protein assays, hOSE cell monolayers were washed with cold PBS and 
lysed in 50mM Tris-HCl pH 7.6, 0.1% sodium dodecyl sulfate (SDS), 1% 
deoxycholate (all from Sigma) and containing a cocktail of proteinase inhibitors 
(Roche Diagnostics Gmbh, Manheim, Germany). Lysis was performed on ice and 
proteins were kept at -80oC until further use. 
2.2 Histological Studies 
2.2.1 Haematoxylin and eosin staining 
 Paraffin wax-embedded tissues were cut into 3μm sections and deparaffinised 
in xylene (2X5min), rehydrated in serial dilutions of ethanol (100, 95, 70 and 50%; 
1min each) and washed in PBS (Sigma) and distilled H2O (2x5min). Then, nuclei 
were stained in haematoxylin (Sigma) for 20sec followed by removal of excess stain 
in tap H2O. Sections were then soaked in eosin for 20sec that specifically stains 
cytoplasm. Sections were washed well in tap H2O prior to dehydration in sequential 
dilutions of ethanol (50, 70, 95 and 100%; 1min each) and cleaning with xylene 
(2X5min). Slides were mounted with Pertex (Sigma) and when dried were visualised 
in an Olympus Provis microscope (Olympus Optical, London, UK).   
 




 Immunocytochemistry is an experimental method that allows investigation of 
the presence or absence of a protein in situ in cultured cells or tissue.  The 
development of this approach is based on the antigen-antibody complex that 
naturally occurs in living organisms.  In particular, a primary antibody specifically 
raised to recognise the target protein (antigen) is applied to the cells or tissue of 
interest.  Then, a secondary antibody against the species in which the primary 
antibody was raised is added to bind the primary antibody. The secondary antibody is 
usually labelled with biotin that allows the recognition and amplification of the 
signal with tertiary antibodies (i.e. avidin-biotin complex; ABC) conjugated to 
horseradish peroxidise (HRP). Finally, a substrate that specifically interacts with 
HRP is added allowing visualisation (colourimetric reaction) of the signal (Boenisch 
2001).  Furthermore, the secondary antibody can be labelled with a fluorescent dye, 
namely Alexa Fluor dyes (usually distributed from Molecular Probes, Poort Gebouw, 
Netherlands). These dyes fluoresce at different wavelengths (colours) across the 
spectral range. As such, this method can be routinely used to target more than one 
protein in the same cell monolayer or tissue section.    
2.2.2.1 Colourimetric immunohistochemistry 
 Sections deparaffinised in xylene, serial dilutions of ethanol, PBS (Sigma, 
Poole, UK) and distilled H2O were permeabilised by pressure cooking (20min) or 
microwaving (15min) in pre-heated 0.01M sodium citrate buffer pH 6.0 (Sigma) 
followed by cooling for a further 20min under running tap H2O. In selective cases 
permeabilisation was not performed. Sequential blocking steps of endogenous 
peroxidase (3% H2O2 in dH2O (v/v); Sigma) and avidin, biotin (Vector, Peterborough, 
UK) were then carried out. Each step was followed by PBS washes (2X). Afterwards, 
slides were submitted to blocking with non-immune normal goat serum (NGS; 
Sigma) diluted in PBS (1:5 v/v) containing 5% (w/v) BSA for 20min followed by 
overnight incubation at 4oC with a rabbit polyclonal antibody raised against 
recombinant human 3β-HSD2 (Thomas et al. 2002b). The dilutions of the 3β-HSD 
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antibody are denoted in the relevant Chapters. Immunostaining with anti-human 
mouse monoclonal cytokeratin 7 or anti-human mouse monoclonal cytokeratin 5, 6, 
8, 17 (Dako, Ely, Cambridgeshire, UK) diluted 1:1000 in NGS/PBS/BSA at 4oC was 
also performed. Negative antibody staining controls incubated with matched 
concentrations of unconjugated rabbit or mouse IgG1 antibody respectively (Vector, 
Peterborough, UK) were included routinely. Sequential incubations with anti-rabbit 
or anti-mouse biotinylated IgG1 (Vector) and RTU-ABC elite kit (avidin-biotin 
complex; HRP conjugated; Vector) were each conducted for 1h before removing 
excess antibody with PBS supplemented with 0.05% Tween 20 (v/v) (PBST; Sigma). 
Sections were washed three times with PBST between steps. Finally, slides were 
incubated with HRP-conjugated diaminobenzidine (DAB; Vector) chromagen for 
5min and after haematoxylin counterstaining, dehydration in serial ethanol dilutions 
(50-100%) and xylene was conducted. Antral ovarian follicles served as positive 
controls for 3β-HSD (Suzuki et al. 1993). The immunostained sections were 
visualized with an Olympus Provis microscope. 
2.2.2.2 Fluorescence immunohistochemistry 
 Cells were passaged into 8-well glass chamber slides (Nunc Lab-Tek; 
Leicestershire, UK) at a density of 25,000 cells/well and incubated at 37oC/5%CO2 
for 24h.  After serum-depletion overnight with medium containing 0.01% BSA 
(Sigma) instead of FBS, cells were fixed in 100% ice-cold methanol at -20oC for 
10min followed by permeabilisation with ice-cold acetone at -20oC for 1min. 
Sections of ovarian tissues and freshly isolated ascites pellets were processed as 
above with minor modifications. Incubation with 3β-HSD antibody or unconjugated 
rabbit IgG1 antibody (negative control) diluted in 1:400 in NGS/PBS/BSA preceded 
immunodetection with anti-rabbit IgG1 antibody directly conjugated to Alexa Fluor 
546 (1:200 in PBS; Molecular Probes, Poort Gebouw, The Netherlands), which 
provides red fluorescent positive staining. After non-immune blocking, incubation 
with the anti-human mouse monoclonal cytokeratin 7 antibody or the mouse 
monoclonal cytokeratin 5, 6, 8 and 17 antibody at 4oC overnight (1:300 in 
Chapter 2                                                                                    Subjects and methods 
82 
 
NGS/PBS/BSA) followed by immunodetection with anti-mouse IgG1 antibody 
conjugated to Alexa Fluor 488 (1:200 in PBS, Molecular Probes) was performed to 
yield green fluorescent cytokeratin-positive staining. Slides were counterstained with 
a nuclear-specific blue fluorescent label, 4,6-diamidino-2-phenylindole (Dapi; 
Sigma) in 1:1000 dilution in PBS for 10min. Mounting was achieved with 
Permafluor Aqueous Medium (Beckman Coulter, High Wycombe, Buckinghamshire, 
UK). Images were captured with a Zeiss LSM 510 Meta Axiovert 100M confocal 
microscope (Carl Zeiss Ltd., Welwyn Garden City, UK) at 40X magnification.  
 Similarly, PR staining was achieved with a commercial mouse anti-human 
antibody (Novacastra, Newcastle, UK) diluted 1:80. The AR antibody (Santa-Cruz 
Biotechnology, Heidelberg, Germany) was used at a 1:100 (v/v) dilution and was 
detected by sequential incubation of biotinylated goat anti-rabbit IgG1 followed by 
avidin Alexa Fluor 488 (Molecular Probes). 
2.3 Molecular Studies 
2.3.1 RNA purification 
 RNA extraction was performed using the RNeasy Mini kit (Qiagen). This kit 
allows the purification of RNA longer than 200nt and is based on the selective 
binding properties of a silica-gel membrane. Addition of 70% ethanol and pure 
ethanol to the samples and the washing buffer (RPE), respectively, was performed to 
provide conditions where RNA binds to the silica-gel membrane and the majority of 
contaminants are washed away (RNeasy Mini Handbook).  
After cell harvesting, RNA extraction was performed according to the 
manufacturer’s guidelines (see Appendix 1). The protocol involved the addition of 
washing buffers (RW and RPE), followed by successive centrifugations. These steps 
resulted in the separation of the RNA from any contaminants. Finally, RNA was 
eluted in 30μl RNase-free water. In order to preclude the presence of any DNA 
which could negatively influence the accuracy of the results in PCR, DNaseI 
Chapter 2                                                                                    Subjects and methods 
83 
 
digestion was carried out using the Qiagen RNase-Free DNase set, on the column 
during RNA purification. RNA was stored at -80oC until required. 
2.3.2 RNA quantity/quality assay 
 Purified RNA was quantified using a Nanodrop spectrophotometer (ND-1000, 
Nanodrop Technologies Inc, Wilmington, DE, USA). Specifically 1.5μL RNA was 
loaded on to an optical fibre to measure its ultraviolet (UV) absorbance. The RNA 
concentration was measured at 260nm. To ascertain purity of the RNA, two 
absorbance ratios were also assessed - the 260/280 and 260/230 ratios to evaluate 
protein and genomic contamination, respectively. Purified RNA samples were used 
further only when the ratios were above 2.0. 
2.3.3 Semi-quantitative reverse transcription polymerase chain reaction (PCR) 
 The presence of gene expression (mRNA) of 3β-HSD1, 3β-HSD2, AR and 
PR mRNA was examined through reverse transcription (RT) and semi-quantitative 
polymerase chain reaction (sqPCR). GAPDH was also used as a loading control. 
DNase-treated RNA was reverse-transcribed to cDNA using the Superscript 
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Reagent Final concentration/volume in the 
reaction mixture 
RT buffer 1 X 
MgCl2 5.5mM 
oligo dT 0.025μg/mL 
0.1M DDT 5mM 
dNTP mix 0.5mM 
RNase Out 2U/μL 
Reverse superscript III transcriptase 10U/μL 
2μg RNA+ H2O 11μL 
Final volume 20μL 
  
 The RNA, oligo dT and dNTP set were incubated at 65oC for 5min 
(annealing of oligo dT) before the addition of the other reagents. A reaction without 
reverse transcriptase (RT-ve) for each initial sample was also used as a negative 
control to ascertain the absence of any genomic contamination. Samples were placed 
on a thermal cycler (Techne, New Jersey, USA) and a cycle was carried out at 50oC 
for 50min (reverse transcription) and at 70oC for 15min (deactivation of RT enzyme, 
denaturation of RNA-cDNA and RNA degradation).  
In order to examine the expression of target genes, cDNA was gene-specific 
PCR-amplified in a 25μL reaction mixture, containing 1X Promega Mastermix 
(Southampton, UK), 2pmol/mL of the specific forward and reverse primer set, 2μL  
cDNA and  DNase-free H2O up to 25μL (final concentrations in the reaction 
mixture). The sequences of each pair of primers and the expected sizes of the 
amplicons are listed in Table 2.1. A reaction with no reverse transcriptase for each 
initial sample was used as a negative control (RT-ve). The annealing temperature on 
the PCR instrument (Techne) was optimised according to the melting temperature 
(Tm) of each primer based on the formula Tm=2oC (A+C) + 4oC (G+C). Therefore, 
samples were PCR-amplified as follows: 




-Initial Denaturation at 94oC for 3min 
37 cycles 
-Denaturation at 94oC for 3min 
 -Annealing: 3β-HSD1 60oC, 3β-HSD2 60oC, AR 60oC, PR 56oC, GAPDH   
60oC for 30sec 
-Extension at 72oC for 1min 
1 cycle 
- Final Extension at 72oC for 5min 
 
 PCR amplicons were electrophoresed in a 1.5% agarose gel at 100V and 
lanes were visualised with 0.03μg/μL (final concentration in the agarose gel mixture) 
ethidium bromide (Sigma) staining under UV light and were assessed with a 100bp 






















Table 2.1 Sequences of sqPCR primers 
Gene FW Primer  
(5’-3’) 











































431 60 BC_083511.1 
       FW: forward, RV: reverse, bp: base pairs, Tm: melting temperature 
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2.3.4 Quantitative reverse transcription polymerase chain reaction (Taqman)  
Two-step Taqman quantitative PCR (qPCR) was performed to measure the 
transcription levels of human 3β-HSD1, 3β-HSD2, IL-1R1, IL-4R, AR, PR, LOX 
and COX-2 mRNA. 
Using a first strand cDNA synthesis kit (AB Applied Biosystems, Applera, 
UK), DNase-treated RNA was reverse transcribed to cDNA in a 10μL reaction 
mixture as follows: 
Reagent Final concentration in the 
reaction mixture 
RT buffer 1X 
MgCl2 5.5mM 
Random hexamers 2.5μM 
RNase inhibitors 0.4U/μL 
dNTP mix 200μM 
Taqman reverse transcriptase 1.25U/μL 
200ng RNA 40-50ng 
RNase-free H2O Up to 10μL 
Final volume 10μL 
  
 Oligo dT primer was not added, since in qPCR, 18S, which does not have a 
poly-A tail, was used as an internal reference. A reaction without reverse 
transcriptase (RT-ve) and a reaction with RNase-free H2O instead of RNA were also 
run to preclude potential genomic or reagent contaminations, respectively (negative 
controls). One cycle was carried out at 25oC for 1h (annealing of random hexamers), 
one cycle at 48oC for 45min (reverse transcription) and one at 95oC for 5min 
(deactivation of RT enzyme, denaturation of RNA-cDNA double strand and RNA 
degradation).  
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Following cDNA synthesis, transcription levels were assessed through 
Taqman Real-Time qPCR. qPCR is a sensitive and reproducible method that detects 
the amount of the product that is amplified relative to the amount of the initial 
template in each cycle of the PCR. The major advantage of this technique is the 
measurement of the kinetics of the reaction in the early phases of the PCR-
amplification (exponential-growth phase) and the detection of even a two-fold 
change (two copies of the product) (Applied Biosystems 2005). In this regard, the 
different amounts of each product at any given cycle number and not at an end-point 
can be determined.    
Real-Time PCR is based on the detection and quantification of a fluorescent 
signal emitted by a fluorescent reporter incorporated in a hydrolysis probe as a result 
of the 5’-exonuclease activity of the Taq polymerase (see below). There are three 
current forms of hydrolysis probes; i) molecular beacons, ii) scorpions and iii) 
Taqman probes (Dorak 2004).  In our methodology, Taqman probes were used as 
fluorescent reporters. 
The Taqman probes are 20-30bp oligonucleotides and are complementary to 
a sequence surrounded by the forward and reverse primers of the target genes. These 
probes are labelled with the fluorescent dye FAM on the 5’- end and the quenching 
dye TAMRA or MGB on the 3’- end. In each reaction, when the probe is intact, 
energy is transferred from its 5’- fluorescent molecule to its 3’- quenching molecule, 
a procedure known as FRET (fluorescence resonance energy transfer).  In contrast, 
when the probe is bound on the replicating template, Taq polymerase cleaves the 5’- 
end of the probe due to its 5’- exonuclease activity. Therefore, FRET ceases and 
fluorescence starts to be emitted proportionally to the probe cleavage (Fig. 2.1) 
(Applied Biosystems 2005, Bustin 2002, Bustin & Nolan 2004, Dorak 2004, 
Ginzinger 2002).  
 
 





Figure 2.1: Function of Taqman probes. The probe anneals to a sequence of the target 
gene between the forward and reverse primers. FRET is generated between the 5’- and 3’- 
end of the intact probe, until the polymerase cleaves the 5’- end of the probe while it adds 
bases to the growing strand of DNA. Therefore, fluorescence is released proportional to the 
probe cleavage. Taken from Ginzinger (2002). 
For the optimization of the results, the ribosomal RNA 18S was used as an 
internal control. The 18S probe was labeled with VIC dye, since FAM and VIC have 
the largest difference in emission maximum (Dorak 2004). 
cDNA (2μL) was used for qPCR, using commercial Applied Biosystems 
reagents. Each reaction was carried out in duplicate. The primers were pre-validated 
(Assay-On-Demand systems, Applied Biosystems) or were designed using the 
Primer-Express software (Perkin-Elmer, Beaconsfield, Bucks, UK). Details of the 
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primers/probes sets are listed in Table 2.3. Each reaction was run in a 25μL mixture 
containing the following (final concentrations): 
• 1X of the universal 2X Taqman mastermix  
      -PCR buffer 10X 
-5.5mM MgCl2  
-200μM dNTPs (400μM dUTP) 
-1.25U/μL AmpliTaq DNA Polymerase,  
-Uracil-N-glycosylase (UNG) 
• 50nmol/L 18S forward and reverse primers and probe mixture 
• 20X of the assay-on-demand primers and probe mixture of the target genes 
(AB Applied Biosystems) 
•  nuclease-free H2O up to 23μL 
A RT-ve, a RT-H2O control (both come from reverse transcription) and a non-
template control (NTC, 2μl nuclease-free H2O instead of cDNA) were used as 
negative controls in each run (Applied Biosystems 2005, Dorak 2004). 
Taqman reactions were carried out in an ABI Prism 7900 Sequence Detector 
(AB Applied Biosystems, Warrington, UK) following the default protocol (Dorak 
2004, Applied Biosystems Manual):  
1 cycle  
- 50 oC for 2min for the activation of UNG [UNG prevents re-
amplification of carry-over PCR products by removing any uracil 
incorporated into amplicons (Dorak, 2004) 
1cycle 
- 95oC for 10min (Taq Polymerase activation) 
40 cycles 
- Denaturation at 95oC for 15sec  
- Annealing and extension at 60oC for 1min  
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Data displayed in linear and logarithmic plots were analysed using the ABI 
Prism 7900 Sequence Detector Software. More precisely, the cycle at which the 
fluorescent signal of the sample (point at which the amplicon starts to be 
accumulated; threshold cycle (CT)) was sufficiently greater (>10standard deviations) 
than the baseline fluorescence (fluorescent signal that is below the limit of detection 
of the instrument) was assessed. Since 18S amplification started very early in each 
run, the baseline for 18S was adjusted between 3 and 8 cycles (start and stop baseline 
values respectively), whereas the baseline of the target genes was, by default, from 
cycles 3-15. The CT was always adjusted within the exponential-growth phase above 
any baseline value (Fig. 2.2) and according to the CT of the internal normaliser (18S). 
This assessment also reflected the cycle at which each separate sample was 
significantly PCR-amplified above the baseline (CT value for each sample). 
Therefore, the CT was set in such a way that replicate CT values were as close as 
possible (Applied Biosystems 2005, Bustin 2002, Bustin & Nolan 2004, Dorak 2004, 















Figure 2.2: Logarithmic amplification plot of a Taqman qPCR run. Detection of the 
amplification of each sample at the exponential-growth phase and not at an end point 
(plateau range). The critical parameters for an efficient analysis are illustrated in the figure. 
Threshold cycle has been set up within the exponential growth phase of the reaction, in a 
way where CT values of replicates are tight. Baseline has been adjusted from 3 to 15 cycles 
(default). Taken from http://docs.appliedbiosystems.com/pebiodocs/04364014.pdf. (2005). 
 The Ct values were used to calculate the abundance of the mRNA of each 
sample.  Firstly, the difference between the CT of the target and the internal control 
was calculated (dCT). As each sample was run in duplicate, the mean dCT was 
ascertained. Then, the mean dCT of the control (sample with no treatments) was 
subtracted from the mean dCt of each sample (ddCT). Finally, the relative copy 
number between the control and each sample was determined by the formula 2-(ddCT). 
            
 




Table 2.2 Sequences of primer/probes sets for qPCR 
Gene FW Primer 
 (5’-3’) 






































































                                    FW: forward, RV: reverse 
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2.4 Protein and Activity Studies 
2.4.1 Protein quantification 
 After homogenisation of cells in protein lysis buffer as described in section 
2.1.4, cell extracts were prepared by sonication for 20sec. A sample of protein 
(20μL) was removed, diluted in distilled H2O 1:50 and quantified with the Bradford 
assay (Bradford 1976) in duplicate using a Cobas Fara analyser (Roche Diagnostics 
Gmbh, Manheim, Germany). Quantification was carried out after the addition of 
Coomassie Brilliant Blue solution (100mg Coomassie Brilliant Blue G-250 in 50mL 
95% ethanol added to 100mL 85% (w/v) phosphoric acid) to the protein samples 
followed by measurement of the absorbance at 595nm. This protein evaluation 
method is based on the finding that the binding of an acidic solution of Coomassie 
Brilliant Blue to a protein is accompanied by a change in absorbance from 465nm to 
595nm. As such, interactions (hydrophobic and ionic) stabilise the anionic form of 
the dye, producing a visible colour change (Bradford 1976, 
http://www.ruf.rice.edu/~bioslabs/methods/protein/bradford.html (2008)). 
2.4.2 Western immunoblotting 
 Total protein (25μg/μL) was size-fractionated by electrophoresis (12% 
SDS/PAGE) and transferred to a PVDF membrane (Millipore, Bedford, MA, USA) 
followed by blocking in 5% dried semi-skimmed milk diluted in PBS containing 
0.05% Tween 20 (PBST) for 2h. An overnight incubation at 4oC with anti-human 
rabbit 3β-HSD (1:20,000) or with anti-human rabbit AR (1:1000) or anti-human 
rabbit actin (1:1000; Abcam, Cambridge, UK)  diluted in 1% dried semi-skimmed 
milk/PBST was followed by 1h-incubation with anti-rabbit IgG1 conjugated to HRP 
(Sigma) in 1:10,000 in 1% milk/PBST. Immunoreactive proteins were detected by 
the enhanced chemiluminescence (ECL) detection kit (Millipore). Human placenta 
(Thomas et al. 1989, Thomas et al. 1988) and human H295 adrenocortical cells 
(Rainey et al. 1994)  were used to ascertain that the 3β-HSD antibody detected both 
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human isoforms. The breast cancer T47D cell line was used as positive control for 
AR (Buchanan et al. 2005, Chalbos et al. 1987). 
2.4.3 3β-HSD activity assay 
After treatments cell monolayers were prepared for 3β-HSD enzymatic assay 
with minor modifications to that previously described (Gingras et al. 1999). 
Treatment media were removed and 1mL serum-free medium containing 0.5μM 
pregnenolone (Preg) and 150,000cpm/μL 3[H]-Preg were added to initiate a reaction 
reflecting 3β-HSD dehydrogenase/isomerase activity. Culture medium with no cells 
inoculated with Preg and 3[H]-Preg as well as Prog and 3[H]-Prog were also included 
and served as standards. After incubation at 37oC for 8h, the medium was transferred 
to a 12mL glass centrifuge tube and mixed well with dichloromethane (8mL) to 
extract steroids into the organic phase. Then, samples were centrifuged at 2,000rpm 
for 15min, the aqueous phase was removed and the organic phase (containing the 
steroids) was concentrated under a nitrogen stream. After reconstitution in 100μL 
dichloromethane and vigorous vortexing, samples were applied to silica-gel pre-
coated sheets (PE, SIL G; Whatman, Maidstan, Kent, UK) and developed for 1.5h in 
a tank containing 92% chloroform/8% ethanol as the mobile phase (150mL). Finally, 
the TLC sheet was scanned using a Bioscan 2000 radioactive imaging detector 
(Lablogic Systems, Sheffield, UK). Radio-labelled steroids were separated according 
to their mobility on the TLC plate. Identification of the mobility of each steroid on 
the silica-gel pre-coated sheet was facilitated with concomitant loading of the 
standards (see above). Radioactivity peaks were measured as percentage (%) of the 
substrate conversion to the active steroid and data were computed as pmoles of 
substrate conversion per hour (pmoles/h). 
2.5 Statistical Analysis 
All data from each experimental set were combined and presented as means 
and standard errors (±sem). The numbers of replicate experiments are denoted by the 
number (n) of independent replicates and are given in figure legends and text.  Basic 
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statistical analysis was performed, using one-way analysis of variance (ANOVA) 
with the GraphPad Prism 4.00 software (GraphPad Software Inc., San Diego, USA). 
Repeated measures ANOVA and Newman-Keuls post-hoc testing were run for 
multiple comparisons, whereas two-tailed paired Student t-tests were performed for 
single comparisons. Regarding Taqman results, in order to avoid any potential bias 
yielded by transformations through the equation 2-ddCt for the optimisation of the 
relative copy number of the target genes related to untreated control, all statistics 
were performed at the dCt level (raw data), thus avoiding a situation of no variability 
about the mean of control groups, and permitting correct interpretation of statistical 











Establishment of hOSE cell culture system: 












3.1.1 Collection and culture of human OSE cells 
 Protocols for the successful collection and culture of human OSE have been 
mainly developed by Nelly Auersperg’s group. First efforts to culture human OSE 
were first described in 1984 (Auersperg et al. 1984), further established in 1988 
(Siemens & Auersperg 1988) and simplified and improved in 1990 (Kruk et al. 
1990). Problems encountered at culturing OSE cells in plastic plates involved 
transformation of cells to a fibroblast-like phenotype with time in culture due to the 
use of inappropriate nutrient media and/or supplementation of growth factors such as 
EGF and cortisol (Auersperg et al. 1984, Siemens & Auersperg 1988). However, the 
method described by Kruk et al. (Kruk et al. 1990) appeared the most efficient one 
and closer to the in vivo biology and behaviour of the human OSE. This method 
involved a gentle scrape of the ovarian surface with a sterile scraper at the time of 
surgery and direct placement of cell scrapings in sterile culture medium. This cultural 
system yielded essentially pure epithelial cell monolayers with minimal or no stromal 
contamination. The growth potential of individual cell cultures was not affected by 
diagnosis, patient age and phase of the menstrual cycle when surgery took place 
(Kruk et al. 1990). Also, there were not apparent phenotype changings even after up 
to four subcultures. Inability of cell monolayers to reach confluency within a month 
outlined senescence (Kruk et al. 1990).  
 Notably, it was demonstrated that OSE cells in culture resembled 
regenerative OSE cells that heal peri- and post-ovulatory after injury rather than 
stationary OSE cells of an anovulatory cycle. Cultured hOSE cells have been shown 
to undertake epithelio-mesenchymal transitions, especially when explanted in three-
dimensional culture (collagen-coated plates, Matrigel), thus mimicking a physiologic 
in vivo post-ovulatory response (Kruk et al. 1994). Indeed, hOSE cell monolayers 
have been proved to express both epithelial and stromal markers (Dyck et al. 1996). 
On the other hand, OSE cells recruited from patients with a strong family history of 
ovarian cancer (FH-OSE) have been demonstrated to be more committed to an 
Chapter 3                                                                                               3.1 Inroduction 
99 
 
epithelial phenotype, a feature of epithelial ovarian cancer, than the OSE of patients 
with no family history for ovarian cancer (NFH-OSE) (Dyck et al. 1996).  
3.1.2 Markers of in vitro culture of the OSE 
 OSE is a multipotent mesothelium that is not committed to an epithelial 
phenotype.  Regarding this, cultured OSE cells are positive for epithelial markers 
such as collagen IV and laminin along with fibroblast markers such as vimentin and 
collagen types I and III. Intriguingly, whereas collagen type III is present in cultured 
hOSE cells, it is absent in stationary hOSE cells in vivo and this phenotype agrees 
with enhanced collagen III secretion in post-ovulatory healing when normal OSE 
cells transit to a more mesenchymal-fibroblastic phenotype (Dyck et al. 1996). 
Cytokeratins 5, 6, 7, 8 and 17 are also present both in situ and in vitro but they are 
progressively lost within time in culture when cells take on a more fibroblastic-like 
phenotype (Auersperg & Maines-Bandiera, Dyck et al. 1996), a feature that is not 
encountered in immortalised OSE cell lines, FH-OSE and EOC cells (Auersperg et al. 
1994a, van Niekerk et al. 1991). Moreover, E-cadherin and CA125, molecules that 
are highly expressed in epithelial ovarian cancers, are not secreted by cultured OSE 
cells or immortalised cell lines, reflecting their non-malignant character (Auersperg 
et al. 1994a, Auersperg et al. 1999). Finally, OSE cells have 17β-HSD activity, an 
invaluable marker to distinguish between OSE and mesothelial cells of extraovarian 
origin (Auersperg et al. 1984, Blaustein 1984). 
3.1.3 3β-HSD expression in different cellular compartments of the human ovary 
 As highlighted in Chapter 1, the importance of 3β-HSD is subject to the fact 
that the synthesis of all classic steroid hormones is downstream of 3β-HSD action. In 
human, the adrenal is the major source of inactive substrates formed by cholesterol 
such as Preg, DHEA-S and DHEA that are subsequently converted into active 
products in situ or are transferred to target tissues through the circulation to be 
catalysed into more active components. The expression pattern, localisation and 
regulation of 3β-HSD in the human ovary were described in detail in Chapter 1 
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(1.4.2.3ii). Briefly, 3β-HSD2 is the principal isoform expressed in human ovarian 
steroidogenic cells with a peak expression in the luteal phase of the menstrual cycle. 
Low amounts of 3β-HSD1 has been reported to be expressed in the corpus luteum as 
well (Rheaume et al. 1991).  
To date, there have been no previous studies on functional 3β-HSD 
expression in the human ovarian surface epithelium, the cellular compartment that is 
believed to be responsible for >85% of ovarian cancers. A microarray analysis 
showed the presence of 3β-HSD1 mRNA in hOSE and its regulation by IL-1α, 
though the biological significance of this response is still obscure (Rae et al. 2004b). 
Interestingly, immunohistochemical studies in rat OSE showed an absence of 3β-
HSD (Adams & Auersperg 1981). As discussed in Chapter 1 (Section 1.4.2), 3β-
HSD is the enzyme which catalyses the final reaction for the intracrine generation of 
active progesterone, the steroid hormone which is considered to protect from ovarian 
cancer (Risch 1998). Therefore, the potential de novo capacity of hOSE for local 
regeneration of progesterone and its downstream signalling could be an additive 
mechanism for hOSE itself to protect OSE cells from genetic damage. Moreover, 
novel aspects of regulation of ovarian steroid biosynthesis in health and disease 
might be revealed. 
3.1.4 Aim  
  The first aim of this chapter is to present the hOSE system we used to study 
the regulation of steroid signalling in the human ovarian surface epithelium in vivo 
and in vitro. Following optimisation of cell cultural conditions based on previous 
protocols (Hillier et al. 1998, Kruk et al. 1990), we propose to investigate the 
potential expression of 3β-HSD in the hOSE cell layer in situ and also in an in vitro 
cell culture system. 
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3.2 Subjects and Methods 
 Assessment of the expression of 3β-HSD protein and activity along with the 
isoform expression pattern was performed using immunohistochemistry 
(colourimetric (IHC) and immunofluorescence (IF) methods), radiometric activity 
assays and PCR respectively. Immunohistochemistry assays involved the use of 
whole ovarian tissue (in situ expression) as well as immunostaining of cultured 
hOSE cell monolayers (in vitro). Also, immunohistochemical studies for cytokeratins 
(CK) were performed to identify whether CK staining overlapped with 3β-HSD 
expression. For an in vivo approach we used human ovaries from pre-menopausal 
women who underwent ovariectomy due to non-malignant gynaecological conditions, 
whereas 4-week cultured hOSE samples from 3 separate patients were used for the in 
vitro approach. Representative pictures are depicted herein. Samples from five other 
patients were used to measure basal 3β-HSD activity. Investigation of the isoform 
expression pattern, 3β-HSD1 and 3β-HSD2 mRNA, was performed using semi-
quantitative (sq) and quantitative (q) RT-PCR (Taqman).The clinical profile of the 
individual patients used for these studies is presented in Tables 3.1 and 3.2. 
Table 3.1 In situ studies 
Patient No Age (yrs) Reason for surgery Phase of 
menstrual cycle  
IHC IF 
1 29 Amenorrhoeic past 5yrs; 
cyclical pain 
- 3β-HSD, CK 3β-HSD, CK 
2 40 Dysmenorrhoea; constant 
bleeding  
- 3β-HSD, CK 3β-HSD, CK 
3 40 Constant bleeding for 7 
months; endometriosis 
history 
- 3β-HSD, CK 3β-HSD, CK 
 IHC: immunohistochemistry, IF: immunofluorescence 
 




Table 3.2 In vitro studies  
Patient 
No 
Code LREC No Age 
(yrs) 





4 5433 04/S1103/36 39 TAH Cyclical pain (5) Follicular TLC 
5 5447 04/S1103/36 42 TAH Fibroids (19) Luteal TLC 
6 5484 05/S1103/14 32 TAH Prolapse (24) Luteal TLC 
7 5497 04/S1103/36 39 TAH Pelvic pain; 
dysmenorrhoea 
n/s TLC 
8 5499 04/S1103/36 47 TAHBSO Fibroids n/s TLC 
9 7229 04/S1103/36 40 TAH HMB (2) Follicular TLC 
10 5536 04/S1103/36 23 DiagLapar HMB/pain n/s sqPCR 
11 5537 04/S1103/36 24 DiagLapar Dysmenorrhoea (28) Luteal sqPCR 
12 7383 04/S1103/36 43 TAHBSO Fibroids n/s sqPCR 
13 7384 04/S1103/36 42 TAH HMB (23) Luteal sqPCR 
14 9014 04/S1103/36 32 DiagLapar Pelvic pain n/s sqPCR 
15 5410 05/S1103/14 36 LAVH HMB; 
Dysmenorrhoea 
(17) Luteal qPCR 
4 5433 04/S1103/36 39 TAH Cyclical pain (5) Follicular qPCR 
16 5434 1998/6/33 41 TAHBSO Fibroids (3) Follicular qPCR 
17 5441 05/S1103/14 44 TAH HMB (25) Luteal qPCR 
18 7246 04/S1103/36 46 TAHBSO Fibroids (16) Luteal qPCR 
19 7249 04/S1103/36 44 STAH Dysmenorrhoea (8) Follicular qPCR 
14 9014 04/S1103/36 32 DiagLapar Pain n/s qPCR 
10 5536 04/S1103/36 23 DiagLapar HMB/pain n/s IF 
20 7423 04/S1103/36 49 TAH Fibroids (30) 
menstruation 
IF 
TAH: total abdominal hysterectomy, TAHBSO: total abdominal hysterectomy and bilateral 
salpingo-oophorectomy, STAH: sub-total abdominal hysterectomy, LAVH: laparoscopic 
assisted vaginal hysterectomy, HMB: heavy menstruation bleeding, DiagLapar: diagnostic 
laparoscopy, n/s: not specified due to irregular cycle, follicular/luteal phases for menstrual 
cycles ranging from 28 to 35 days. TLC: thin layer chromatography, IF: 
immunofluorescence




3.3.1 Morphology of the human ovary and human ovarian surface epithelium 
3.3.1.1 Haematoxylin and eosin staining of human ovary  
 Prior to immunostaining, ovaries were subjected to haematoxylin and eosin 
(H+E) staining to identify the structure of the different cell compartments and 
populations. Fig. 3.1 depicts the morphology of the various ovarian compartments of 
a representative human pre-menopausal ovary. As described in previous sections, the 
hOSE is a single cellular layer that surrounds the ovary and consists of heterogenous 
epithelial cells (Fig. 3.1 a,d,e). Representative pictures of columnar (d) and rounded 
(e) epithelial cells are illustrated. Intriguingly, some sloughed OSE is also depicted 
(d), showing that hOSE can easily detach from the surface. A well-structured corpus 
luteum, the most steroidogenic structure of the female body, is also illustrated (b). 
The corpus luteum consists of acute steroidogenic cells with big nuclei (lutein-
granulosa), as well as small cells (lutein-theca) (c) and stromal cells such as 
fibroblast-like and immune cells. Finally, an antral follicle is also shown (f) that 
consists of several layers of granulosa cells that expand between the cumulus 
oophorus (not shown here) and the membrana granulosa (f). The membrana 
granulosa layer is surrounded by a basal lamina that separates granulosa cells from 













Figure 3.1: Haematoxylin and eosin staining of a human ovary. a) hOSE layer surrounds 
the ovary and is separated from the stroma by a basal lamina. A mature follicle (antrum) is 
also demonstrated, b) a well-structured corpus luteum, the most vasculature and 
steroidogenic structure of the female body, c) lutein-cells of the corpus luteum, d), e) hOSE 
cells; notice that this layer consists of cuboidal cells that differ in shape and size (columnar 
and rounded at this slide), f) a closer approach of a big follicle. Granulosa cells are 
enveloped by a basal lamina that separates them from theca interna and theca externa. Slides 
were visualised in Olympus Provis microscope and pictures were captured with a digital D30 
Canon camera. Scale bars: a, b) 200μm, c-f) 50μm. 
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3.3.1.2 Morphology of hOSE cell cultures   
 As described in Chapter 2, the surface of the ovary was scraped and flakes of 
hOSE cells were transferred into DCS-precoated T75 culture flasks for in vitro 
manipulation. Cells were cultured until confluency (2-4 weeks) and were either 
processed for further experimentation and/or passed to another flask (passage 1) for 
later use. Figure 3.2 illustrates hOSE cell morphology at different stages of culture. 
On day 0, hOSE flakes float in culture medium (a). Cell attachment is achieved 
between day 1 and 5 (not shown) and hOSE colonies start to form until they cover 
the surface of the flask, forming a ‘cobblestone’ monolayer (b, c). As seen in (b) and 
(c), cells have a squamous-to-cuboidal shape, typical of their epithelial phenotype 
and are kept tightly the one to the other. Cells subcultured for another 1 week do not 
differ morphologically from the primary (passage 0) cultures (d, e). In some cases, 
stromal contaminations were observed to interrupt epithelial colonies and fibroblast-
like cells appeared to predominate over epithelial cells (f). Those cell cultures were 
discarded and not processed for experimentation. Bright field phase-contrast 
microscopy appeared essential to monitor stromal contamination that could 
negatively affect confidence of data obtained in subsequent assays. In selective cases, 















Figure 3.2: Morphology of cultured hOSE cell monolayers. a) hOSE cell scrapings on the 
day of collection, b, c) a confluent hOSE cell monolayer after 21 days in culture (pictures 
captured with different lenses of inverted microscope), d, e) hOSE cell monolayers in 
subculture, f) hOSE cell culture that is contaminated with fibroblast-like cells. Pictures were 
captured with a Zeiss phase contrast microscope, 5X magnification (scale bars for the 
camera used are not provided). 
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3.3.2 Characterisation of hOSE cells by immunostaining with epithelial-specific 
markers 
 Recognition of epithelial cells of the human ovary was achieved through 
immunostaining with epithelial-specific markers (Fig. 3.3). Cytokeratin 7 (left 
column) and pancytokeratin 5, 6, 8, 17 (centre column) antibodies (both in 1:1000 
dilution) stained the OSE layer of the human ovary. As expected, neither antibody 
stained ovarian granulosa (3rd slide left and centre columns). Unconjugated mouse 
IGg1 as negatives did not react with DAB chromagen, showing that production of the 
brown staining came from specific antibody-antigen interaction. Slides were 
visualised with an Olympus Provis microscope and pictures captured with the 


















Figure 3.3: Immunostaining of a human ovary for cytokeratins (CK). Cytokeratin 
staining was performed with two different mouse monoclonal antibodies. The left column 
shows staining for CK 7. Granulosa cells were used as negative controls (left column, 3rd 
slide). Centre column shows staining with the CK panel (5, 6, 8, 17). Granulosa again served 
as the negative control (centre column, 3rd slide). The right panel shows negative controls for 
both antibodies. Pictures were captured with an Olympus Provis microscope in 4X and 40X 
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3.3.3 Expression of 3β-HSD in the human ovarian surface epithelium 
 As described above, 3β-HSD is present in ovarian follicular cells with a peak 
expression in the corpus luteum. Investigation of the potential expression of 3β-HSD 
in the hOSE monolayer required strict optimisation of the antibody, because antibody 
dilutions suitable for granulosa and corpus luteum staining might not be optimal for 
hOSE cells if expression levels were greatly different; inversely, strong 
immunostaining of hOSE cells could yield background elsewhere in the ovary. In 
this section, immunostaining with different protocols are presented. Only satisfactory 
antibody dilutions are demonstrated. 
3.3.3.1 Colourimetric immunolocalisation of 3β-HSD in the hOSE layer of the 
human ovary (DAB staining) 
i) No antigen retrieval treatment 
 Immunostaining of human ovaries with 3β-HSD antibody in serial dilutions 
(1:500, 1:1000, 1:2000) without an antigen retrieval step (Fig. 3.4 A) showed intense 
staining of human granulosa cells of a pre-ovulatory follicle (c,d) but staining in 
hOSE layer was very low at the 1:1000 dilution (a) and undetectable at a 1:2000 
dilution (b). Data with 1:500 are not shown, since there was unspecific background 
throughout the whole tissue. Profound cytoplasmic staining in corpus luteum was 
also observed (Fig. 3.4 Da).  
ii) Pressure cooker treatment 
 Another approach used for 3β-HSD immunolocalisation was unmasking the 
epitopes through pressure cooking. Serial antibody dilutions (1:1000, 1:2000, 1:4000 
and 1:6000) showed notable immunostaining, however staining was expanded into 
nuclei as well as stromal cells even at highest dilutions (1:6000, Fig 3.4 B). Corpus 
luteum staining was cytoplasmic and specific to steroidogenic cells (Fig. 3.4 Db). 
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iii) Microwave treatment 
 A revelation of 3β-HSD loci in human ovarian tissue was also achieved using 
a microwave heating step. Serial dilutions of the 3β-HSD antibody (1:1000, 1:2000, 
1:4000 and 1:6000) showed specific and cytoplasmic staining in the granulosa and 
theca interna (1:6000; Fig. 3.4 Ca-c) as well as in hOSE cells (d-f) with minimal or 
no unspecific staining of stroma (d-f). Cytoplasmic-specific staining is illustrated 
more clearly in slides Fig. 3C (j,k). Importantly, the staining intensity differed among 
OSE cells of different shape. Columnar (d) and rounded (e) (cells A) OSE cell 
staining appeared stronger relative to flat OSE (cells B) (f) cells (Gillett et al. 1991, 
Papadaki & Beilby 1971). The 3β-HSD antibody specifically stained steroidogenic 
cells of the corpus luteum (Fig. 3.4 Dc). Negative slides with unconjugated IgG1 
antibodies at matched concentrations were run routinely with all the different 
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Figure 3.4 A 
 
Figure 3.4 B 
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Figure 3.4 D 
 
Figure 3.4 (p 111-113): 3β-HSD immunostaining of the human ovary. A) 
Immunostaining without antigen retrieval yielded the optimal staining in human granulosa 
(c,d), though low or no detection of 3β-HSD was observed in hOSE (a,b; 1:1000, 1:2000). B) 
Antigen retrieval with pressure cooker treatment (1:6000 dilution of 3β-HSD antibody) 
strongly stained hOSE cells, although, staining was expanded to nuclei of both hOSE and 
granulosa cells (a,b,c). C) Antigen retrieval with microwave heating system and the use of 
1:6000 dilution of the antibody. Cytoplasmic staining was observed in both follicular (a-c) 
and hOSE (d-f) cells with different intensity among different cell types of OSE (d-f). 
Cytoplasmic staining is more obvious in j and k pictures that reflect part of the (a) and (e) 
ones (cropped). Negatives were not stained after DAB exposure (g-i). D) Staining of the 
corpus luteum with all three protocols. Cytoplasmic staining was observed in all three cases. 
As expected, the antibody stained specifically steroidogenic cells, with no staining in stroma 
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3.3.3.2 Co-localisation of 3β-HSD with epithelial-specific cytokeratins in hOSE layer 
 Further confirmation of epithelial-specific immunostainig of 3β-HSD was 
performed through indirect double immunofluorescence and confocal microscopy 
(Fig 3.5). Ovarian tissue was submitted to serial staining with 3β-HSD antibody 
(1:400 dilution; red fluorescence) and two different cytokeratin antibodies (1:300 
dilution; green fluorescence); a mouse monoclonal that reacts with 5, 6, 8, 17 
cytokeratins (a-d) and a mouse monoclonal antibody that binds to cytokeratin 7 (e-h). 
Confocal microscopy revealed cytoplasmic staining of cytokeratins and 3β-HSD as 
expected with no staining in stroma. Granulosa cells and theca interna of a big 
follicle served as controls for antibody staining specificity (i-l). They appeared 
positive for 3β-HSD and negative for cytokeratins (only granulosa stained with CK7 
are shown here). Counterstaining with Dapi was performed to visualise cell nucleus 
(a, e, i). Pictures were captured with Zeiss LSM 510 Meta Axiovert 100M confocal 















Figure 3.5: Double staining of 3β-HSD with epithelial-specific cytokeratins (CK). (a-d) 
Immunostaining with serial incubations with 3β-HSD (red) and cytokeratins 5, 6, 8, 17 
(green) antibodies. Cytoplasmic staining of both antibodies was observed with no staining in 
stroma. (e-h) Double immunostaining with 3β-HSD (red) and cytokeratin 7 (green) showed 
epithelial-specific localisation of 3β-HSD. (i-l) Ovarian follicular cells were challenged with 
3β-HSD (red) and cytokeratins (green). 3β-HSD was present to ovarian granulosa at high 
levels with no staining with cytokeratins. Nuclei were counterstained with Dapi (blue). 
Pictures were captured with Zeiss LSM 510 Meta Axiovert 100M confocal microscope at 
40X magnification. Scale bars represent 20μm. 
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3.3.4 Expression of 3β-HSD in cultured hOSE cells 
 As shown in Section 3.3.3, 3β-HSD was expressed in the hOSE cellular 
compartment. However, as noted above, hOSE cell numbers at the time of collection 
were very low and so culture of such cells for at least two weeks was essential not 
only to get enough cells for further experimentation but also to balance the steroid 
milieu among samples that were collected at different stages of the menstrual cycle 
and might potentially reflect a variability among different patients. Therefore, prior 
investigation of the role and regulation of 3β-HSD in hOSE cells in vitro, an 
essential step was to establish that basal 3β-HSD functionality is maintained in our 
culture system. Regarding this, 3β-HSD protein and activity were measured in 
cultured hOSE cells using immunofluorescence and radiometric activity assays, 
respectively. 
3.3.4.1 Expression of 3β-HSD protein in hOSE cell cultures 
 hOSE cells serum-depleted for 24h were subjected to serial incubations with 
3β-HSD antibody and epithelial-specific cytokeratins (CK) (Fig. 3.6 a-d). The 
epithelial character of these cells (green) and their ability to express functional 3β-
HSD (red) was revealed by overlapping staining of the two antibodies in cytoplasm. 
This suggests that our culture system gives epithelial cells of high purity that 
maintain expression of 3β-HSD. Dapi was used to stain nuclei. Representative 
pictures are shown.  
 
 




Figure 3.6: Double staining of 3β-HSD with epithelial-specific cytokeratins (CK) in 
cultured hOSE cells. (a-d) 3-week cultured hOSE cells were subjected to serial incubations 
with 3β-HSD (red) and cytokeratins 5, 6, 8, 17 (green) antibodies. Clear cytoplasmic staining 
of both antibodies shows epithelial character of those cells (c) and their capacity to express 
3β-HSD.  Nuclei were counterstained with Dapi (blue). Pictures captured with Zeiss LSM 
510 Meta Axiovert 100M confocal microscope at 40X magnification. Scale bars represent 
20μm. 
3.3.4.2 Radiometric assay of 3β-HSD activity in hOSE cell cultures 
 Basal 3β-HSD activity in cultured hOSE cells was measured using a 
radiometric substrate conversion assay that involved measurement of [3H]-
progesterone after treatment of hOSE with [3H]-pregnenolone as a substrate and 
separation according to their polarity/mobility on TLC (Fig. 3.7). Following a 3-
week cell culture, 100,000 cells were re-plated and serum-depleted before 
investigating 3β-HSD activity in vitro. The hOSE cells of all patients tested 
displayed basal 3β-HSD activity. There was variability in activity levels among 
different patients (Fig. 3.7 A). However, these differences did not appear to correlate 
with the clinical profile of patients, although this was beyond the scope of this thesis. 
Similar data were also obtained with the use of DHEA as a substrate for 3β-HSD 
(data not shown). Representative radiographs of pregnenolone and progesterone 
mobility are illustrated (Fig. 3.7 B). 
 






Figure 3.7: 3β-HSD activity in 6 distinct hOSE samples. A) After 3 weeks in culture, 
100,000 hOSE cells/sample were re-plated and serum-depleted for 24h to measure basal 3β-
HSD activity. All the samples were tested for their capacity to convert [3H]-Preg to [3H]-
Prog, reflecting 3β-HSD activity B) Representative radiograph that shows [3H]-Preg (upper 
radiograph) and [3H]-Prog (centre radiograph) migration on silica-gel coated TLC plate. 




Chapter 3                                                                                                      3.3 Results 
119 
 
3.3.5 3β-HSD isoform expression pattern in hOSE cell monolayers 
 The sections described above established expression and functionality of 3β-
HSD in hOSE both in vivo and in vitro.  However, the approaches described above 
were not conclusive of the isoform expression pattern of 3β-HSD isoforms. As noted 
in Chapter 1 (Secion 1.4.2.1), 3β-HSD1 and 3β-HSD2 share at least 93% similarity, 
making therefore the separation of the two isoforms in the same cellular 
compartment very difficult. Unfortunately, development of mouse monoclonal 
isoform-specific antibodies has not been successful to date. In order to investigate the 
gene regulation of 3β-HSDs in hOSE, it was essential to establish the isoform-
expression pattern in this cell population. To achieve that, semi-quantitative and 
quantitative RT-PCR were performed with the use of isoform-specific primers as 
described in Chapter 2. 
3.3.5.1 Semi-quantitative PCR (sqPCR) 
 DNase-treated RNA hOSE samples recruited from 5 patients were reversed 
transcribed and subjected to gene-specific PCR amplification to measure 3β-HSD1 
and 3β-HSD2 transcript levels. Both gene products (Fig. 3.8, a, b) were expressed in 
5 out of 5 hOSE samples. Samples transcribed without RT enzyme (RT –ve) were 
also run for each distinct sample to ascertain the absence of genomic contamination. 
The GAPDH gene was tested to control for the equal loading of initial cDNA 
template (c). 3β-HSD1 and 3β-HSD2 primer specificity was assessed with the 
inclusion of placental explants and ovarian lutein-granulosa cells, respectively. As 
expected, placenta was positive only for 3β-HSD1 mRNA (d), whereas lutein-
granulosa expressed high levels of 3β-HSD2 mRNA (e). GAPDH mRNA 
amplification ascertained the equal loading and integrity of samples (f). 
   
 
 







Figure 3.8: Semi-quantitative RT-PCR for 3β-HSD1 and 3β-HSD2 mRNA expression. 
hOSE samples from 5 patients were assessed for 3β-HSD1 and 3β-HSD2 mRNA expression 
(a, b). RT-ve was also run to control genomic contamination. Placenta (d) and ovarian lutein-
granulosa cells (e) served as positive controls for 3β-HSD1 and 3β-HSD2 primers 
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3.3.5.2 Quantitative PCR (Taqman) 
 Because semi-quantitative PCR showed the presence of gene products for 
both 3β-HSD1 and 3β-HSD2 isoforms, absolute quantification of the products was 
performed with Taqman qPCR and the use of isoform-specific primers that had the 
same amplification efficiency. Moreover, in order to ascertain equal conditions of 
gene amplification, all samples were assessed relative to the house-keeping 18S gene, 
ensuring that the values obtained among different samples were tightly contained.  
Equal concentrations (200ng) of DNase-treated RNA of hOSE samples recruited 
from 7 patients were reversed transcribed and measured for 3β-HSD1 and 3β-HSD2 
transcript levels. Both gene products (Fig. 3.9) were present in the hOSE of all 
patients tested (A, upper graph), although there was some variability of expression 
levels among patients (A, upper panel). 3β-HSD2 mRNA expression, however, 
appeared to be expressed at lower levels relative to 3β-HSD1 mRNA in all cases (A, 
upper panel). The combined data showed a mean 5-fold increase of 3β-HSD1 mRNA 
relative to 3β-HSD2 mRNA (A, lower panel; n=7, two-tailed paired student t-test, 
b=p<0.001). Noteworthy and albeit beyond the scope of the thesis, hOSE samples 
that were collected at the luteal phase of the menstrual cycle (Table 3.2, patients 14, 
15, 17, 18) appeared to be correlated with higher 3β-HSD1 mRNA levels relative to 
samples collected at the follicular phase of the menstrual cycle (Table 3.2, patients 4, 
16, 19); however this did not reach statistical significance (Fig. 3.9 B, upper panel). 
On the contrary, there was no such correlation regarding 3β-HSD2 mRNA levels (B, 
lower panel). 3β-HSD1 and 3β-HSD2 primer specificity was assessed with the 
inclusion of placental explants and ovarian lutein-granulosa cells respectively (C). 
Expectedly, placenta was positive only for 3β-HSD1 mRNA (C, upper panel), 
whereas lutein-granulosa expressed 70-fold higher levels of 3β-HSD2 mRNA 
relative to 3β-HSD1 mRNA (C, lower panel). Mean dCt values for hOSE cells, 
granulosa and placenta for 3β-HSD1 and 3β-HSD2 mRNA are illustrated in Table 
3.3.  
 





Figure 3.9: Quantitative RT-PCR for 3β-HSD1 and 3β-HSD2 mRNA expression. A) 
hOSE samples from 7 patients were assessed for 3β-HSD1 and 3β-HSD2 mRNA expression, 
using Taqman qPCR (n=7, b=p<0.001). B) Measurement of 3β-HSD1 or 3β-HSD2 mRNA 
levels and the phase of the menstrual cycle when samples were collected. C) Placenta and 
ovarian lutein-granulosa cells served as positive controls for 3β-HSD1 and 3β-HSD2 primers 
respectively.  









Table 3.3 Mean dCT values for Taqman Real-Time PCR 
 3β-HSD1 mean dCT 3β-HSD2 mean dCT 
Placenta 7.19 Not detected 
Lutein-granulosa cells 14.32 7.89 
hOSE cells 14.03 18.12 
The dCT values represent the PCR cycle that the target gene started to be accumulated 
relative to the internal reference 18S. Note that differences in dCT values between different 











 Investigation of the pathophysiology of hOSE cells is important since this 
cellular compartment can be quite easily transformed and give rise to ovarian cancer 
(Auersperg et al. 2001, Runnebaum & Stickeler 2001). Although ovarian cancer is 
more common in post-menopausal women, it is believed to be a result of processes 
and genetic errors that are accumulated during reproductive age (Murdoch & 
McDonnel 2002) with ‘incessant ovulation’ the predisposing hypothesis of ovarian 
cancer (Fathalla 1971). Simultaneously, the ovarian environment at this age, 
develops mechanisms that protect the ovary from tumourigenesis. Elucidation of 
these mechanisms could contribute in the development of therapeutic strategies of 
ovarian cancer. Therefore, the study of normal pre-menopausal hOSE is an essential 
model to identify molecular mechanisms that could promote or protect from 
development of neoplasia.  
 Ovarian steroid environment is subject to periodic alterations during the 
menstrual cycle and it radically alters after menopause when most ovarian cancers 
appear, suggesting a possible role in the function of the OSE.  Regarding this, it has 
been demonstrated that hOSE is a target of steroid metabolism and reception (Lau et 
al. 1999, Rembiszewska & Brynczak 1985). Intriguingly, progestogens and 
androgens, formation of both catalysed by 3β-HSD, exert apoptotic  and 
cytoproliferative effects, respectively in human and sheep OSE (Bu et al. 1997, 
Edmondson et al. 2002, Murdoch et al. 2001) .  
 This chapter delineates some basic aspects for the optimal in vitro culture 
conditions of hOSE cells, a critical prerequisite for the validity of the data that are 
elaborated in the present and later chapters. Moreover, we provide direct evidence of 
notable expression of 3β-HSD mRNA, protein and activity in the hOSE layer of the 
human pre-menopausal ovary. We also show that our culture system can be 
successfully applied to study the in vitro role and regulation of 3β-HSD in this cell 
type. 
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 Light phase-contrast microscopy was proved useful to study the in vitro 
growth and morphology of hOSE scrapings. Low numbers of cells recruited from 
each inoculum made impossible a comparison of growth potential between different 
hOSE samples. Nevertheless, it was noticed that the larger an inoculum was, the 
quicker it reached confluence. No correlation between cell growth potential and age 
of patient or stage of menstrual cycle when sample was collected was observed. Also, 
there were not any apparent differences in hOSE morphology and growth capacity 
among samples recruited from different harvesting methods. However, nothing of the 
above has been studied systematically by us or other groups and as such solid 
conclusions cannot be made. 
 As shown in the Results section of this chapter, confluent hOSE cells formed 
‘cobblestone’-like monolayers according to previous reports (Kruk et al. 1990). The 
fact that this cell morphology was maintained in subculture allowed significantly 
increased cell numbers and facilitated downstream analyses. It was consistently 
observed that primary cell inoculums that reached confluence within two weeks gave 
confluent cell monolayers following subculture for one more week, whilst hOSE 
scrapings with poor growth capacity senesced in subculture and could not be used 
further. 
  Epithelial-specific markers such as cytokeratins 5, 6, 8, 17 and 7 that were 
previously reported to stain hOSE cells in situ and in vitro but not stromal cells was a 
useful approach to ascertain epithelial purity of our cultures (Auersperg et al. 1994a, 
Czernobilsky et al. 1985, van Niekerk et al. 1991). Intriguingly, passaged cells also 
maintained cytokeratin staining, encouraging, therefore the use of those cultures for 
further experimentation (not shown). The latter was expected since subcultured cells 
were grown for a total of 4 weeks (2 weeks for primary inoculum plus 1 week in 
subculture plus 1 week maximum following re-plating for experimentation), 
consistent with the published period of time when those cells start to senesce or lose 
their epithelial character (Dyck et al. 1996). However, a solid assumption after that 
period of time cannot be made. Published data suggest maintenance of hOSE 
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monolayers and an average 70% keratin immunopositivity up to passage 3 with 
significant loss of cytokeratin staining after this period due to epithelio-mesenchymal 
transitions (Dyck et al. 1996). 
 Various experimental techniques showed the presence of functional 3β-HSD 
in hOSE cells obtained from pre-menopausal patients. A specific polyclonal rabbit 
antibody was used to immunolocalise 3β-HSD protein in hOSE layer of whole 
ovarian sections as well as in 3-week cultured hOSE cells. Interestingly, 3β-HSD 
immunolocalisation in hOSE was notable with the use of various 
immunohistochemical protocols, showing that the staining achieved was antibody-
specific and not an artefact. Among various colourimetric protocols applied, antigen 
retrieval combined with microwave heating system appeared to give the most 
optimal protein staining, not only in hOSE but elsewhere in the ovary. Cytoplasmic 
staining of 3β-HSD was clearer however, when fluorescence immunohistochemistry 
was practised, suggesting that this method is probably more sensitive and accurate. 
Furthermore, the latter allowed the establishment of 3β-HSD co-localisation with 
epithelial-specific markers which further ascertained expression of this enzyme in 
hOSE in vivo and in vitro. Concomitant immunopositivity of pre-ovulatory follicles 
and corpus luteum for 3β-HSD further confirmed the data obtained. In support of this, 
activity assays of 6 distinct hOSE samples in vitro revealed capacity of those cells to 
convert [3H]-pregnenolne to [3H]-progesterone, reflecting active 3β-HSD in hOSE 
cells. 
 Whereas 3β-HSD expression has been reported in ovarian cancers (Abd-
Elaziz et al. 2005), to our knowledge, these are the first data to show functional 3β-
HSD protein and activity in the hOSE of the pre-menopausal ovary. 3β-HSD is at the 
top of the steroidogenic pathway and is considered a prerequisite for the generation 
of all active steroid hormones, namely mineralocorticoids, glucocorticoids, 
oestrogens, progestogens and androgens, all essential for body homeostasis. 3β-HSD 
is responsible for the generation of progesterone from pregnenolone as well as for 
androstenedione from DHEA. The latter can be subsequently reduced to more potent 
Chapter 3                                                                                                3.4 Discussion 
127 
 
androgens such as testosterone and 5α-DHT by 17β-HSD that has been shown to be 
present in hOSE (Rae et al. 2004b). Therefore, our data suggest that hOSE has all the 
dynamics required to actively participate in ovarian steroidogenesis and any 
deficiency at this point may result in ovarian disorder. Importantly, this becomes 
more complicated given the opposite effects of androgens and progestogens noted 
previously in hOSE (Bu et al. 1997, Edmondson et al. 2002, Murdoch et al. 2001). 
However, in physiology, maintenance of steroid balance is probably critical for the 
maintainence of homeostasis in this cellular compartment. 
 Another aspect of interest that arose from our immunohistochemical studies 
was the differences in immunostaining intensity among different cell types within the 
hOSE compartment. Columnar and rounded cells (A cells) appeared to be stained 
stronger for 3β-HSD than flattened cells (B cells) (Gillett et al. 1991), suggesting 
disparity in steroidogenic capacity of different cell types within the hOSE cell 
compartment and this might have biological significance in processes that precede 
pre-neoplastic transformation of those cells. Though, this aspect could not be 
investigated thoroughly since recruitment of ovaries with a completely intact hOSE 
cell layer was not practically possible. Intriguingly, it has been reported that the B 
cell zone was mainly encountered adjacent to ovulatory sites (stigma), suggesting 
that those cells might be a result of re-epithelisation following ovulation-associated 
healing of the cell surface and that they could particularly acquire neoplastic features 
(Gillett et al. 1991). It remains to be elucidated if loss of 3β-HSD is an acquired 
feature of pre-neoplastic transformation of OSE cells. 
 Since both antibody and activity studies are not 3β-HSD isoform-specific, we 
further analysed the pattern of 3β-HSD isoform expression at the mRNA level 
through semi-quantitative and quantitative gene-specific PCR. Semi-quantitative and 
quantitative RT-PCR showed that both 3β-HSD gene products are present to hOSE 
cells, with 3β-HSD1 mRNA predominating over 3β-HSD2 mRNA. The caveat here 
could be that we compared two genes assayed with specific but different sets of 
primers/probes. It should be noted, however, that both primers and probes used for 
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each separate isoform were purchased pre-validated, both recognised fragments that 
span between exons 2 and 3 and had the same amplification efficiency. Also, we 
confirmed specificity by using lutein-granulosa cells and placenta as positive 
controls for 3β-HSD2 and 3β-HSD1 mRNA, respectively. Expectedly, placenta did 
not express 3β-HSD2 at all, while lutein-granulosa cells expressed both isoforms, 
though 3β-HSD2 mRNA was at much higher levels (70-fold) (Rheaume et al. 1991). 
The isoform-expression pattern in hOSE, therefore, differs to what has been 
previously observed in the other cell compartments of the ovary, where 3β-HSD2 is 
the primary isoform expressed in female gonad. Preponderance of 3β-HSD1 mRNA 
to hOSE as opposed to the other ovarian compartments is notable since 3β-HSD1 has 
a higher catalytic efficiency than 3β-HSD2 (Rheaume et al. 1991). Given that the 
hOSE layer is considered to have limited capacity to produce steroids de novo from 
cholesterol, at least in vitro (Rae et al. 2004b), 3β-HSD1 predominance is consistent 
with expression of this isoform in peripheral non-steroidogenic tissues.  
 In summary, we have characterised further the cell culture system used for 
the study of hOSE cells. Also, the limitations of this cultural system along with the 
approaches we undertook to overcome low cell numbers without affecting validity of 
data have been presented. Moreover, we have shown that hOSE expresses notable 
levels of 3β-HSD protein both in vivo and in vitro that might well have a biological 
role in ovarian (patho)physiology. Intriguingly, studies at the transcriptional level 
suggested that the predominant isoform expressed is 3β-HSD1, contrasting with the 
principal expression of 3β-HSD2 that has been observed elsewhere in the female 
gonad. However, this is consistent with a preference of the expression of this isoform 
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4.1.1 Steroid-associated inflammatory action in the human ovarian surface 
epithelium 
 As stated in Chapter 1, the post-ovulatory wound healing cycles that the 
ovarian cell surface undergoes are regulated by a tightly controlled interplay among 
immune mediators such as cytokines and associated hormones including 
gonadotrophins and steroids. This multi-component machinery monitors the 
proliferation of genetically healthy hOSE cells, thereby securing the integrity of the 
ovarian cell surface following follicular rupture. Any cell that escapes from 
surveillance by this complex system can progress to neoplastic transformation and 
clonal expansion of a scarred cell, giving rise to EOC (Murdoch & McDonnel 2002). 
Identifying the mechanisms that physiologically control ovulation-associated wound 
healing could contribute to the development of new molecular markers for the 
diagnosis and/or treatment of EOC (Rae & Hillier 2005). In this regard, studies 
focusing on how hOSE cells recover after ovulation-associated inflammation have 
established a fundamental role of steroid pre-receptor metabolism and downstream 
steroid signalling in the scar-free post-ovulatory healing of hOSE. Glucocorticoid 
pre-receptor metabolism and subsequent glucocorticoid action through GR-α has 
been proved an essential pathway to alleviate hOSE cells from inflammatory 
cascades (Gubbay et al. 2004, Rae et al. 2004a, Rae et al. 2004b, Yong et al. 2002). 
Moreover, progesterone has been shown to suppress pro-inflammatory mediators 
such as COX-2 and also to induce poly(ADP)-ribose polymerase and polymerase-β, 
both involved in the inflammation-associated cytoproliferation of hOSE to repair the 
wound (Murdoch 1998, Murdoch et al. 2001, Rae et al. 2004a). As discussed in 
Chapters 1 and 3, 3β-HSD1 and 3β-HSD2 are the isoforms that regulate intracrine 
formation of progesterone in hOSE. Although the relevant contribution of the two 
isoforms to overall 3β-HSD activity cannot be predicted, total 3β-HSD activity 
monitors the bioavailability in hOSE of apoptotic and anti-inflammatory 
progesterone as well as of cytoproliferative androgens for signalling through PR and 
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AR, respectively (Edmondson et al. 2002, Rae et al. 2004a, Rae et al. 2004b). 
Regarding this, a screening of steroid-related markers showed that IL-1α suppressed 
3β-HSD1 mRNA transcript levels suggestive that progesterone and androgen pre-
receptor metabolism in hOSE was under inflammatory control (Rae et al. 2004b). 
However, no evidence has been reported concerning the expression and regulation of 
the 3β-HSD2 isoform in hOSE. Investigation of the regulation of both isoforms 
separately and as a whole is essential to elucidate further the nature of 3β-HSD in 
hOSE post-ovulatory wound healing processes.  
 As stated in Chapter 1, along with IL-1α that affects a series of pro-
inflammatory and anti-inflammatory genes, including 3β-HSD1, in the ovulatory 
hOSE (Rae et al. 2004b), a number of other cytokines are also secreted pre- and post-
ovulatory not only from hOSE itself but also from follicular and stromal cells. It is 
therefore quite reasonable to speculate that several cytokines could have paracrine or 
autocrine roles in 3β-HSD-associated regulation of hOSE prior to and after ovulation. 
For example, IL-6, TNF-α, IL-18 and GM-CSF are pro-inflammatory cytokines that 
are released pre-ovulatory and they might well affect local steroid biosynthesis 
during ovulation. Moreover, IL-4 and IL-10, two classic anti-inflammatory T 
lymphocyte-associated cytokines, are secreted peri- and post-ovulatory and might 
well mediate intracrine formation of steroids that mediate post-ovulatory responses. 
It is also of interest that all these cytokines or at least their cognate receptors have 
been identified in the ovarian tumour microenviroment, suggesting that they might 
exert tumourigenic or anti-tumourigenic responses in EOC and this may have 
profound implications in the aetiology and treatment of the disease. 
4.1.2 Aim  
 Following establishment of functional expression of 3β-HSD1 and 3β-HSD2 
in the human ovarian cell surface in Chapter 3, we shall investigate regulation of the 
two isoforms by the aforementioned cytokines that are naturally secreted pre-, peri- 
and/or post-ovulatory and could have a role in post-ovulatory tissue remodelling of 
hOSE.  
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4.2 Subjects and Methods 
 Investigation of the role of several inflammatory and anti-inflammatory 
cytokines was assessed using primary hOSE cell monolayers as described in Chapter 
2. Precisely, 3.5 X 105 viable hOSE cells were plated in 6-well culture plates and 
were allowed to attach for 24h. Following serum-depletion for another 24h, cells 
were treated with serial doses of cytokines for 48h before cell harvest and 
homogenisation in cell lysis buffer. RNA purification, RNA quantity and quality 
analyses preceded reverse transcription and quantitative Real-Time PCR for 3β-
HSD1 and 3β-HSD2 mRNA to assess relative levels between untreated control and 
cytokine-treated hOSE cells. Following establishment of the cytokine dose that had a 
maximal effect on transcriptional levels of the target genes after 48h in culture, 
primary hOSE cells were treated in a time-course manner (0h, 12h, 24h, 48h) with 
this cytokine. Subsequently, a fixed dose of cytokine treatment was used to measure 
total 3β-HSD protein and activity through western immunoblotting and 3β-HSD 
radiometric activity assay, respectively. The cytokines tested are illustrated in Table 
4.1. The basic clinical profile of patients involved with the respective assays 



















Number of hOSE 
samples (n) 
IL-1α 0.02, 0.1, 0.5 n=4 
TNF-α 0.1, 0.5, 1.0 n=4 
IL-6 0.1, 0.5, 1.0 n=5 
GM-CSF  0.1, 0.5, 1.0 n=3 




IL-4 0.02, 0.1, 0.5 n=4 
IL-10 0.1, 0.5, 1.0 n=2 
All cytokines were purchased from R&D systems (Abingdon Science Park, Abingdon, UK) 
lyophilised in PBS+0.2% BSA, aliquoted and stored at -80oC. All treatments were inoculated 







Chapter 4                                                                                4.2 Subjects and methods 
134 
 
Table 4.2 Clinical profile of patients used for quantitative Real-Time PCR 
Patient 
No 
Code LREC No Age 
(yrs) 
Surgery Reason for surgery Cycle day/phase  Study 
21 7304 04/S1103/36 34 DiagLapar Dysmenorrhoea (7) Follicular IL-1α 
22 7318 04/S1103/36 51 TAHBSO HMB n/s IL-1α 
23 7324 04/S1103/36 44 DiagLapar Pelvic pain (15) Luteal IL-1α 
24 5505 04/S1103/36 48 TAH HMB  (21) Luteal IL-1α 
21 7357 05/S1103/14 33 TAH HMB  n/s IL-1α (TR) 
25 7304 04/S1103/36 34 DiagLapar Dysmenorrhoea (7) Follicular IL-1α (TR) 
26 7361 04/S1103/36 39  LapSter Constant bleeding  n/s  IL-1α (TR) 
27 9012 04/S1103/36 34   LapSter Prophylactic  n/s  IL-1α (TR) 
18 7246 04/S1103/36 46 TAHBSO HMB (16) Luteal TNF-α 
28 5289 04/S1103/36 23 DiagLapar Dysmenorrhoea (32) Luteal TNF-α 
19 7249 04/S1103/36 44 STAH Dysmenorrhoea (8) Follicular TNF-α 
29 7277 05/S1103/14 45 TAHBSO Menorrhoea n/s TNF-α 
18 7246 04/S1103/36 46 TAHBSO Dysmenorrhoea (16) Luteal IL-6 
30 7248 04/S1103/36 32 TAH Dysmenorrhoea (19) Luteal IL-6 
31 7296 1998/6/33 51 Oophere-
ctomy 
Prophylactic n/s IL-6 
15 5410 05/S1103/14 36 LAVH Dysmenorrhoea (17) Luteal IL-6 
32 7308 05/S1103/14 31 TAH HMB (24) Luteal IL-6 
15 5410 05/S1103/14 36 LAVH Dysmenorrhoea (17) Luteal IL-18 
32 7308 05/S1103/14 31 TAH HMB (24) Luteal IL-18 
33 7247 04/S1103/36 46 TAH Fibroids (31) Luteal IL-10 
30 7248 04/S1103/36 32 TAH Dysmenorrhoea (19) Luteal IL-10 
4 5433 04/S1103/36 39 TAH Cyclical pain (5) Follicular GM-CSF 
16 5434 1998/6/33 41 TAHBSO Fibroids (3) Follicular GM-CSF 
34 5444 04/S1103/36 45 TAH Fibroids (18) Luteal GM-CSF 
20 7423 04/S1103/36 49 TAH Fibroids (30) Luteal IL-4 
35 7435 04/S1103/36 43 TAH Dysmenorrhoea (14) Luteal IL-4 
36 7437 04/S1103/36 32 DiagLapar Pelvic pain         (1) Mens/Fol IL-4 
37 7414 04/S1103/36 22 DiagLapar Pelvic pain n/s IL-4 
6 5484 05/S1103/14 32 TAH Prolapse (24) Luteal IL-4 (TR) 
7 5497 04/S1103/36 39 TAH Pelvic pain (10) n/s IL-4 (TR) 
8 5499 04/S1103/36 47 TAHBSO Fibroids n/s IL-4 (TR) 
38 7314 04/S1103/36 43 Oophere-
ctomy 
HMB n/s IL-1α+IL-4 
8 5499 04/S1103/36 47 TAHBSO Fibroids n/s IL-1α+IL-4 
39 7326 04/S1103/36 43 TAH Fibroids n/s IL-1α+IL-4 
12 7383 04/S1103/36 43  TAHBSO Fibroids n/s IL-1α+IL-4 
37 7414 04/S1103/36 22 DiagLapar Pelvic pain n/s IL-1α+IL-4 
See Table 4.3 for all abbreviations. 
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Code LREC No Age 
(yrs) 





7 5497 04/S1103/36 39 TAH Dysmenorrhea (10) n/s IL-1α, IL-4 
protein 
23 7324 04/S1103/36 44 DiagLapar Pelvic pain (15) Luteal IL-1α, IL-4 
protein 
12 7383 04/S1103/36 43 TAHBSO Fibroids (13) n/s IL-1α, IL-4, 
IL-1+IL-4 
protein 
37 7414 04/S1103/36 22 DiagLapar Pelvic pain (9)  n/s IL-1α, IL-4, 
IL-1+IL-4 
protein 








5 5447 04/S1103/36 23 DiagLapar HMB/pain (4) n/s IL-1α, IL-4 
TLC 
7 5497 04/S1103/36 39 TAH Dysmenorrhoea (10) n/s IL-1α, IL-4 
TLC 
6 5484 05/S1103/14 32 TAH Prolapse (24) Luteal IL-1α, IL-4 
TLC 
23 7324 04/S1103/36 44 DiagLapar Pelvic pain (15) Luteal IL-1α, IL-4 
TLC 
38 7314 04/S1103/36 43 Oopherec-
tomy 
HMB  n/s IL-1α, IL-4 
TLC 
TAH: total abdominal hysterectomy, TAHBSO: total abdominal hysterectomy and bilateral 
salpingo-oophorectomy, STAH: sub-total abdominal hysterectomy, LAVH: laparoscopic 
assisted vaginal hysterectomy, HMB: heavy menstruation bleeding, DiagLapar: diagnostic 
laparoscopy, LapSter: laparoscopic sterilisation, n/s: not specified due to irregular cycle, 
follicular/luteal phases for menstrual cycles ranging from 28 to 35 days. TLC: thin layer 
chromatography, TR: time-response. 




4.3.1 Effects of pro-inflammatory cytokines on 3β-HSD1 and 3β-HSD2 mRNA 
in primary hOSE cells 
4.3.1.1 Effect of IL-1α on 3β-HSD1 and 3β-HSD2 transcripts  
 Treatment of 4 individual hOSE cell monolayers with IL-1α in vitro in a 
dose-response manner for 48h resulted in suppression of 3β-HSD1 mRNA levels 
(Fig.4.1, upper panel). The suppression mode was dose-dependent with 
approximately 3-fold decrease when 0.1 and 0.5ng/mL of IL-1α was added 
(b=p<0.05, c=p<0.01). No effect was observed with the lowest concentration tested. 
On the other hand, IL-1α dose-dependently induced 3β-HSD2 mRNA with an at least 




Figure 4.1: Effect of IL-1α on 3β-
HSD1 and 3β-HSD2 mRNA. 
Combined data of 4 individual hOSE 
cell cultures. Primary hOSE cells 
were treated with increasing doses of 
IL-1α (0.02-0.5ng/mL) for 48h and 
expression of 3β-HSD1 mRNA 
(upper panel) and 3β-HSD2 mRNA 
(lower panel) were measured with 
Taqman qPCR (n=4, b=p<0.05, 
c=p<0.01) 
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4.3.1.2 Effect of TNF-α on 3β-HSD1 and 3β-HSD2 transcripts 
 Treatment of 4 individual hOSE cell monolayers in vitro with TNF-α in a 
dose-response mode for 48h did not affect expression levels of 3β-HSD1 or 3β-
HSD2 mRNA (Fig.4.2, upper panel and lower panel, respectively). However, a trend 
towards down-regulation of 3β-HSD1 and up-regulation of 3β-HSD2 mRNA was 
noticed, although there was variability among separate hOSE samples and thus 
combined data did not reach statistical significance (p>0.05). 
 
Figure 4.2: Effect of TNF-α on 3β-HSD1 and 3β-HSD2 mRNA. Combined data of 4 
individual hOSE cell cultures. Cells were treated with increasing doses of TNF-α for 48h and 
effects on 3β-HSD1 and 3β-HSD2 mRNA were assessed (n=4). 
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4.3.1.3 Effect of IL-6 on 3β-HSD1 and 3β-HSD2 transcripts 
 Cell monolayers of hOSE cells collected from 5 separate patients were treated 
in vitro with serial doses of the inflammatory cytokine IL-6 for 48h. Following cell 
harvest and RNA/cDNA preparation, quantitative PCR showed that none of the 3β-
HSD1 or 3β-HSD2 mRNA expression levels were affected relative to the untreated 
control samples (Fig. 4.3 upper and lower panels; p>0.05).  
 
Figure 4.3: Effect of IL-6 on 3β-HSD1 and 3β-HSD2 mRNA. Combined data of 5 
individual hOSE cell cultures. Treatment with serial doses of IL-6 for 48h was applied and 
then effects on 3β-HSD1 and 3β-HSD2 mRNA with Taqman qPCR were evaluated (n=5). 
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4.3.1.4 Effect of GM-CSF on 3β-HSD1 and 3β-HSD2 transcripts 
 Cell monolayers of hOSE cells collected from 3 separate patients were treated 
in vitro with serial doses of the inflammatory cytokine GM-CSF for 48h. 
Measurement of 3β-HSD1 and 3β-HSD2 mRNA expression levels in control 
untreated and treated samples did not show significant alterations in relative 
transcriptional expression levels of any of the target genes (Fig. 4.4 upper and lower 
panels; n=3, p>0.05), although a trend towards down-regulation of 3β-HSD2 mRNA 
was observed (Fig. 4.4 lower panel). 
 
Figure 4.4: Effect of GM-CSF on 3β-HSD1 and 3β-HSD2 mRNA. Combined data of 3 
individual hOSE cell cultures.  Expression levels of 3β-HSD1 and 3β-HSD2 mRNA were 
measured after in vitro addition of serial doses of GM-CSF for 48h (n=3). 
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4.3.1.5 Effect of IL-18 on 3β-HSD1 and 3β-HSD2 transcripts 
 Cell monolayers of hOSE cells collected from 2 separate patients were treated 
in vitro with serial doses of the inflammatory cytokine IL-18 for 48h and relative 3β-
HSD1 and 3β-HSD2 mRNA expression levels in control untreated and treated 
samples were measured with quantitative Real-Time PCR. Although insufficient 
replicates did not allow statistical analysis, IL-18 did not appear to affect basal 
expression levels of target genes at any dose tested (Fig. 4.5 upper and lower panels; 
n=2).  
 
Figure 4.5: Effect of IL-18 on 3β-HSD1 and 3β-HSD2 mRNA. Combined data of 2 
individual hOSE cell cultures. Measurement of 3β-HSD1 (upper panel) and 3β-HSD2 (lower 
panel) mRNA expression levels was performed after in vitro addition of serial doses of IL-18 
for 48h. Insufficient replicates (n=2) did not allow statistical analysis. 
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4.3.2 Effects of T lymphocyte-associated cytokines on 3β-HSD1 and 3β-HSD2 
mRNA in primary hOSE cells  
4.3.2.1 Effect of IL-4 on 3β-HSD1 and 3β-HSD2 transcripts 
 We also tested the regulation of 3β-HSD1 and 3β-HSD2 mRNA by IL-4, a T 
lymphocyte-associated cytokine. Treatment of 4 distinct primary hOSE cell cultures 
with increasing doses of IL-4 (0.02-0.5ng/mL) for 48h resulted in substantial 
stimulation of both 3β-HSD1 and 3β-HSD2 mRNA expression levels (Fig. 4.6, upper 
and lower panels, respectively; n=4, b=p<0.05, c,d=p<0.001). This response was 
dose-dependent with an approximately 15-fold increase in 3β-HSD1 mRNA levels 
when 0.5ng/mL of IL-4 was added (Fig. 4.6, upper panel). Regarding 3β-HSD2 
mRNA expression levels, IL-4 dose-dependently led to a 65-fold enhancement when 
0.5ng/mL of IL-4 was added (Fig. 4.6, lower panel). 
 
 
Figure 4.6: Effect of IL-4 on 
3β-HSD1 and 3β-HSD2 
mRNA. Combined data of 4 
individual hOSE cell cultures. 
IL-4 treatment in a dose-
dependent manner was applied 
for 48h and effects on 3β-
HSD1 mRNA (upper panel) 
and 3β-HSD2 mRNA (lower 
panel) expression levels were 
tested with Taqman Real-Time 
PCR (n=4, b=p<0.05, 
c,d=p<0.001).
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4.3.2.2 Effect of IL-10 on 3β-HSD1 and 3β-HSD2 transcripts 
 A separate T lymphocyte-associated cytokine that we used to perturb 3β-
HSD1 and 3β-HSD2 transcriptional regulation was IL-10. Treatment of 2 distinct 
hOSE cell cultures with this cytokine for 48h did not show any changes on either 3β-
HSD1 or 3β-HSD2 mRNA expression levels (Fig. 4.7, upper and lower panels, 
respectively). Lack of sufficient replicates did not permit a statistical analysis of 
these data. 
 
Figure 4.7: Effect of IL-10 on 3β-HSD1 and 3β-HSD2 mRNA. Combined data of 2 
individual hOSE cell cultures treated with sequential doses of IL-10 for 48h. Effects on 3β-
HSD1 (upper panel) and 3β-HSD2 (lower panel) mRNA levels were assessed with Taqman 
qPCR (n=2). 
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4.3.3 Effects of increasing incubation time of IL-1α and IL-4 on 3β-HSD1 and 
3β-HSD2 transcripts in primary hOSE cells 
 After establishment of the cytokines that might regulate 3β-HSD1 and 3β-
HSD2 transcript levels, cytokine effects on 3β-HSD transcriptional regulation in 
time-course studies were investigated further.  
4.3.3.1 Time-dependent studies of IL-1α on 3β-HSD1 and 3β-HSD2 transcripts 
 As shown above, treatment of hOSE cells with serial doses of IL-1α for 48h, 
differentially affected 3β-HSD1 and 3β-HSD2 mRNA. The same effect was 
observed when a fixed dose of IL-1α (0.5ng/mL) was added in hOSE cell 
monolayers in a time-response mode. Intriguingly, IL-1α-suppression of 3β-HSD1 
mRNA was achieved progressively with a significant 8-fold inhibition after addition 
of IL-1α for 48h (Fig. 4.8, upper panel; n=4, b=p<0.05). On the other hand, an IL-1α 
stimulatory effect on 3β-HSD2 mRNA was more rapid with a significant up-
regulation at the 12h time-point with no further induction within time (Fig. 4.8 lower 














Figure 4.8: Time-dependent studies of IL-1α on 3β-HSD1 and 3β-HSD2 mRNA. 
Combined data of 4 separate experiments. IL-1α treatment (0.5ng/mL) was applied in a time-
dependent mode (12, 24, 48h). Effects on 3β-HSD1 mRNA (upper panel) and 3β-HSD2 
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4.3.3.2 Time-dependent studies of IL-4 on 3β-HSD1 and 3β-HSD2 transcripts 
 Time-course (12, 24, 48h) studies with 0.5ng/mL IL-4 further supported its 
substantial stimulatory effect on both 3β-HSD transcripts (Fig. 4.9). Intriguingly, the 
effect was achieved by the 12h time-point with an apparent steady state achieved 
through to the 48h time-point (Fig. 4.9, upper and lower panels, respectively; n=3, 
b=p<0.01, c=p<0.001). IL-4 treatment of hOSE cells led to a mean 15-fold increase 
of 3β-HSD1 mRNA (Fig. 4.9, upper panel) and a mean 55-fold up-regulation of 3β-
HSD2 mRNA levels. 
 
Figure 4.9: Time-dependent studies of IL-4 on 3β-HSD1 and 3β-HSD2 mRNA. 
Combined data of 3 independent experiments. Treatments with IL-4 (0.5ng/mL) for 12, 24 
and 48h took place and 3β-HSD1 (upper panel) and 3β-HSD2 (lower panel) mRNA levels 
were measured with Taqman qPCR (n=4, b=p<0.01, c=p<0.001).  
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4.3.4 Effects of IL-1α and IL-4 on 3β-HSD protein and activity in primary 
hOSE cells 
Following investigation of individual responses of IL-1α and IL-4 to 3β-
HSD1 and 3β-HSD2 mRNA, our next step was to establish the differential cytokine 
effects on total 3β-HSD protein and activity, since intracrine bioavailability of 
steroids in hOSE is controlled by total 3β-HSD action. As such, treatment of hOSE 
collected from 7 patients with 0.5ng/mL IL-1α for 48h did not significantly affect 3β-
HSD protein (Fig. 4.10, upper panel) or total 3β-HSD activity (Fig. 4.10 lower panel). 
On the other hand, 0.5ng/mL IL-4 treatment for 48h significantly induced 3β-HSD 
protein (Fig. 4.10, upper panel) as well as progesterone formation by pregnenolone in 
hOSE, thereby reflecting an increase in total 3β-HSD activity (Fig. 4.10, lower 
panel). Similar data were also obtained with treatment with DHEA as a substrate for 
3β-HSD activity (data not shown). Human placenta and human adrenocortical H295 
cells (Fig. 4.10, upper panel) were used as positive controls for 3β-HSD1 and 3β-
HSD2 proteins, respectively. 
 
Figure 4.10: IL-1α and IL-4 effects on total 3β-HSD protein and activity in hOSE cells.  
Western immunoblotting was performed to measure 3β-HSD protein after treatment of hOSE 
cells with IL-1α and IL-4 (upper panel). 3β-HSD activity assay was performed after 
treatment of 7 independent hOSE cell cultures with IL-1α and IL-4 (lower panel; n=7, 
b=p<0.001). 
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4.3.5 Effects of IL-4 plus IL-1α co-treatment on 3β-HSD1 and 3β-HSD2 
transcripts and 3β-HSD protein in primary hOSE cells 
4.3.5.1 Morphology of hOSE cell monolayers after treatment with IL-4 in the 
presence or absence of IL-1α  
 Following the establishment of cytokine effects on 3β-HSD mRNA and 
protein, we then asked if there was any synergy between IL-1α and IL-4 signalling. 
To fulfil this, we co-treated hOSE cell monolayers with IL-1α plus IL-4 (0.5ng/mL) 
for 48h. Bright-field microscopy allowed us to monitor morphological changes of 
hOSE cells before and after treatments (Fig. 4.11). Relative to the untreated control 
cells, challenge of the cells with IL-1α for 48h affected hOSE cell morphology. 
Precisely, cells looked more elongated, displaying a fibroblast-like appearance, 
typical of regenerative hOSE cells. IL-4 treatment for 48h did not affect the hOSE 
cell epithelial phenotype in vitro. In IL-1α plus IL-4 co-treated cell monolayers, there 
was a mixture of epithelial and fibroblast-like cells. 
 
Figure 4.11: Morphology of hOSE cells treated with IL-1α, IL-4 or both. Phase contrast 
microscopy of live cell monolayers in the presence or absence of IL-1α, IL-4 or both 
cytokines (0.5ng/mL) for 48h. Morphology of cells in untreated hOSE cells (1st capture, 
control), treated with IL-1α (2nd capture), IL-4 (3rd capture) or IL-1α plus IL-4 are depicted 
(4th capture).   
 
Chapter 4                                                                                                      4.3 Results 
148 
 
4.3.5.2 Effects of IL-4 co-treated with IL-1α on 3β-HSD1 and 3β-HSD2 transcripts 
along with total 3β-HSD protein   
To investigate further a potential synergy between pro-inflammatory IL-1α 
and anti-inflammatory IL-4 in 3β-HSD1 and 3β-HSD2 transcriptional regulation (Fig. 
4.12 A) along with total 3β-HSD protein (Fig. 4.12 B), we measured relative mRNA 
and protein levels of target genes in treated and untreated hOSE cells. At the 
transcriptional level, IL-4 (0.5ng/mL) appeared to override the IL-1α response 
(0.5ng/mL), as there was not any additive effect in co-treated cells (Fig. 4.12 A upper 
and lower panels; n=5, b=p<0.05, c=p<0.001). However, co-treatment of hOSE cells 
with IL-1α and IL-4 for 48h significantly increased total 3β-HSD protein compared 

































Figure 4.12: Effects of IL-1α and IL-4 co-treatment on 3β-HSD mRNA and protein. 
A) Combined data of 5 independent experiments. Treatment of hOSE cells with IL-1α plus 
IL-4 (0.5ng/mL) for 48h were performed. Effects on 3β-HSD1 and 3β-HSD2 mRNA levels 
were measured by Taqman qPCR (n=5, b=p<0.05, c=p<0.001). B) Representative western 
immunoblotting of co-treated hOSE cells with IL-1α and IL-4 (0.5ng/mL) for 48h to 
measure total 3β-HSD protein. 
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4.3.6 Summary of Results 
4.3.6.1 Summary of data obtained through Taqman qPCR 
Table 4.4 Summary of cytokine effects on 3β-HSD1 and 3β-HSD2 mRNA 
Pro-inflammatory cytokines 3β-HSD1 mRNA 3β-HSD2 mRNA 
IL-1α ↓ ↑ 
TNF-α n/s n/s 
IL-6 n/s n/s 
GM-CSF n/s n/s 




IL-4 ↑ ↑ 
IL-10 n/s n/s 
Co-treatment   
IL-1α+IL-4 ↑ ↑ 
n/s: non-significant; ↑: up-regulation; ↓: down-regulation 
 
4.3.6.2 Summary of data obtained at the protein and activity level 
Table 4.5 Summary of cytokine effects on total 3β-HSD protein and activity 
Cytokines 3β-HSD protein 3β-HSD activity 
IL-1α n/s n/s 
IL-4 ↑ ↑ 
IL-1α+IL-4 ↑ - 
n/s: non-significant; ↑: up-regulation; -: not tested 




 In Chapter 3, we established that both 3β-HSD isoforms are present in hOSE 
cells but we did not distinguish their relative functional importance. In the present 
Chapter, we elaborate the regulation of both 3β-HSD isoforms by inflammatory-
associated mediators, reflecting therefore the intracrine formation of androgens and 
progesterone in hOSE under the control of these immune factors. We screened the 
effects of a panel of ‘inflammatory’ and ‘anti-inflammatory’ cytokines on 3β-HSD1 
mRNA, 3β-HSD2 mRNA and total 3β-HSD protein and activity. Intriguingly, all the 
cytokines tested are naturally secreted in the ovary pre- and post-ovulatory and are 
also part of the ovarian tumour microenvironment. Moreover, mRNAs for all the 
pro-inflammatory cytokines assessed, namely IL-1α, TNF-α, IL-6, IL-18 and GM-
CSF are expressed in hOSE, primary EOC and cell lines along with their cognate 
receptors (Burke et al. 1996, Lidor et al. 1993, Merogi et al. 1997, Wang et al. 2002b, 
Ziltener et al. 1993), suggesting autocrine and paracrine loops thereof in hOSE and 
ovarian cancer cells. On the other hand, the T lymphocyte-associated cytokines 
assessed, namely IL-4 and IL-10 do not appear to be secreted by hOSE or malignant 
ovarian cells, although cognate receptors are present (Burke et al. 1996). This 
implies possible paracrine roles of the latter in the normal and malignant epithelial 
ovarian cells. 
 We identified two cytokines, the pro-inflammatory IL-1α and the T 
lymphocyte- associated cytokine IL-4, to differentially mediate 3β-HSD action, at 
least in vitro, in pre-menopausal hOSE cells. Previously, a microarray analysis 
focusing on candidate inflammatory-associated genes showed that IL-1α suppressed 
3β-HSD1 mRNA (Rae et al. 2004b). Herein, we confirmed this observation but we 
also demonstrated for the first time that IL-1α induced 3β-HSD2 mRNA. A novel 
finding was that the differential effects of IL-1α in the two 3β-HSD mRNA isoforms 
resulted in maintenance of basal levels of total 3β-HSD protein and activity, at least 
in the treatment window applied. Although 3β-HSD1 mRNA appeared to 
predominate in quantity over 3β-HSD2 mRNA levels, the latter appeared to be 
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equally functional and rapidly induced under particular circumstances i.e. 
inflammation and ovulation. This in turn could restore progressive but significant 
steroid biosynthesis attenuation caused by IL-1α-suppressed 3β-HSD1 mRNA, 
enabling therefore hOSE cells to secure bioavailability of steroid synthesis during 
inflammatory ovulation and post-ovulatory tissue remodelling. This might well 
represent an efficient mechanism of hOSE cells to protect cell integrity during post-
ovulatory repair and could also explain in part why ovulation is a scarless 
inflammatory event. Precisely, a decrease of 3β-HSD1 mRNA by IL-1α is 
suggestive that the initiation of ovulation requires minimal local steroid biosynthesis. 
Concomitantly, IL-1α-induced 3β-HSD2, favouring synthesis of active ligands for 
cognate nuclear steroid receptors, could be a functional post-ovulatory mechanism to 
counteract ovulation-associated inflammation and minimise susceptibility of tissue 
to genetic damage. Androgens, such as mibolerone, a synthetic androgen that 
specifically couples to AR, have been shown to induce cell proliferation and inhibit 
cell death (Edmondson et al. 2002), whereas progesterone has been shown to be anti-
inflammatory (Rae et al. 2004a), apoptotic (Bu et al. 1997, Murdoch & Van Kirk 
2002) and to inhibit cell growth (Ivarsson et al. 2001a) in hOSE and ovarian cancer. 
Therefore, androgen synthesis may be essential for post-ovulatory repair that 
involves DNA cell proliferation, whereas associated progesterone synthesis might be 
vital to nullify the proliferation of genetically damaged cells.   
 A caveat on the studies regarding treatment of hOSE cells with IL-1α is that 
in the total 3β-HSD protein and activity assays, we examined responses over a fixed 
incubation time of the cytokine. It would be intriguing to investigate if total 3β-HSD 
protein and activity levels were influenced by IL-1α in response to time in culture. 
Based on transcriptional studies of IL-1α in response to time, we would expect an 
induction of total 3β-HSD activity at early time-points, as a result of the 3β-HSD2 
isoform, followed by progressive restoration to the basal levels due to attenuated 3β-
HSD1 mRNA at a later time. We were not able to perform these studies due to 
limited primary cell availability. However, this weakness could be overcome by the 
fact that we used primary hOSE cell samples from distinct patients and not a single 
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cell line to prove reproducibility of responses, thereby taking into account potential 
variability among patients. As such, this could better reflect physiological responses 
of hOSE in vivo. 
 The ‘anti-inflammatory’ cytokine IL-4 strongly stimulated 3β-HSD1 mRNA 
and 3β-HSD2 mRNA as well as total 3β-HSD protein and activity in normal hOSE 
cells. Up-regulation of 3β-HSD mRNA and activity, enhancing progesterone and 
androgen biosynthesis, might be part of in vivo post-ovulatory healing and repair 
mechanisms. At this time, controlled proliferation is essential for integral 
regeneration of the ovarian cell surface. As referred to earlier, androgens are 
cytoproliferative for hOSE, thereby important in post-ovulatory healing (Edmondson 
et al. 2002). However, as discussed in Chapter 1, an androgenic dominant 
environment could promote EOC due to uncontrolled cell growth and thus clonal 
expansion of transformed OSE cells (Murdoch & McDonnel 2002, Risch 1998). To 
prevent this, hOSE physiologically has developed mechanisms to monitor the death 
of damaged cells. Mechanisms that promote formation and downstream signalling of 
apoptotic and anti-proliferative progesterone could fulfil this fundamental role (Bu et 
al. 1997, Murdoch 1998, Murdoch & Van Kirk 2002, Rae et al. 2004a). Therefore, 
IL-4-induced 3β-HSD implies an anti-proliferative mechanism in hOSE. Intriguingly, 
hOSE cells have no capacity to secrete IL-4 de novo but they do express high levels 
of IL-4 receptor (Burke et al. 1996, Ziltener et al. 1993). The main source of IL-4 
secretion in the pre-menopausal ovary is the peripheral blood mononuclear cells that 
infiltrate the peri-ovulatory follicle and later the corpus luteum. IL-4 is highly up-
regulated at the luteal phase of the menstrual cycle when progesterone is also at its 
peak (Hashii et al. 1998). Accordingly, during the progestogenic luteal phase, when 
OSE repair takes place, genetically scarred cells become committed to die (Murdoch 
& Van Kirk 2002b). This paracrine mechanism might well be partially mediated by 
the local induction of 3β-HSD in hOSE due to elevated IL-4 secretion in ovarian 
environment. It is also interesting that IL-4 levels are increased in the corpus luteum 
of pregnancy (Hashii et al. 1998) which is consistent with the protective role that 
pregnancy and multiparity have against ovarian cancer (Adami et al. 1994). In 
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support of this and similarly to pregnancy, it has been shown that progesterone in the 
presence or absence of IL-4 treatment inhibits Th-1 development of T cells and 
promotes their differentiation into Th-2 cells that have a fundamental role in 
alleviation of an inflammatory environment (Miyaura & Iwata 2002). 
Given the differential effects of the pro-inflammatory IL-1α and anti-
inflammatory IL-4 in hOSE, we next investigated if there is any cross-talk between 
them in the regulation of 3β-HSD1 mRNA, 3β-HSD2 mRNA and total protein. We 
achieved that by setting up co-treatment studies in primary hOSE cell cultures. 
Morphological observations suggested that IL-1α impacts upon hOSE phenotype, as 
propagation of cells in its presence displayed a  fibroblast-like appearance typical of 
epithelio-mesenchymal transitions the hOSE undergoes during ovulation-associated 
regeneration (Auersperg et al. 2001). On the other hand, IL-4 appears to maintain the 
epithelial phenotype of hOSE, probably representing integrity of hOSE layer after 
repair. Co-treatment of hOSE cells with both cytokines resulted in a mixture of 
epithelio-fibroblast-like cells, implying that a probable role of IL-4 is to alleviate IL-
1α-related inflammation. To further investigate this hypothesis, it would be 
interesting to quantify relative levels of cytokeratin positive cells in response to 
treatments (control, IL-1α, IL-4, IL-1α+IL-4).  
Regarding 3β-HSD1 and 3β-HSD2 mRNA expression levels, IL-4 appeared 
to override the effects of IL-1α. Strikingly, at the protein level, IL-1α and IL-4 co-
treatment up-regulated total 3β-HSD protein relative to IL-4-induced 3β-HSD 
protein. This is implicative of a positive feedback loop mechanism where IL-4 anti-
inflammatory action is further potentiated to restore IL-1α-induced wounding of 
hOSE. 
 None of the remaining pro-inflammatory (TNF-α, IL-6, GM-CSF and IL-18) 
and T lymphocyte-associated cytokines (IL-10) tested affected 3β-HSD1 or 3β-
HSD2 mRNA, showing that the role of these cytokines in post-ovulatory wound 
healing of hOSE, if any, is other than controlling local bioavailability of 
progesterone and androgens. Surprisingly, nor TNF-α or IL-6 affected any of 3β-
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HSD transcripts. We could expect all three cytokines to regulate similar genes, since 
TNF-α and IL-1α share common signalling properties and IL-6 secretion has been 
shown to be dependent on IL-1α action (Nash et al. 1999, Offner et al. 1995, Rae et 
al. 2004b, Verstrepen et al. 2008). However, an effect on downstream steroid 
signalling (i.e. at the receptor level) cannot be excluded. For example, IL-6/STAT-3 
pathway is constitutively active in FSH-, LH- and oestrogen-stimulated hOSE  and 
as such it deactivates PR, thereby abrogating progesterone-dependent signalling and 
promoting cytoproliferation (Mukherjee et al. 2005, Syed et al. 2002). Moreover, an 
effect of these two cytokines on 3β-HSD mRNA transcripts at earlier time-points 
cannot be excluded either, but as discussed above, restrictions on primary cell 
availability did not allow us to set up experiments with additional parameters. 
 In conclusion, in Chapter 4, we have demonstrated that both 3β-HSD1 and 
3β-HSD2 mRNA are functional in hOSE cells. Both transcripts appear to be under 
inflammatory control during post-ovulatory wound healing processes. Opposite 
effects of IL-1α and IL-4 on the same target genes is an excellent paradigm of the 
tuning between inflammatory and anti-inflammatory activities of cytokines to restore 
homeostasis of a tissue. IL-1α differential regulation of 3β-HSD mRNA transcripts 
appears to monitor local steroid bioavailability during ovulation-associated 
inflammatory wounding of hOSE, whilst IL-4 responses appear to tightly control 
cytoproliferation of only genetically integral hOSE cells during post-ovulatory repair. 













Figure 4.13: Role of IL-1α and IL-4 in post-ovulatory injury and repair of hOSE cells. 
This diagram briefly illustrates potential roles of IL-1α and IL-4 in ovulation-associated 
regeneration of hOSE cells. Ovulation associated wounding leads to reduced steroid 
biosynthesis as a result of IL-1α-attenuated 3β-HSD1 that is counteracted by IL-1α-induced 
3β-HSD2. On the other hand, IL-4-induced 3β-HSD and therefore elevated steroid 
biosynthesis controls integral post-ovulatory repair of hOSE. Absence of arrow means no 
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 In Chapter 4 it was demonstrated that 3β-HSD in the human ovarian surface 
epithelium is under inflammatory control during ovarian post-ovulatory injury and 
repair with 3β-HSD1 and 3β-HSD2 mRNA being differentially regulated by the pro-
inflammatory IL-1α and T lymphocyte-associated IL-4. As described in Chapter 1, 
IL-1α action is mediated through transactivation of the IL-1 receptor type 1 (IL-1R1), 
whereas IL-4 action requires binding to the IL-4 receptor (IL-4R), both resulting in 
the initiation of cascades that control the regulation of IL-1α- and IL-4-responsive 
genes, respectively. In particular, IL-1α commonly activates the transduction of the 
classical inflammatory pathway, NF-κB as well as the MAPK pathways with 
SAPK/JNK and p38 MAPK the most common. On the other hand, IL-4R 
transactivation can result in the activation of PI-3K and ERK1/2 pathways, both 
mediating the cell cycle, as well as the STAT-6 pathway that is mainly involved in 
gene transcription. However, all three pathways can be parallel or complementary 
and may cooperate to mediate cell responses, from cell survival to gene expression.  
The proper response at every moment of the cell life is critical for the fate of the cell. 
The transcriptional regulation of genes that fulfil these services are under the control 
of a complex machinery that differs between different cell types at various stages of 
the cell cycle.  
 It was established in Chapter 4 that IL-1α suppressed 3β-HSD1 mRNA levels, 
whilst it stimulated 3β-HSD2 mRNA levels. Opposite activities of IL-1α on 3β-
HSD1 and 3β-HSD2 mRNA species suggests that IL-1α exerts its effects through 
activation of distinct pathways. Moreover, it was demonstrated that IL-4 induced 
both 3β-HSD1 mRNA and 3β-HSD2 mRNA, attesting to a role of IL-4 in the 
alleviation of inflammation and restoration of post-ovulatory stigma. Collectively, 
the aim of the present studies is to investigate the signalling transduction pathways 
that are potentially part of the network that regulates IL-1α- and IL-4-mediated 3β-
HSD1 and 3β-HSD2 mRNA expression.  
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5.2 Subjects and Methods 
 As referred to above, IL-1α mainly exerts its effects through the NF-κB 
pathway and MAPK family. On the other hand, IL-4 generally acts through 
activation of the PI-3K, ERK1/2 MAPK and STAT-6 signalling pathways. Therefore, 
in order to elucidate the pathways through which IL-1α and IL-4 mediate 3β-HSD1 
and 3β-HSD2, we treated primary culture hOSE cells with specific inhibitors for 
each of several pathways in the presence or absence of IL-1α or IL-4 (0.5ng/mL). 
Following incubation for 48h, cell harvest, RNA purification and RNA 
quantification/quality analysis were performed as described in Chapter 2. Then, RNA 
extracts where submitted to reverse-transcription and Taqman quantitative PCR to 
examine relative mRNA alterations among control, cytokine-treated and cytokine 
plus inhibitor-treated samples. Specific inhibitors along with their target pathways 
are depicted in Table 5.1. The basic clinical profiles of patients used for these studies 
are given in Table 5.2.  






PD98059 MEK1/2 ERK1/2 50μM (Moon et al. 2007) 
SB203580 p38 protein 
(ATP-pocket) 
p38 MAPK 10μM (Bazuine et al. 
2005) 
BAY117082 IκB NF-κB 1μM (Skurk et al. 2004) 
LY294002 p110 subunit PI-3K 10μM (Vlahos et al. 1994) 
Leflunomide Stat-6 
(pyrimidine) 
STAT-6 100μM (Akiho et al. 2005) 
All pathway inhibitors used were purchased from Merck Biosciences (Beeston, Nottingham, 
UK) and were diluted in DMSO. Untreated control cells were treated with empty vehicle 
(DMSO) 
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Table 5.2 Clinical picture of patients used for hOSE inhibitor studies 
 
TAH: total abdominal hysterectomy, TAHBSO: total abdominal hysterectomy and bilateral 
salpingo-oophorectomy, HMB: heavy menstruation bleeding, DiagLapar: diagnostic 
laparoscopy, n/s: not specified due to irregular cycle, follicular/luteal phases for menstrual 
cycles ranging from 28 to 35 days. BAY11: BAY117082, SB20: SB203580, PD98: 







Code LREC No Age 
(yrs) 





38 7332 1998/6/33 42 TAHBSO Prophylactic (21) Luteal BAY11 
23 7324 04/S1103/36 44 DiagLapar Pelvic pain (15) Follicular BAY11 
39 7336 04/S1103/36 40 TAH Prophylactic (22) Luteal BAY11 
40 7345 04/S1103/36 28 DiagLapar Pain (9) Follicular BAY11 
41 7320 04/S1103/36 47 TAHBSO HMB  n/s SB20 
38 7332 1998/6/33 42 TAHBSO Prophylactic (21) Luteal SB20 
23 7324 04/S1103/36 44 DiagLapar Pelvic pain (15) Follicular SB20 
39 7336 04/S1103/36 40 TAH Prophylactic (22) Luteal SB20 
42 7354 04/S1103/36 46 TAH HMB n/s PD98 
43 7348 04/S1103/36 40 TAH Fibroids n/s PD98 
44 9018 04/S1103/36 33 DiagLapar Mid-cycle pain (19) Luteal PD98 
44 9018 04/S1103/36 33 DiagLapar Mid-cycle pain (19) Luteal LY29 
45 5517 04/S1103/36 43 LapSter Fibroids (21) Luteal LY29 
10 5536 04/S1103/36 23 DiagLapar Dysmenorrhoea (4) Follicular LY29 
11 5537 1998/6/33 24 DiagLapar Dysmenorrhoea (28) Luteal LEF 
12 7383 04/S1103/36 43 TAHBSO Fibroids (13) Luteal LEF 
37 7414 04/S1103/36 22 DiagLapar Pelvic Pain (9) Follicular LEF 




5.3.1 Involvement of MAPK signalling transduction pathways in IL-1α- and IL-
4-mediated 3β-HSD1 and 3β-HSD2 mRNA expression 
5.3.1.1 The role of the ERK1/2 signalling pathway in IL-1α and IL-4 mediation of 
3β-HSD mRNA expression 
 In order to examine if IL-1α and IL-4 exert their effects on 3β-HSD1 and 3β-
HSD2 mRNA through activation of an ERK1/2-related pathway, hOSE cells were 
treated in vitro with 50μM of PD98059, a selective inhibitor for this pathway, in the 
presence or absence of 0.5ng/mL of IL-1α or IL-4 for 48h. Suppression of ERK1/2 
pathway did not affect IL-1α-mediated (b=p<0.05) or IL-4-elevated 3β-HSD1 and 




Figure 5.1: The role of 
the ERK1/2 signalling 
pathway in 3β-HSD 
mRNA expression.  
PD98959 (50μM) was 
added in IL-1α- or IL-4-
treated hOSE cells for 48 
hours (n=3, b=p<0.05, 
c=p<0.001). 
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5.3.1.2 The role of the p38 MAPK signalling pathway in IL-1α and IL-4 mediation of 
3β-HSD mRNA species  
 Investigation of the potential involvement of a p38 MAPK signalling 
pathway in 3β-HSD1 and 3β-HSD2 transcriptional regulation was assessed by 
suppression of this pathway with SB203580 (10μM), a selective inhibitor of this 
pathway. Intriguingly, addition of the inhibitor to hOSE cells significantly reduced 
basal 3β-HSD1 and 3β-HSD2 mRNA levels (Fig. 5.2, upper and lower panel 
respectively, b=p<0.05). However, it did not further inhibit IL-1α-decreased 3β-
HSD1 mRNA levels and it did not affect the IL-4-increased levels of 3β-HSD1 
mRNA (Fig. 5.2, upper panel; n=4, b=p<0.05, c=p<0.001). On the other hand, 
induction of 3β-HSD2 mRNA levels by IL-1α and IL-4 (0.5ng/mL) for 48h were 



























Figure 5.2: The role of the p38 MAPK signalling pathway in 3β-HSD mRNA expression. 
SB203580 (10μM) was added in IL-1α- or IL-4-treated hOSE cells (0.5ng/mL) for 48 hours. 
qPCR was performed to investigate the effects of the inhibitor alone or in the presence of IL-
1α and IL-4 on the levels of 3β-HSD1 and 3β-HSD2 mRNA (upper panel, n=4, b=p<0.05, 
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5.3.2 Involvement of the NF-κB signalling transduction pathway in IL-1α- and 
IL-4-mediated 3β-HSD1 and 3β-HSD2 mRNA expression 
 Considering that inflammatory responses are commonly mediated by NF-κB-
associated inflammatory pathways, we suppressed NF-κB signalling pathways by 
addition of BAY117082 (1μM) for 48h and tested IL-1α and IL-4 (0.5ng/mL) effects 
on the transcriptional regulation of 3β-HSD1 and 3β-HSD2 mRNA levels (Fig. 5.3, 
upper and lower panel, respectively). Abrogation of 3β-HSD1 mRNA levels by IL-
1α was blocked in the presence of BAY117082, whilst IL-4-induced 3β-HSD1 
mRNA levels were not affected (Fig. 5.3, upper panel; n=4, b=p<0.05, c=p<0.001). 
Similarly, IL-1α-elevated 3β-HSD2 mRNA levels were suppressed on the addition of 
the inhibitor, but no influence on the IL-4 stimulatory effect on 3β-HSD2 mRNA 




Figure 5.3: The role of the 
NF-κB signalling pathway 
in 3β-HSD mRNA 
expression. hOSE cells 
collected from 4 distinct 
patients were treated with 
0.5ng/mL of IL-1α or IL-4 
in the presence or absence of 
1μM BAY117082 for 48h to 
inhibit NF-κB signalling 
pathway (n=4, b=p<0.05, 
c=p<0.001). 
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5.3.3 Involvement of the PI-3K signalling transduction pathway in IL-1α- and 
IL-4-mediated effects on 3β-HSD1 and 3β-HSD2 mRNA expression 
We next tested if IL-1α and/or IL-4 action utilised the PI-3K signalling 
transduction pathway to exert their effects on the transcriptional regulation of 3β-
HSD1 and 3β-HSD2 mRNA. Therefore, we suppressed the PI-3K signalling pathway 
with the selective inhibitor, LY294002 (10μM) (Fig. 5.4). Stimulatory effects of IL-4 
(0.5ng/mL) on 3β-HSD1 and 3β-HSD2 mRNA levels were attenuated (Fig. 5.4 upper 
and lower panel, respectively; n=3, c=p<0.001, d=p<0.01). Moreover, in vitro 
addition of LY294002 completely blocked IL-1α-increased 3β-HSD2 mRNA (Fig. 
5.4, lower panel; n=3, b=p<0.05).   
 
Figure 5.4: The role of the PI-3K signalling pathway in 3β-HSD mRNA expression. 
LY294002 (10μM) was added in IL-1α- or IL-4-treated hOSE cells (0.5ng/mL) for 48h. 
Effects of the inhibitor alone or in the presence of the cytokine on the levels of 3β-HSD1 and 
3β-HSD2 mRNA was studied by Taqman qPCR (n=3, b=p<0.05, c=p<0.001, d=p<0.01). 
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5.3.4 Involvement of the STAT-6 signalling transduction pathway in IL-1α- and 
IL-4-mediated effects on 3β-HSD1 and 3β-HSD2 mRNA expression 
An additional candidate pathway that could be part of the signalling cascades 
initiated by IL-1α and/or IL-4 was STAT-6. As such, we suppreseed the STAT-6 
pathway in vitro by treatment of hOSE cells with the STAT-6 inhibitor, leflunomide 
(100μM), in the presence or absence of IL-1α or IL-4 (0.5ng/mL). Following 
incubation with those cytokines for 48 hours and RNA preparation, RNA samples 
were submitted to reverse transcription and Taqman Real-Time PCR to assess 
mRNA levels of 3β-HSD1 and 3β-HSD2 (Fig. 5.5 upper and lower panels, 
respectively). Stimulatory effects of IL-4 on 3β-HSD1 and 3β-HSD2 mRNA levels 
were significantly reduced. IL-1α responses were not affected (Fig. 5.5 upper and 
lower panels, respectively; n=3, b=p<0.05, c=p<0.001, d=p<0.01). 
 
 
Figure 5.5: The role of 
the STAT-6 signalling 
pathway in 3β-HSD 
mRNA expression. 
Leflunomide (100μM) 
was added in IL-1α- or 
IL-4-treated hOSE cells 
(0.5ng/mL) for 48h and 
effects of 3β-HSD1 and 
3β-HSD2 mRNA levels 
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5.3.5 Effects of IL-1α and IL-4 on IL-1 receptor type 1 and IL-4 receptor mRNA 
levels 
 Following establishment of the signalling transduction pathways that 
potentially relate to IL-1α and IL-4 action in 3β-HSD1 and 3β-HSD2 transcriptional 
regulation, we then explored if there was any cross-reaction of IL-1α or IL-4 in the 
expression of IL-1 receptor type 1 (IL-1R1) and IL-4 receptor (IL-4R), respectively.  
IL-1α (0.5ng/mL) did not affect IL-4R mRNA levels (Fig. 5.6, lower panel) while 
IL-4 (0.5ng/mL) also did not impact upon IL-1R1 mRNA levels (Fig. 5.6, upper 
panel). 
 
Figure 5.6: Effects of IL-1α and IL-4 on IL-1R1 and IL-4R mRNA expression. 
Combined data of 3 independent experiments. IL-1α and IL-4-treated hOSE cells (0.5ng/mL) 
were evaluated for IL-1R1 and IL-4R mRNA expression levels (n=3, upper panel and lower 
panel, respectively). 
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5.3.6 Control experiment: Effects of the various inhibitors employed on the IL-
1R1 and IL-4R mRNA levels 
 To ascertain specificity and sensitivity of the inhibitors for components 
downstream of receptor transactivation, we examined whether the various selective 
inhibitors used affected IL-1R1 and IL-4R mRNA. Experiments with 3 separate 
hOSE samples showed that none of the inhibitors assayed affected either IL-1R (Fig. 
5.7, upper panel) or IL-4R mRNA (Fig. 5.7, lower panel).  
 
Figure 5.7: Effects of pathway inhibitors on IL-1R1 and IL-4R mRNA levels. Combined 
experiments of 3 distinct hOSE samples. The doses of the inhibitors used to elucidate 
mechanisms through which cytokines affect 3β-HSD1 and 3β-HSD2 mRNA were applied 
and effects on IL-1R1 (upper panel) or IL-4R (lower panel) mRNA were tested (n=3).   
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5.3.7 Summary of pathway inhibitor experiments 
Table 5.3 Effects of inhibitors on transcriptional regulation of target genes 
 
↓: down-regulation, ↑: up-regulation, n/s: not significant, -: not tested 
Treatment Target 
Pathway 
Transcriptional regulation of target genes 
  3β-HSD1 3β-HSD2 IL-1R1 IL-4R 
PD98059 ERK1/2 n/s n/s n/s n/s 
SB203580 p38 
MAPK 
↓ ↓ n/s n/s 
BAY117082 NF-κB n/s n/s n/s n/s 
LY294002 PI-3K n/s n/s n/s n/s 
Leflunomide STAT-6 n/s n/s n/s n/s 
IL-1α  ↓ ↑ n/s n/s 
PD98059+IL-1α ERK1/2 ↓ ↑ - - 
SB203580+IL-1α p38 
MAPK 
↓ n/s - - 
BAY117082+IL-1α NF-κB n/s n/s - - 
LY294002+IL-1α PI-3K ↓ ↑ - - 
Leflunomide+IL-1α STAT-6 ↓ n/s - - 
IL-4  ↑ ↑ n/s n/s 
PD98059+IL-4 ERK1/2 ↑ ↑ - - 
SB203580+IL-4 p38 
MAPK 
↑ n/s - - 
BAY117082+IL-4 NF-κB ↑ ↑ - - 
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5.4 Discussion  
 In Chapter 4, we showed that IL-1α differentially regulated 3β-HSD1 and 3β-
HSD2 mRNA in primary cultured hOSE cells, resulting in a balance of steroid 
biosynthesis as suggested by 3β-HSD protein and activity studies. In this Chapter, we 
show that IL-1α utilises a number of pathways to fulfil these opposing effects on the 
two isoforms. IL-1α commonly uses NF-κB pathways for both transcripts, however 
p38 MAPK and PI-3K also appear to be required for IL-1α-increased 3β-HSD2 
mRNA expression. Moreover, we demonstrate that IL-4-induced 3β-HSD1 and 3β-
HSD2 mRNAs in post-ovulatory repair are mediated by PI-3K and STAT-6 
pathways. Also, at the case of 3β-HSD2 mRNA, a cross-talk of these two signalling 
pathways with p38 MAPK appears essential for this effect.   
The involvement of p38 MAPK in IL-1α and IL-4 activities in 3β-HSD1 and 
3β-HSD2 mRNA was studied through inhibition of this pathway with the pyridinyl 
imidazole compound, SB203580. This inhibitor specifically interacts with the ATP 
pocket of the p38 MAPK protein, thereby suppressing its action (Tong et al. 1997). 
Inhibition of the p38 MAPK pathway resulted in a blocking of IL-1α- and IL-4-
induced 3β-HSD2 mRNA suggesting a role for this pathway in cytokine responses. 
Intriguingly, the inhibitor alone down-regulated basal 3β-HSD1 and 3β-HSD2 
mRNA levels, suggesting that the regulation of these genes is dependent on this 
pathway. Involvement of the p38 MAPK signalling pathway in the transcriptional 
regulation of 3β-HSD is a novel finding in the documented record of 3β-HSD 
regulation in a variety of tissues (see Chapter 1, Section 1.4.2.2). However, this 
effect is consistent with p38 MAPK involvement in cell death and cell apoptosis (Xia 
et al. 1995). Although IL-1α is a strong activator of p38 MAPK in several cell 
systems, there is no evidence that it directly induces cell apoptosis, at least in vitro 
(Xia et al. 1995), suggesting that the p38 MAPK pro-apoptotic effects are probably 
exerted indirectly. Our data suggest that, at least in hOSE cells, IL-1α-induced p38 
MAPK triggers apoptotic effects through induction of transcriptional activity of 
apoptotic-associated genes such as 3β-HSD1 and 3β-HSD2 mRNA. Physiologically, 
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follicular rupture is followed by sloughing of the ovarian cell surface, a process that 
is considered to be mediated by apoptosis (Murdoch 1995). Accordingly, in a 
number of studies that were acknowledged in Chapter 1 (Section 1.5), most of the 
IL-1-regulated genes that involve p38 MAPK are proteolytic (e.g. t-PA), ECM-
related (e.g. gelatinase) or pro-inflammatory (e.g. COX-2). Intriguingly, all of these 
genes have been reported to be mediated in post-ovulatory inflammation and tissue 
remodelling of hOSE (Gubbay et al. 2005, Murdoch 1999, Rae et al. 2004a, Yang et 
al. 2004). Besides the pro-inflammatory-related genes mediated by IL-1α-induced 
p38 MAPK, herein we now show that transcriptional regulation of anti-inflammatory 
and apoptotic genes such as 3β-HSD is also possible, potentially reflecting a negative 
feedback loop mechanism of IL-1α action through which hOSE recovers from tissue 
damage.  Further support of this concept is the fact that IL-1α massively up-regulates 
11β-HSD1 mRNA and activity in hOSE, thereby sustaining local anti-inflammatory 
glucocorticoid regeneration to counteract hOSE post-ovulatory damage (Yong et al. 
2002). Remarkably, IL-1α-induction of 11β-HSD1 mRNA is reversed by SB203580, 
a p38 MAPK inhibitor (Rae M.T., unpublished observations). Moreover, TAK-1 that 
is upstream of p38 MAPK and is induced by IL-1R1 has been reported to be 
stimulated in response to TGF-β treatment in mink lung epithelial and murine 
osteoblastic cells (Yamaguchi et al. 1995). It is notable that TGF-β has been 
established to  have an apoptotic role in hOSE (Berchuck et al. 1992, Choi et al. 
2001c, Evangelou et al. 2000). Moreover, TGF-β1 has been shown to highly up-
regulate 3β-HSD1 in OSE-C2 cells, an immortalised non-malignant hOSE cell line 
(Papacleovoulou, unpublished observations). A relevant anti-inflammatory and 
protective role of p38 MAPK pathway has been also established in prostate cancer. 
Blockage of this pathway through over-expression of the MKP-1 phosphatase or 
addition of the SB203580 inhibitor rescued cells from cell death (Wu & Bennett 
2005).  
 Regarding IL-4-induced 3β-HSD1 and 3β-HSD2 mRNA, the p38 MAPK 
pathway appeared to be indispensable for 3β-HSD2 transcriptional activity but not 
for 3β-HSD1 mRNA expression, indicative that the same signal can result in 
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differential regulation of target genes. This concordance with the studies on IL-1α-
induced 3β-HSD2 mRNA indicates that transcriptional regulation of this gene 
involves p38 MAPK action. Interestingly, p38 MAPK is not notable as a universal 
signalling pathway for IL-4 action but is cell type-dependent (Hunt et al. 2002). For 
instance, IL-4 can stimulate the p38 MAPK signalling pathway in murine T and B 
lymphocyte cell lines, CT6 and BA/F3 respectively, but not in a murine macrophage 
cell line (Hunt et al. 2002). Moreover, IL-4-induced TIMP-2, an anti-inflammatory 
response, has been reported to be mediated by p38 MAPK activation as shown in 
human dermal fibroblasts (Ihn et al. 2002). Additionally, the suppressor of the 
cytokine signalling-3 (SOCS-3) has been demonstrated to be triggered by IL-4-
induced p38 MAPK in murine splenic cells (Canfield et al. 2005).   
Collectively, it appears that anti-inflammatory responses of IL-4 and IL-1α to 
3β-HSD2 mRNA in hOSE are mediated by the stimulation of the p38 MAPK 
signalling pathway. The same role could be also fulfilled by the other stress-induced 
pathway, the JNK signalling pathway. However, we were unable to study potential 
involvement of this kinase due to the poor specificity of the inhibitors available for 
this pathway (data not shown). Additional reports that question the specificity of 
these inhibitors have been previously described (Bain et al. 2003, Wu & Bennett 
2005).  
The effects of the cytokines on 3β-HSD1 and 3β-HSD2 mRNA did not 
appear to involve ERK1/2 signalling pathways as the specific inhibitor for the 
ERK1/2 activator, MEK1/2, did not alter IL-1α or IL-4 activities in 3β-HSD1 and 
3β-HSD2 mRNA levels. However, these responses are in accordance with the 
mitogenic role of this group of MAPKs along with the proposed anti-inflammatory 
and pro-apoptotic roles that 3β-HSD1 and 3β-HSD2 mRNA have at least in hOSE. 
On the other hand, ERK1/2 activation by FSH and HGF to trigger cytoproliferation 
of hOSE has been described (Choi et al. 2002, Gubbay et al. 2004).  
 Along with participation of p38 MAPK in mRNA transcriptional regulation 
of 3β-HSDs, NF-κB was also involved in IL-1α-mediated 3β-HSD1 and 3β-HSD2 
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mRNA responses. As mentioned in Chapter 1 (Section 1.5), NF-κB signalling is an 
indispensable component of the TIR superfamily, through which IL-1α exerts its 
actions. Remarkably, whereas most of the genes regulated by NF-κB are pro-
inflammatory, we are the first to show that an NF-κB pathway is involved in 
transduction of 3β-HSD1 and 3β-HSD2 mRNA by cytokines in hOSE cells as 
revealed by blockage of IL-1α-mediated 3β-HSD mRNA species after treatment with 
BAY117082 that specifically abolishes phosphorylation of IκB and hence 
translocation of NF-κB into nucleus. The involvement of this pathway in pro-
inflammatory IL-1α effects on 3β-HSD1 is consistent with the nature of NF-κB 
responses. However, and somehow surprisingly, this pathway also appears to be 
involved in an anti-inflammatory effect such as the stimulation of 3β-HSD2 mRNA 
by IL-1α. A negative feedback loop mechanism could be behind this effect. It can be 
speculated that IL-1α-activated NF-κB to induce 3β-HSD2 and thus progesterone 
formation and action through PR could in turn abolish pro-inflammatory NF-κB 
responses. In support of this, it has been proposed previously that NF-κB and PR 
mutually suppress each other’s activity (van der Burg & der Saag 1996). Precisely, it 
has been demonstrated that progesterone’s immunosuppressive and anti-
inflammatory action is subject to its ability to harness the initiation of inflammatory 
processes such as ovulation through inhibition of NF-κB signalling. For instance, in 
endometrium it has been found that progesterone through nuclear PR impacts upon 
anti-apoptotic NF-κB through driving transcription of genes that inhibit NF-κB and 
suppression of genes that activate NF-κB (Davies et al. 2004). On the other hand, 
NF-κB activation abrogates PR-associated action, thereby promoting pro-
inflammatory responses (Kalkhoven et al. 1996). Our data suggest that these effects 
might well be mediated by 3β-HSD regulation that essentially controls local 
bioavailability of the active ligand and access to PR, a crucial event for 
transactivation of downstream progesterone signalling.  
 IL-4-induced 3β-HSD1 and 3β-HSD2 mRNA levels were not affected by the 
presence of BAY117082, implying that IL-4 activity is not controlled by this 
pathway. On the other hand, another possible explanation could be that IL-4 exerts 
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its anti-inflammatory effects through antagonising IL-1α-induced pro-inflammatory 
effects. This appears to be the case in IL-1α plus IL-4 co-treatment studies described 
in Chapter 4 (Section 4.3.5). If this is the case, it is interesting that these antagonistic 
effects appear to be mediated downstream of IL-1R and IL-4R transactivation, as 
neither IL-1α nor IL-4 altered IL-4R or IL-1R mRNA. As such, it could be 
speculated that IL-4 anti-inflammatory activities are achieved through inhibition of 
the pro-inflammatory NF-κB responses and activation of pro-apoptotic p38 MAPK 
pathway. In support of this, antagonistic effects between NF-κB and p38 MAPK 
have been demonstrated. Precisely, in primary embryonic fibroblasts of a mouse 
model, it has been illustrated that inhibition of anti-apoptotic NF-κB pathway results 
in increased JNK and p38 MAPK activities (Garcia-Cao et al. 2003). Nevertheless, a 
further complexity of this issue is that NF-κB transcription factor, as described 
earlier, was shown to be involved in the IL-1α-induced 3β-HSD2 mRNA action, an 
anti-inflammatory effect, possibly reflecting a negative feedback loop mechanism. 
Another or a complementary explanation for this anti-inflammatory response could 
be a cross-talk mechanism of NF-κB with the PI-3K and the p38 MAPK-induced 
pathways (see below).   
IL-1α-induced 3β-HSD2 mRNA levels were also found to be a result of 
activation of the PI-3K signalling pathway. Although the PI-3K pathway is not the 
most common target of IL-1R1 transactivation, recent reports suggest involvement of 
this pathway in IL-1 signalling cascades. A role of this pathway in IL-1β-mediated 
metabolic pathways (i.e. lactate production) has been reported in rat Sertoli cells 
(Riera et al. 2007). Moreover, this pathway has been shown to be an intermediate of 
IL-1-regulated NF-κB transcription factor action, mediating IL-8 mRNA and 
secretion in human glioblastoma cells (Funakoshi et al. 2001). Importantly, in the 
HepG2 cell line, PI-3K appears to trigger NF-κB transcriptional activity through p65 
phosphorylation (Sizemore et al. 1999), consistent with the concept that IκB 
phosphorylation and ubiquitination are not sufficient for NF-κB activation and 
nuclear translocation (Zhong et al. 1997). Moreover, it has been also found that both 
p38 MAPK and PI-3K signalling pathways co-operate in IL-1-induced AP-1 
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transcriptional activity in glioblastoma cells (Funakoshi et al. 2001). Additionally, t-
PA activity in osteosarcoma cells appears to be dependent on PI-3K and p38 MAPK 
activation (Chang et al. 2006). Jointly, these findings suggest that PI-3K could be an 
intermediate activator of the p38 MAPK- and NF-κB-dependent 3β-HSD2 mRNA 
expression. Therefore, it is intriguing that IL-1α utilises different signalling pathways 
to regulate different genes, and this is probably part of the opposite effects that this 
proxy exerts on the two 3β-HSD mRNA species. 
Additionally, the PI-3K pathway appeared a component in the effects of IL-4 
on 3β-HSD1 and 3β-HSD2 mRNA species as these effects were partially but 
significantly suppressed when LY294002, a specific inhibitor of PI-3K activity, was 
added. As noted in Chapter 1 (Section 1.5), this pathway is mainly involved in 
mitogenic activities of IL-4, since it usually activates the Akt proto-oncogene that 
sustains cell proliferation and survival and blocks apoptosis (Franke et al. 1997). As 
discussed in Chapter 4, IL-4 is mainly secreted during the luteal phase of the 
menstrual cycle when ovarian tissue remodelling and repair of the stigma take place, 
suggesting that IL-4 promotes hOSE cell proliferation to heal the wound. 
Physiologically, IL-4-stimulated 3β-HSDs through PI-3K activation to induce local 
generation of progesterone in hOSE might be a mechanism through which IL-4 
monitors controlled proliferation of only integral hOSE cells. As such, genetically 
damaged cells undergo progesterone-associated apoptosis during post-ovulatory 
repair. Consistent with this model, it has been previously shown that IL-4-treated 
porcine endothelial cells are protected from TNF-α-induced injury through activation 
of PI-3K-associated cell survival responses (Grehan et al. 2005). Furthermore, in 
breast cancer cell lines PI-3K signalling pathways were demonstrated to be an 
intermediate component of IL-4-induced 3β-HSD1 activity (Gingras et al. 2000). On 
the other hand, impaired PI-3K signalling at post-ovulatory repair might lead to 
dysfunction of related transcriptional machinery. This could have profound 
implications in the aetiology of ovarian cancer as links between amplification of PI-
3K components and EOC have been described (Mills et al. 2001, Shayesteh et al. 
1999, Wong et al. 2001, Yuan et al. 2000).  
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The STAT-6 pathway is ubiquitously activated by IL-4 and is the major 
component of transcriptional regulation of IL-4-responsive genes. Leflunomide, a 
STAT-6 inhibitor, moderately though significantly suppressed IL-4-induced 3β-
HSD1 and 3β-HSD2 mRNA levels. Accordingly, the promoter of the gene for 3β-
HSD1 includes two STAT-6 recognition sites. Similarly, the gene for 3β-HSD2 also 
contains a putative STAT-6 recognition site in the promoter (Gingras et al. 2000). It 
is not clear from the present data if the multiple signalling pathways that participate 
in IL-4 responses are parallel or complementary. Thus, STAT-6 transactivation 
might involve PI-3K activity as seen in the case of 3β-HSD1 or even p38 MAPK as 
seen in the case of 3β-HSD2 mRNA. Indeed, it has been established that 
transactivation of STAT-6-induced transcriptional regulation of IL-4-responsive 
genes is mediated by p38 MAPK activity (Pesu et al. 2002). Besides, in the 
keratinocyte HaCaT cell line, it has been demonstrated that IL-4 exerts some of its 
anti-inflammatory effects through enhancement of the IL-13 receptor αII mRNA and 
protein (Th-2 response) and this is achieved through p38 MAPK activation that in 
turn facilitates IL-4-dependent STAT-6 transcriptional regulation (David et al. 2001). 
Moreover, albeit that involvement of PI-3K is mainly in cell cycle activities of IL-4, 
its participation in transcriptional regulation of IL-4-mediated genes has been also 
established (Gingras et al. 2000, Wang et al. 1997, Wang et al. 1998). 
 The participation of multiple signalling pathways in the regulation of 3β-HSD 
protein/activity cannot be predicted at the moment. It is widely accepted that protein 
kinases can impact upon transcriptional and/or post-transcriptional and/or 
translational and/or post-translational regulation of responsive genes. For example, in 
human fibroblasts, it has been shown that p38 MAPK regulates IL-6 production, but 
it does not affect IL-6 mRNA synthesis (Ridley et al. 1997).  
 In order to ascertain that the tested inhibitors as well as the doses used 
exclusively abolish target molecules of signalling pathways and all the effects 
obtained are not a consequence of cytokine receptor activation/suppression, we 
assessed the effects of inhibitors alone on the respective receptors. Basal levels of IL-
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1R1 and IL-4R did not alter in response to any of the pathway inhibitors, suggestive 
of action of the latter in downstream of the receptors signalling molecules. 
 In conclusion, we have demonstrated that IL-1α utilises different panels of 
signalling molecules to mediate 3β-HSD1 and 3β-HSD2 mRNA transcription, 
probably explaining its opposing effects on these genes. Its pro-inflammatory effect 
on 3β-HSD1 is mediated by NF-κB, whereas the anti-inflammatory action in 3β-
HSD2 is monitored by NF-κB, p38 MAPK and PI-3K signalling pathways. On the 
other hand, the IL-4 anti-inflammatory effects on hOSE during post-ovulatory repair 
are mediated through STAT-6 and PI-3K signalling networks. Moreover, in the case 
of 3β-HSD2, p38 MAPK is essential for IL-4 action and this implies that these two 
very similar genes are regulated by different mechanisms. A summary of our 
proposed model is presented in Fig. 5.8. 
 
Figure 5.8: Signalling pathways involved in IL-1α and IL-4 responses to 3β-HSD1 and 
3β-HSD2 mRNA. Schematic representation of the proposed model and mechanisms for the 
role of IL-1α and IL-4 in injury and repair of hOSE with respect to 3β-HSD involvement. 
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 In Chapters 3, 4 and 5, the focus was on the mechanisms that control 
progesterone and androgen pre-receptor metabolism and bioavailability in primary 
hOSE cells through investigation of the regulation of 3β-HSD1 mRNA and 3β-HSD2 
mRNA expression along with total 3β-HSD protein and activity. However, local 
bioavailability of androgens and progestogens is not sufficient for their local action. 
As discussed in Chapter 1 (Section 1.4), the action of these two hormones is 
achieved through their binding to the cognate receptors, namely androgen (AR) and 
progesterone (PR) receptors. As described in Chapter 1 (Section 1.2.3), apart from 
the capacity of hOSE to form active steroid ligands, it has the ability to promote 
them through expression of nuclear steroid receptors. As such, the human ovarian 
surface expresses functional AR and PR, suggesting that the active products of the 
3β-HSD enzyme, androstenedione and progesterone can directly exert their 
cytoproliferative and apoptotic/anti-inflammatory effects respectively in hOSE. So 
far, it has been established that 3β-HSD mRNA species are differentially regulated 
by IL-1α and IL-4, implying altered bioavailability of steroid ligands during post-
ovulatory wounding and healing of the ovarian cell surface. Nonetheless, there is a 
lack of evidence whether these two cytokines could also affect downstream 
signalling of androgens and progestogens through regulation of the AR and PR 
during post-ovuatory injury and repair of hOSE. 
 Therefore, the aim of this Chapter is the investigation of the effects of IL-1α 
and IL-4 on AR and PR mRNA and protein expression in primary hOSE cells. After 
establishment of a potential role of any of these two cytokines in AR and PR 
expression, we further investigated the mechanisms through which these effects 
might be exerted, focusing on pathway inhibitor studies as described in Chapter 5.   
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6.2 Subjects and Methods 
 In order to investigate the effects of cytokines on AR and PR mRNA and 
protein expression, we first ascertained that AR and PR proteins were present in the 
ovarian surface epithelium. We achieved that through fluorescence 
immunohistochemistry as described in Chapter 2. Then, using sqPCR, we confirmed 
that AR and PR mRNA expression levels remain in vitro in primary hOSE cell 
cultures. Treatments with IL-1α and IL-4 were applied to cultured hOSE monolayers 
and then Taqman qPCR and western immunoblotting were performed to measure the 
effects of these cytokines on AR and PR mRNA and protein levels, respectively 
relative to untreated control samples. Further treatments with pathway inhibitors in 
the presence or absence of cytokines were also conducted to elucidate the 
mechanisms through which cytokines might exert their effects on AR or PR mRNA 
expression levels. The basic clinical profile of patients used to complete these studies 
is presented in Tables 6.1, 6.2 and 6.3.  









1 29 Amenorrhoeic past 5yrs; 
cyclical pain 
- AR, PR 
2 40 Dysmenorrhoea; 
constant bleeding  
- AR, PR 
3 40 Constant bleeding for 7 
months; endometriosis 
history 
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Table 6.2 Clinical profile of patients whose hOSE used for in vitro studies for 




Code LREC No Age 
(yrs) 





10 5536 04/S1103/36 23 DiagLapar HMB/pain (4) n/s sqPCR  
11 5537 04/S1103/36 24 DiagLapar Dysmenorrhoea (28) Luteal sqPCR  
12 7383 04/S1103/36 43 TAHBSO Fibroids (13) n/s sqPCR 
13 7384 04/S1103/36 42 TAH HMB (23) Luteal sqPCR 
14 9014 04/S1103/36 32 DiagLapar Pelvic pain (6) n/s sqPCR 
21 7357 05/S1103/14 33 TAH HMB  n/s IL-1α (TR) 
25 7304 04/S1103/36 34 DiagLapar Dysmenorrhoea (7) Follicular IL-1α (TR) 
26 7361 04/S1103/36 39  LapSter Constant bleeding  n/s  IL-1α (TR) 
27 9012 04/S1103/36 34   LapSter Prophylactic  n/s  IL-1α (TR) 
6 5484 05/S1103/14 32 TAH Prolapse (24) Luteal IL-4 (TR) 
7 5497 04/S1103/36 39 TAH Pelvic pain (10) n/s IL-4 (TR) 
8 5499 04/S1103/36 47 TAHBSO Fibroids n/s IL-4 (TR) 
38 7314 04/S1103/36 43 Oopherectomy HMB n/s IL-1α+IL-4 
8 5499 04/S1103/36 47 TAHBSO Fibroids n/s IL-1α+IL-4 
39 7326 04/S1103/36 43 TAH Fibroids (27) n/s IL-1α+IL-4 
12 7383 04/S1103/36 43  TAHBSO Fibroids (13) n/s IL-1α+IL-4 
37 7414 04/S1103/36 22 DiagLapar Pelvic pain (9) n/s IL-1α+IL-4 
20 7423 04/S1103/36 49 TAH Fibroids (30) Luteal IL-4 
35 7435 04/S1103/36 43 TAH Dysmenorrhoea (14) Luteal IL-4 
36 7437 04/S1103/36 32 DiagLapar Pelvic pain (1)Mens/Fol IL-4 
37 7414 04/S1103/36 22 DiagLapar Pelvic pain n/s IL-4 
7 5497 04/S1103/36 39 TAH Dysmenorrhea (10) n/s IL-4 protein 
23 7324 04/S1103/36 44 DiagLapar Pelvic pain (15) Luteal IL-4 protein 
46 7437 04/S1103/36 32 DiagLapar Pelvic pain n/s IL-4 protein 
TAH: total abdominal hysterectomy, TAHBSO: total abdominal hysterectomy and bilateral 
salpingo-oophorectomy, HMB: heavy menstruation bleeding, DiagLapar: diagnostic 
laparoscopy, LapSter: laparoscopic sterilisation, n/s: not specified due to irregular cycle, 
follicular/luteal phases for menstrual cycles ranging from 28 to 35 days. TR: time-response 
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Table 6.3 Clinical picture of patients used for pathway inhibitor studies 
 
TAH: total abdominal hysterectomy, TAHBSO: total abdominal hysterectomy and bilateral 
salpingo-oophorectomy, HMB: heavy menstruation bleeding, DiagLapar: diagnostic 
laparoscopy, n/s: not specified due to irregular cycle, follicular/luteal phases for menstrual 
cycles ranging from 28 to 35 days. BAY11: BAY117082, SB20: SB203580, PD98: 





Code LREC No Age 
(yrs) 





38 7332 1998/6/33 42 TAHBSO Prophylactic (21) Luteal BAY11 
23 7324 04/S1103/36 44 DiagLapar Pelvic pain (15) Follicular BAY11 
39 7336 04/S1103/36 40 TAH Prophylactic (22) Luteal BAY11 
40 7345 04/S1103/36 28 DiagLapar Pain (9) Follicular BAY11 
41 7320 04/S1103/36 47 TAHBSO HMB  n/s SB20 
38 7332 1998/6/33 42 TAHBSO Prophylactic (21) Luteal SB20 
23 7324 04/S1103/36 44 DiagLapar Pelvic pain (15) Follicular SB20 
39 7336 04/S1103/36 40 TAH Prophylactic (22) Luteal SB20 
42 7354 04/S1103/36 46 TAH HMB n/s PD98 
43 7348 04/S1103/36 40 TAH Fibroids n/s PD98 
44 9018 04/S1103/36 33 DiagLapar Mid-cycle pain (19) Luteal PD98 
44 9018 04/S1103/36 33 DiagLapar Mid-cycle pain (19) Luteal LY29 
45 5517 04/S1103/36 43 LapSter Fibroids (21) Luteal LY29 
10 5536 04/S1103/36 23 DiagLapar Dysmenorrhoea (4) Follicular LY29 
11 5537 1998/6/33 24 DiagLapar Dysmenorrhoea (28) Luteal LEF 
12 7383 04/S1103/36 43 TAHBSO Fibroids (13) Luteal LEF 
37 7414 04/S1103/36 22 DiagLapar Pelvic Pain (9) Follicular LEF 




6.3.1 Expression of androgen receptor in the human ovarian surface epithelium 
 Fluorescence immunohistochemistry in whole ovarian tissue was performed 
to immunodetect AR in the ovarian cell surface. It was demonstrated that AR (green) 
was located in the nuclei of ovarian surface epithelial cells (Fig. 6.1A, b-c). An antral 
follicle was used as a positive control (Fig. 6.1A, e-f). 
 In order to ascertain that AR mRNA expression remains in the primary 
cultured hOSE cells, sqPCR analysis of five hOSE independent samples was 
performed. AR was expressed in five hOSE samples from five patients (Fig. 6.1B, 
upper gel). Lutein-granulosa cells were used as a positive control (Fig. 6.1B, upper 
gel). cDNA integrity/quality was assessed with GAPDH mRNA (Fig. 6.1B, lower 
gel).    
 
Figure 6.1: Expression of AR protein and mRNA in hOSE. A) Immunofluorescence to 
whole ovarian tissue for AR (green). White arrows in a-c denote hOSE cells, whereas arrows 
in d-f denote follicular cells. Nuclei were stained with Dapi (blue). Scale bars 20μm. B) 
sqPCR for AR mRNA (upper gel) and GAPDH mRNA (lower gel)  in lutein-granulosa cells 
and five hOSE samples. 
Chapter 6                                                                                                 6.3 Results 
184 
 
6.3.2 Expression of progesterone receptor in the human ovarian surface 
epithelium 
 Fluorescence immunohistochemistry was performed to immunodetect PR in 
whole ovarian tissue. PR (red) was immunodetected in the nuclei of the ovarian 
surface epithelial cells (Fig. 6.2A, b-c) as well as in the corpus luteum (Fig. 6.2A, e-
f). 
 Moreover, sqPCR for PR mRNA expression was performed in five separate 
primary cultured hOSE cells. PR was expressed in five hOSE samples from five 
patients (Fig. 6.2B, upper gel). Lutein-granulosa cells were again used as a positive 
control (Fig. 6.2B, upper gel). cDNA integrity/quality was assessed with GAPDH 
mRNA (Fig. 6.2B, lower gel). 
 
Figure 6.2: Expression of PR protein and mRNA in hOSE. A) Fluorescence 
immunohistochemistry in whole ovarian tissue shows nuclear immunodetection of PR (red) 
in hOSE and corpus luteum (arrows). Nuclei were stained with Dapi (blue). Scale bars 
represent 20μm. B) sqPCR was performed in lutein-granulosa cells and five hOSE samples 
to investigate mRNA expression of PR (upper gel) and GAPDH (lower gel).  
Chapter 6                                                                                                 6.3 Results 
185 
 
6.3.3 Effects of IL-1α on AR and PR mRNA expression in primary hOSE cells 
 Taqman qPCR was performed in primary hOSE cell cultures to investigate 
the effects of IL-1α (0.5ng/mL) on AR mRNA and PR mRNA.  Combined data from 
four independent hOSE samples that were treated with IL-1α for 0, 12, 24 and 48h 
showed that IL-1α did not affect basal mRNA levels of AR (Fig. 6.3A) or PR (Fig. 
6.3B). 
 
Figure 6.3: Effect of IL-1α on AR and PR mRNA expression. Combined data of 4 
independent experiments. Time-course studies to investigate the effects of IL-1α (0.5ng/mL) 
on AR mRNA (A) and PR mRNA (B) (n=4).  
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6.3.4 Effects of IL-4 on AR and PR mRNA expression in primary hOSE cells 
 To further investigate androgen and progesterone action in hOSE cells, we 
treated cell monolayers with IL-4 (0.5ng/mL) for 0, 12, 24 and 48h and assessed its 
effects on AR and PR mRNA levels. IL-4 treatment did not affect PR mRNA (Fig. 
6.4B), but it down-regulated AR mRNA (Fig. 6.4A). AR mRNA suppression 
appeared slow and progressive with a significant decrease observed after 48h 
treatment with IL-4 (2-fold inhibition; Fig. 6.4B, n=3, b=p<0.05).  
 
Figure 6.4: Effect of IL-4 on AR and PR mRNA expression.  Combined data of 3 
independent replicates. Primary hOSE cells were treated with IL-4 (0.5ng/mL) for 0, 12, 24 
and 48h. Then, effects on AR (A) and PR (B) mRNA were measured with Taqman qPCR 
(n=3, b=p<0.05).   
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6.3.5 The effects of IL-1α and IL-4 co-treatment on AR and PR mRNA 
expression in primary hOSE cells 
  To further confirm the responses of IL-1α and IL-4 to AR and PR mRNA 
levels, we treated the same hOSE sample with both cytokines (0.5ng/mL) for 48h in 
five independent replicates. Treatment with IL-1α did not affect either AR mRNA 
(Fig. 6.5A) or PR mRNA (Fig. 6.5B), whereas IL-4 suppressed AR mRNA with no 
influence on PR mRNA (Fig. 6.5A and 6.5B, respectively). Co-treatments did not 
affect the inhibitory IL-4 effect on AR mRNA (Fig. 6.5A, n=5, b=p<0.05).  
 
Figure 6.5: The effects of IL-1α and IL-4 on AR and PR mRNA expression. Combined 
data from 5 independent hOSE samples. The same hOSE sample was treated with both IL-1α 
and IL-4 and the effects on AR mRNA and PR mRNA levels were assessed with Taqman 
qPCR (n=5, b=p<0.05). 
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6.3.6 The dose-dependent effects of IL-4 on AR mRNA and AR protein in 
primary hOSE cells 
 To further investigate the effect of IL-4 on AR mRNA expression, we treated 
primary hOSE cells with increasing doses of IL-4 (0.02, 0.1, 0.5ng/mL) for 48h (Fig. 
6.6A). Taqman qPCR showed that the suppression of AR mRNA levels relative to 
untreated control was observed only at the highest dose of IL-4 treatment (0.5ng/mL) 
(Fig. 6.6A, n=4, b=p<0.05). To assess if this effect also remained at the protein level, 
we treated hOSE cells with 0.5ng/mL and 5ng/mL IL-4 for 48h and we assessed the 
effects of IL-4 on AR protein extracts using western immunoblotting (Fig. 6.6B). 
Moderate inhibition of AR protein was demonstrated only when 5ng/mL of IL-4 was 
added (Fig. 6.6B, upper blot). Protein loading was ascertained with probing for actin 
(Fig. 6.6B, lower blot). The specificity of the AR antibody was assessed with T47D 
cells as described in Chapter 2. 
 
Figure 6.6: The effects of IL-4 on AR mRNA and protein in hOSE cells. A) Combined 
data of 4 hOSE cell cultures. Cells were treated with increasing doses of IL-4 in a dose-
response manner (0.02-0.5ng/mL) for 48h  and effects on AR mRNA were measured. B) A 
representative blot shows effects of IL-4 (0.5 and 5ng/mL) on AR protein. Actin was used as 
a loading control. Human T47D cell line was used as a positive control for AR protein. 
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6.3.7 Signalling pathways involved in the transduction of IL-4-mediated AR 
mRNA expression in primary hOSE cells  
 As discussed in Chapter 1, IL-1α and IL-4 mediate their effects through 
binding to their cognate cell surface receptors IL-1R1 and IL-4R, respectively, 
followed by transactivation of the latter and initiation of signalling cascades. To 
investigate the signalling pathways involved in IL-4 suppression of AR mRNA, we 
treated primary hOSE cells with IL-4 in the presence or absence of inhibitors specific 
for ERK1/2, p38 MAPK, NF-κB, PI-3K and STAT-6 signalling pathways.  
6.3.7.1 The role of the MAPK pathways in IL-4 suppression of AR mRNA levels  
 In order to investigate if IL-4-decreased AR mRNA expression involved the 
ERK1/2 pathway, we treated hOSE cells with IL-4 (0.5ng/mL) in the presence or 
absence of PD98059 (50μM) for 48h. Taqman qPCR for AR mRNA, showed that 
inhibition of the ERK1/2 pathway did not reverse suppression of AR mRNA levels 
by IL-4 treatment (Fig. 6.7A, n=3, b=p<0.05).  
 Investigation of a potential role of the p38 MAPK pathway in IL-4-mediated 
AR mRNA was achieved through inhibition of the p38 MAPK pathway with 
addition of SB203580 (10μM) in the presence of IL-4 (0.5ng/mL) for 48h. Taqman 
qPCR in 4 independent experiments demonstrated that SB203580 reversed the IL-4 
suppression of AR mRNA levels, whilst it did not affect AR mRNA levels in the 











Figure 6.7: The effects of (A) an ERK1/2 and (B) a p38 MAPK pathway inhibitors on 
AR mRNA levels. Combined data of 3 (A) and 4 (B) independent experiments. Effects of 
inhibitors of ERK1/2, PD98059 (50μM) (A) and p38 MAPK, SB203580 (10μΜ) (B) 
pathways on the AR mRNA levels in the presence or absence of IL-4 (0.5ng/mL) for 48h 
(b=p<0.05).
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6.3.7.2 The role of the NF-κB pathway in IL-4 suppression of AR mRNA levels 
 Primary hOSE cells were treated with IL-4 (0.5ng/mL) in the presence or 
absence of BAY117082 (1μM) for 48h to determine if an NF-κB inflammatory 
pathway plays a role in the suppression of AR mRNA levels by IL-4.  Although IL-4 
in the presence of the inhibitor did not significantly inhibit AR mRNA relative to 
untreated control cells, cells treated with both IL-4 plus inhibitor were not 
significantly different from the IL-4-treated cells (Fig. 6.8; n=4, b=p<0.05). 
 
 
Figure 6.8: The effect of an NFκ-B pathway inhibitor on AR mRNA levels. Combined 
data of 4 independent replicates. Taqman qPCR was performed to investigate whether the 
inhibitor of the NF-κB pathway, BAY117082 (1μM) affects IL-4 (0.5ng/mL; 48h) 
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6.3.7.3 The role of the PI-3K pathway in IL-4 suppression of AR mRNA levels 
 IL-4 treatment (0.5ng/mL) for 48h was applied to primary hOSE samples in 
the absence or presence of LY294002 (10μM) in order to investigate any potential 
role of the PI-3K pathway in IL-4-decreased AR mRNA expression. As established 
with Taqman qPCR, abrogation of AR mRNA levels by IL-4 were not affected by 
inhibition of the PI-3K pathway (Fig. 6.9; n=3, b=p<0.05).    
 
 
Figure 6.9: The effect of a PI-3K pathway inhibitor on AR mRNA levels. Combined data 
of 3 independent experiments. Taqman qPCR was performed to investigate whether the 
inhibitor of the PI-3K pathway, LY294002 (10μM) affects IL-4 suppression of AR mRNA 
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6.3.7.4 The role of the STAT-6 pathway in IL-4 suppression of AR mRNA levels 
 IL-4 treatment (0.5ng/mL) for 48h was applied to primary hOSE samples in 
the absence or presence of leflunomide (100μM) in order to investigate any potential 
role of the STAT-6 pathway in IL-4 abrogation of AR mRNA levels. As determined 
by Taqman qPCR, IL-4 action on AR mRNA levels was not reversed by inhibition of 
the STAT-6 pathway (Fig. 6.10; n=3, b=p<0.05).   
 
 
Figure 6.10: The effect of a STAT-6 pathway inhibitor on AR mRNA levels. Combined 
data of 3 independent experiments with distinct primary hOSE cells. Taqman qPCR was 
performed to investigate whether the inhibitor of the STAT-6 pathway, leflunomide (100μM) 





Chapter 6                                                                                                 6.3 Results 
 194 
6.3.8 Summary of the effects of IL-1α and IL-4 on AR and PR mRNA and 
protein expression 
Table 6.4 IL-1α and IL-4 effects on AR mRNA/protein and PR mRNA 
expression 
Treatment AR mRNA/protein PR mRNA 
IL-1α n/s n/s 
IL-4 ↓ n/s 
IL-1α+IL-4 ↓ n/s 
n/s: not significant, ↓: down-regulation 
Table 6.5 Effects of signalling pathway inhibitors on transcriptional regulation 




PD98059 ERK1/2 n/s 
SB203580 p38 MAPK n/s 
BAY117082 NF-κB n/s 
LY294002 PI-3K n/s 
Leflunomide STAT-6 n/s 
IL-4  ↓ 
PD98059+IL-4 ERK1/2 ↓ 
SB203580+IL-4 p38 MAPK n/s 
BAY117082+IL-4 NF-κB n/s 
BAY117082+IL-4 vs IL-4 NF-κB n/s 
LY294002+IL-4 PI-3K ↓ 
Leflunomide+IL-4 STAT-6 ↓ 
                    ↓: down-regulation, n/s: not significant
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6.4 Discussion 
 In previous Chapters we demonstrated 3β-HSD expression in the ovarian 
surface, suggesting that this ovarian compartment is capable of producing PR- and/or 
AR-activating ligands. Herein, we illustrate that besides 3β-HSD, AR and PR are 
also expressed in hOSE cells. More importantly, we have demonstrated that IL-4 
suppressed AR mRNA and protein levels without affecting expression of PR levels, 
suggesting that IL-4 sustains progesterone rather than androgen signalling in hOSE. 
Notably, this effect appeared to be mediated by an IL-4-induced p38 MAPK 
signalling pathway. 
 Fluorescence immunohistochemistry confirmed the presence of AR and PR 
immunoreactive proteins in the human ovarian surface epithelium, confirming 
previous reports (Edmondson et al. 2002, Li et al. 2003). These data show that 3β-
HSD active ligands can act through binding to the cognate AR and PR receptors. As 
such, the human ovarian cell surface possesses the enzyme and receptor machinery 
for functional signalling of the 3β-HSD potent PR ligand, progesterone and the weak 
AR ligand, androstenedione. The latter can subsequently be converted to the more 
potent AR ligand, testosterone, a reaction catalysed by 17β-HSD that is also 
expressed in hOSE (Rae et al. 2004b).  After establishment of AR and PR 
localisation in the ovarian cell surface, it was next demonstrated that measurable AR 
and PR mRNA levels remain in primary cultures of hOSE cells, allowing therefore a 
study of the regulation of these receptors in vitro using this cell culture system. 
 Although previous studies have established the responsiveness of hOSE to 
androgen and progesterone, it has not been determined whether AR and PR levels are 
affected during post-ovulatory injury and repair of hOSE cells. To this end, we 
treated hOSE cell monolayers with IL-1α to mimic post-ovulatory wounding of 
hOSE or with IL-4 to mimic post-ovulatory repair of hOSE and then assessed AR 
and PR mRNA expression levels relative to untreated control cells. IL-1α did not 
affect basal mRNA levels of either AR or PR, supporting the hypothesis that during 
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post-ovulatory injury of hOSE there is not only a balance in local steroid 
biosynthesis but also in access of ligands to the cognate nuclear receptors. As such, 
at the apex of ovulation, when IL-1α is produced, steroid biosynthesis and 
downstream signalling does not alter and this might well be part of the mechanisms 
that monitor homeostasis of the ovarian cell surface during injury.         
 We also found that IL-4 significantly suppressed AR mRNA and protein 
levels, albeit at a progressive and rather sluggish manner as revealed in time-course 
and dose-response studies. On the other hand, IL-4 did not alter PR mRNA levels. 
Collectively, these effects imply that IL-4 sustains progesterone rather than androgen 
action in hOSE during the post-ovulatory healing processes. The importance of this 
finding is subject to the general concept proposed in Chapter 4 that IL-4 plays a role 
in post-ovulatory repair by monitoring proliferation of integral only hOSE cells, 
whilst it commits genetically damaged cells to die. It appears that IL-4 fulfils this 
effect in two stages; firstly, it stimulates local 3β-HSD activity, thereby triggering 
formation of progestogens and androgens and secondly, it sustains progesterone 
action through suppression of AR function. Hence, during the luteal phase of the 
menstrual cycle when repair takes place, IL-4 activity on hOSE allows progesterone 
to induce cell apoptosis and repair of genetically scarred hOSE cells (Murdoch 1998, 
Murdoch & Van Kirk 2002). Notably, a role of IL-4 in mediation of stress 
inflammatory responses has been also demonstrated in bovine adrenal cells, where 
IL-4 increased ACTH-induced release of the anti-inflammatory cortisol through 
abolishment of ACTH-stimulated secretion of androgens (Woods & Judd 2008). 
Also, another study concluded that the expression of IL-4 and AR was negatively 
correlated in fibroblast cells collected from patients with gingival overgrowth or 
control patients (Huang et al. 2003). In general, it is possible that a way by which IL-
4 alleviates inflammatory responses could be through the suppression of AR 
transactivation. This could have profound implications in the aetiology of EOC 
where a positive link between androgens and development of the disease has been 
constantly proposed (Edmondson et al. 2002, Evangelou et al. 2000, Evangelou et al. 
2003, Risch 1998, Shaw et al. 2001). However, it should be noted at this point, that 
Chapter 6                                                                                                6.4 Discussion  
 197 
in the prostate cancer cell line LNCaP, IL-4 has been shown to activate rather than 
suppress AR activity (Lee et al. 2003), showing that effects of IL-4 on AR might 
differ between cell types or importantly might alter between normal and malignant 
tissues. This could be a mechanism of tumour cells to escape from T cell surveillance, 
an aspect that was discussed in Chapter 1 (Section 1.3).  
 Specific inhibitors for several signal transducing pathways were used to 
identify the mechanisms through which IL-4 suppresses AR function, at least 
regarding mRNA transcriptional levels. These studies showed that only the p38 
MAPK signalling pathway appears essential for the transcriptional regulation of AR 
mRNA by IL-4. Surprisingly, the STAT-6 and PI-3K signalling pathways that are 
commonly activated by IL-4 did not appear to be involved in IL-4-attenuated AR 
mRNA expression. It is noteworthy, therefore, that IL-4 mediates its effects on 
several responsive genes by the activation of different panels of signalling pathways. 
Despite the fact that IL-4 can influence the regulation of AR not only in hOSE cells, 
but also in other cell systems (see above), there is no evidence of STAT-6 
involvement in these effects and there are also no reports of STAT-6 recognition 
sites in the promoter of AR gene. Moreover, inhibition of NF-κB pathways partially 
but not significantly reversed IL-4-decreased AR mRNA expression levels. Based on 
the effects of this pathway on the IL-4-induced 3β-HSD mRNA species, it is unlikely 
that NF-κB is involved. However, the nature of this borderline effect does not allow 
us to draw any firm conclusion from the present data.  
 The potential involvement of the p38 MAPK pathway in IL-4 suppression of 
AR mRNA levels further confirmed the anti-inflammatory nature that this pathway 
displays when induced by IL-4R transactivation. As discussed in Chapter 5, the p38 
MAPK pathway appeared to mediate anti-inflammatory responses in hOSE cells 
such as IL-4-elevated 3β-HSD2 mRNA expression levels. Moreover, it was 
demonstrated to be part of IL-1α-related anti-inflammatory responses as revealed by 
IL-1α-induced 3β-HSD2 (Chapter 5) and 11β-HSD1 (Rae M.T., unpublished 
observations) mRNA expression levels. This may well reflect a negative feedback 
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loop mechanism that hOSE cells use to alleviate tissue damage during ovulation-
associated wounding.  
 In conclusion, we have demonstrated that AR and PR mRNA levels are not 
affected during post-ovulatory wounding of hOSE cells, suggesting a balance in 
access of 3β-HSD-associated ligands to AR and PR. Also, IL-4 attenuated AR 
mRNA and protein levels without affecting PR mRNA expression, thereby favouring 
progesterone rather than androgen signalling in post-ovulatory repair. Importantly, 
this effect required an activated p38 MAPK pathway, further demonstrating the anti-
inflammatory nature of this pathway in hOSE cells. An illustration of the proposed 
model is depicted in Fig. 6.11. 
 
 
Figure 6.11: Regulation of steroid signalling by IL-1α and IL-4 in the human ovarian 
surface epithelium. Schematic illustration of the proposed model and mechanisms regarding 
the role of IL-1α and IL-4 in steroid biosynthesis and downstream signalling through the 









Regulation of cyclooxygenase 2 and lysyl oxidase by 
cytokines. Further support for an anti-inflammatory 
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7.1 Introduction 
 In the previous Chapters it has been shown that IL-1α and IL-4 differentially 
regulate the expression of steroid-related genes such as 3β-HSD1, 3β-HSD2 and AR 
during post-ovulatory injury and repair of the ovarian surface. It is widely accepted 
that IL-1α exerts pro-inflammatory effects to prepare the ovarian cell surface to host 
ovulation-associated wounding. As such, at the apex of ovulation, the pro-
inflammatory-related genes, COX-2 and MMP-9 are up-regulated (Murdoch 2000, 
Rae et al. 2004a, Rask et al. 2006), whilst 3β-HSD1 and peroxisome proliferator-
activated receptor-γ (PPAR-γ), both exerting anti-inflammatory actions, are down-
regulated (Rae et al. 2004b). Simultaneously, genes involved in counteracting tissue 
damage such as 11β-HSD1 mRNA (Yong et al. 2002) and 3β-HSD2 mRNA (see 
Chapter 4) also appear to be induced in response to IL-1α to trigger the intracrine 
generation of anti-inflammatory glucocorticoid and progesterone, respectively. In 
particular, cortisol has been demonstrated to contribute to the alleviation of post-
ovulatory damage of hOSE as it triggered elevation of the IL-1α-induced 11β-HSD1 
mRNA and blocked IL-1α-induced COX-2 mRNA (Rae et al. 2004a) and IL-1α-
induced MMP-9 mRNA (Rae et al. 2008). Moreover, progesterone has been 
established to suppress IL-1α-increased COX-2 mRNA levels, attesting its anti-
inflammatory nature in hOSE cells (Rae et al. 2004a). Additionally, progesterone has 
been illustrated to play a role in apoptosis and repair of the ovarian cell surface 
(Murdoch 1998, Murdoch & Van Kirk 2002, Murdoch et al. 2001), indicative of its 
essential action during post-ovulatory remodelling of hOSE, so that only genetically 
integral cells proliferate to restore the wounded tissue. As shown in Chapter 4, 
intracrine generation of progesterone is driven by the 3β-HSD activity that is 
elevated substantially by IL-4 treatment of hOSE cells, suggesting that this cytokine 
may exert anti-inflammatory effects during the post-ovulatory healing of hOSE.  
 Also, important in the successful regeneration of hOSE following ovulation-
associated wounding and tissue remodelling, is the prevention of uncontrolled cell 
proliferation that in turn could lead to cell adhesion and invasion, functions that 
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might well contribute to tumourigenesis and metastasis. In that context, successful 
deposition of the extracellular matrix (ECM) during post-ovulatory repair could be 
an efficient mechanism for hOSE to restore homeostasis. Given the anti-
inflammatory nature of IL-4, one might speculate that IL-4 could also contribute to 
ECM deposition as part of its role in the post-ovulatory healing processes at the 
ovarian cell surface. An ECM-related gene that has been shown to be altered during 
hOSE-associated post-ovulatory wounding processes is lysyl oxidase (LOX) (Rae et 
al. 2004b).  
 LOX is an extracellular copper-containing enzyme that catalyses the 
oxidative deamination of tropoelastin and procollagen for the subsequent cross-
linkages of elastin and collagen fibrils (Bedell-Hogan et al. 1993). This process is 
fundamental for the biosynthesis of a functional ECM. LOX has been reported to be 
secreted as a N-glycosylated 50kDa precursor that is post-translationally cleaved by 
procollagen C-terminal proteinase (PCP) activity to a non-glycosylated 35kDa active 
enzyme (Trackman et al. 1992, Uzel et al. 2001). Of the two procollagen proteinases 
- the mammalian Toloid (mTLD) and its shorter variant bone morphogenetic protein-
1 (BMP-1) - encoded by the Bmp1 gene - BMP-1 has been reported to process pro-
lysyl oxidase more efficiently (Hartigan et al. 2003, Uzel et al. 2001). Interestingly, 
PCP/BMP-1 activity is enhanced by its interaction with an extracellular multidomain 
glycoprotein, the PCP enhancer (PCPE) (Ricard-Blum et al. 2002).  
 LOX has been shown to be secreted in multiple cell types including gingival 
fibroblasts (Hong et al. 1999), osteosarcoma cells (Uzel et al. 2000) and aortic 
smooth muscle cells (Maki et al. 2002). Notably, impaired LOX function is 
correlated with colorectal cancer (Csiszar et al., 2002). Also, LOX has been shown to 
inhibit ERK1/2 and Akt mitogenic activities in human lung cancer cells as well as in 
a mouse fibroblast cell line, whilst it was shown to block NF-κB protein and the anti-
apoptotic bcl-2 gene in the PANC-1 pancreatic cancer cell line (Jeay et al. 2003, Wu 
et al. 2007). It has been also documented that a mechanism through which 
tumourigenesis can develop is by methylation-induced silencing of LOX. This 
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appears to be the case in several cancer cell lines such as colon, lung, ovarian, gastric 
and pancreatic cancer cell lines, establishing LOX as a tumour suppressor gene 
(Kaneda et al. 2004). 
 Therefore, in order to further support the importance of IL-4 function in post-
ovulatory tissue remodelling of hOSE, we investigated its potential effects on 
alleviation of inflammation and on ECM deposition. To achieve this, we selected two 
key genes as paradigms for these two responses; first, we assessed the effects of IL-4 
on the pro-inflammatory COX-2 mRNA in the presence or absence of IL-1α and 
secondly, we asked whether LOX mRNA expression levels are altered by IL-4 
differently in the presence or absence of IL-1α. 
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7.2 Subjects and Methods 
 To further elaborate the anti-inflammatory nature of IL-4 in hOSE, we 
assessed the effects of this cytokine on the pro-inflammatory COX-2 mRNA and the 
ECM-related LOX mRNA expression levels in the presence or absence of IL-1α as a 
pro-inflammatory proxy. Primary hOSE cells were treated with IL-1α and IL-4 
(0.5ng/mL) for 48h followed by cell harvest, RNA purification and quality/quantity 
assessment. Then, samples were submitted for Taqman qPCR of the target genes to 
compare treated with untreated hOSE samples.  
 To elucidate further the mechanisms through which these effects are exerted, 
we treated primary hOSE cell monolayers with IL-1α and IL-4 in the presence or 
absence of various transducing pathway inhibitors as described in Chapter 5. 
Afterwards, reverse transcription and Taqman qPCR were performed on RNA 
extracts to identify the signalling pathways that potentially may be involved in the 
mediation of LOX mRNA alterations in response to IL-1α and IL-4. 
 The basic clinical information of the patients who consented to provide tissue 
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Table 7.1 Clinical profile of patients whose hOSE were used for treatments with 
IL-1α and IL-4 
 
TAH: total abdominal hysterectomy, TAHBSO: total abdominal hysterectomy and bilateral 
salpingo-oophorectom, HMB: heavy menstruation bleeding, DiagLapar: diagnostic 
laparoscopy, n/s: not specified due to irregular cycle, follicular/luteal phases for menstrual 
cycles ranging from 28 to 35 days 
 
Table 7.2 Clinical profile of patients whose hOSE were used to study pathway 
inhibitor effects 
 
TAH: total abdominal hysterectomy, TAHBSO: total abdominal hysterectomy and bilateral 
salpingo-oophorectomy, HMB: heavy menstruation bleeding, DiagLapar: diagnostic 
laparoscopy, LapSter: laparoscopic sterilisation, n/s: not specified due to irregular cycle, 





Code LREC No Age 
(yrs) 





38 7314 04/S1103/36 43 Oopherectomy HMB n/s IL-1α+IL-4 
8 5499 04/S1103/36 47 TAHBSO Fibroids n/s IL-1α+IL-4 
39 7326 04/S1103/36 43 TAH Fibroids n/s IL-1α+IL-4 
12 7383 04/S1103/36 43  TAHBSO Fibroids n/s IL-1α+IL-4 
37 7414 04/S1103/36 22 DiagLapar Pelvic pain n/s IL-1α+IL-4 
Patient 
No 
Code LREC No Age 
(yrs) 





41 7320 04/S1103/36 47 TAHBSO HMB  n/s SB20 
38 7332 1998/6/33 42 TAHBSO Prophylactic (21) Luteal SB20 
23 7324 04/S1103/36 44 DiagLapar Pelvic pain (15) Follicular SB20 
39 7336 04/S1103/36 40 TAH Prophylactic (22) Luteal SB20 
44 9018 04/S1103/36 33 DiagLapar Mid-cycle pain (19) Luteal LY29 
45 5517 04/S1103/36 43 LapSter Fibroids (21) Luteal LY29 
10 5536 04/S1103/36 23 DiagLapar Dysmenorrhoea (4) Follicular LY29 
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7.3 Results 
7.3.1 The effects of IL-1α and IL-4 on pro-inflammatory COX-2 mRNA  
expression in primary hOSE cells 
 Primary hOSE cells that were treated with IL-1α, IL-4 or a combination of 
both (0.5ng/mL) for 48h were harvested and assessed for mRNA expression levels of 
COX-2. Untreated cells were used as controls. As expected from previous reports, 
IL-1α significantly augmented COX-2 mRNA levels with an average 7-fold increase 
(Fig. 7.1; n=5, b=p<0.001). On the other hand, IL-4 treatment did not alter COX-2 
mRNA levels. However, when IL-4 was applied in the presence of IL-1α, IL-1α-
induced COX-2 mRNA was significantly suppressed (Fig. 7.1, b vs c p<0.05). 
 
 
Figure 7.1: The effects of IL-1α and IL-4 on COX-2 mRNA expression. Combined data 
from 5 independent hOSE samples. Taqman qPCR was performed to assess COX-2 mRNA 
levels in response to IL-1α, IL-4 or both (0.5ng/mL) for 48h. (b=p<0.001, c=p<0.05, b vs c 
p<0.05). 
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7.3.2 The effects of IL-1α and IL-4 on LOX mRNA expression in primary hOSE 
cells 
 We then assessed alterations of LOX mRNA levels in RNA extracts from 
primary hOSE cells treated with IL-1α, IL-4 or both (0.5ng/mL) for 48h relative to 
untreated control samples. Taqman qPCR in five separate hOSE samples revealed 
that both IL-1α and IL-4 had a stimulatory effect on LOX mRNA levels relative to 
untreated control samples. IL-1α increased LOX mRNA levels at least 2 times, 
whereas IL-4 had a mean 6-fold stimulatory effect. Combination of both cytokines 
did not result in an additive effect (Fig. 7.2; n=5, b=p<0.05, c=p<0.01). 
 
 
Figure 7.2: The effects of IL-1α and IL-4 on LOX mRNA expression. Combined data 
from 5 independent hOSE samples. Taqman qPCR was performed to assess LOX mRNA 
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7.3.3 Signalling pathways involved in the transduction of IL-1α and IL-4-
mediated LOX mRNA expression in primary hOSE cells 
 As described in Chapter 5, in order to elucidate the mechanisms through 
which IL-1α and IL-4 exert their effects on the transcriptional regulation of 
responsive genes, primary hOSE cells were treated with cytokines in the presence or 
absence of specific pathway inhibitors. From the panel of the pathway inhibitors 
tested, namely ERK1/2, p38 MAPK inhibitors, NF-κB, PI-3K and STAT-6 pathway 
inhibitors, only p38 MAPK and PI-3K were identified as intermediate regulators of 
the IL-1α and/or IL-4-induced machinery for mediation of transcriptional regulation 
of LOX mRNA. As such, data for only these two pathways are demonstrated herein. 
7.3.3.1 Regulation of IL-1α and IL-4-mediated LOX mRNA expression by the p38 
MAPK signalling pathway 
 Primary hOSE cells were treated with IL-1α or IL-4 (0.5ng/mL) in the 
presence or absence of an inhibitor of the p38 MAPK pathway, SB203580 (10μM) 
for 48h. Taqman qPCR of mRNA from treated and untreated hOSE cell monolayers 
revealed that IL-1α-induced LOX mRNA was suppressed when SB203580 was 
included. Similarly, IL-4-induced LOX mRNA levels were suppressed 














Figure 7.3:  The effect of the p38 MAPK pathway inhibitor on LOX mRNA levels. 
Combined data of 4 independent hOSE samples. Taqman qPCR for LOX mRNA levels in 
cells treated with SB203580 (1μM) in the presence or absence of IL-1α or IL-4 (0.5ng/mL) 
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7.3.3.2 Regulation of IL-1α and IL-4-mediated LOX mRNA expression by the PI-3K 
signalling pathway 
 Primary hOSE cell monolayers collected from 3 distinct patients were treated 
with LY294002 (10μM) in the presence of IL-1α or IL-4 (0.5ng/mL) for 48h. 
Assessment of LOX mRNA levels in target samples was achieved with Taqman 
qPCR. IL-4-induced LOX mRNA levels were suppressed when LY294002 was 
added. However, the inhibitor did not significantly affect IL-1α-induced LOX 
mRNA levels, albeit that LOX mRNA levels were slightly suppressed (Fig. 7.4; n=3, 
b, c=p<0.05, d=p<0.01). 
 
 
Figure 7.4: The effect of the PI-3K pathway inhibitor on LOX mRNA levels. Combined 
data of 3 independent hOSE samples. Taqman qPCR for LOX mRNA levels in cells treated 
with LY294002 (10μM) in the presence or absence of IL-1α or IL-4 (0.5ng/mL) for 48h (n=3, 
b, c=p<0.05, d=p<0.01).  
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7.3.4 Summary of effects of IL-1α and IL-4 on COX-2 and LOX mRNA 
expression 
Table 7.3 Effects of cytokines and pathway inhibitors on COX-2 and LOX 
mRNA levels 
Treatment                                   Target 
pathway 
Target genes 
  COX-2 mRNA LOX mRNA 
IL-1α  ↑ ↑ 
IL-4  n/s ↑ 
IL-1α+IL-4  ↑ ↑ 
IL-1α+IL-4 vs IL-1α  ↓ ↑ 
SB203580 p38 MAPK - n/s 
SB203580+IL-1α p38 MAPK - n/s 
SB203580+IL-4 p38 MAPK - ↑ 
SB203580+IL-4 vs IL-4 p38 MAPK - ↓ 
LY294002 PI-3K - ↓ 
LY294002+IL-1α PI-3K - n/s 
LY294002+IL-1α vs IL-1α PI-3K  n/s 
LY294002+IL-4 PI-3K - n/s 
n/s: not significant, -: not tested, ↑: up-regulation, ↓: down-regulation 
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7.4 Discussion 
 Herein, we provide further evidence of a role for IL-4 in post-ovulatory 
healing mechanisms in hOSE. IL-4 counteracts IL-1α induction of COX-2 mRNA. 
Also, it induces LOX mRNA, participating in ECM deposition, a critical process for 
integral regeneration of hOSE. The latter process appears to be mediated by p38 
MAPK and PI-3K pathways. Importantly, IL-4-induced LOX expression is more 
profound than that occurring with IL-1α treatment, suggesting that expression of 
lysyl oxidase is essential during post-ovulatory repair of the stigma. 
 The treatment of primary hOSE cells with IL-4 alone did not affect COX-2 
mRNA levels. However, in the presence of IL-1α, IL-4 attenuated IL-1α-induced 
COX-2 mRNA expression levels approximately 2-fold, suggesting that IL-4 
inhibited prostaglandin synthesis during post-ovulatory repair, alleviating the 
degradation of connective tissue. At the same time, as shown in Chapter 4, IL-4 
massively induced 3β-HSD activity and thus local progesterone biosynthesis. It is 
interesting that progesterone has been also documented to impede IL-1α-stimulation 
of COX-2 mRNA levels (Rae et al. 2004a). Therefore, it is notable that IL-4 directly 
impacts upon IL-1α-stimulated COX-2 mRNA levels, but at the same time it 
promotes intracrine generation of progesterone (through induction of 3β-HSD) that 
in turn also suppresses IL-1α-increased COX-2 mRNA expression (Rae et al. 2004a), 
indicative of a potential positive feedback loop mechanism. 
 The treatment of primary hOSE cells with IL-4 also resulted in the induction 
of LOX mRNA expression. Proper transcriptional and translational regulation of 
LOX is fundamental for the deposition of ECM and as such for the integral 
construction of the hOSE cell layer. Moreover, the LOX mRNA increase appeared to 
be triggered by IL-1α treatment as well, confirming previous studies (Rae et al. 
2004b). Nevertheless, the effects of IL-4 were more profound than those of IL-1α. 
Importantly, combined effects of both cytokines were not additive, suggesting either 
independent action of the two proxies or a predominance of IL-4 action in LOX 
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transcriptional regulation. In physiology, LOX mRNA expression in response to IL-
1α at the apex of ovulation is probably essential for minimisation of the injury of the 
inflammed tissue; however a profound elevation during post-ovulatory repair secures 
regeneration of the ovarian cell surface on a fully structured connective tissue. This 
is further supported by the finding that IL-4 abolished IL-1α-elevated COX-2 mRNA 
expression levels that potentially reflects an attenuated synthesis of prostaglandins 
that participate in degradation of the ECM. Additionally, we have shown that TGF-
β1 up-regulated LOX mRNA in a benign immortalised hOSE cell line 
(Papacleovoulou et al., unpublished observations), consistent with the anti-
proliferative effects of TGF-β1 in hOSE cells (Choi et al. 2001c). Accordingly, LOX 
has been demonstrated to be elevated after ovulation in perch (Langenau et al. 1999) 
and rabbit ovary (Himeno 1986), indicating a potential role of LOX in post-ovulatory 
ovarian tissue remodelling. Moreover, in the rat ovary, LOX has been established to 
exert its effects on the maintenance of the ECM when the follicle was approaching 
final maturation (Harlow et al. 2003). Collectively, all these responses further 
support the potential function of LOX in the early stages of wound healing processes 
and protection from malignant transformation as shown in rat skin studies (Fushida-
Takemura et al. 1996).  
 Importantly, p38 MAPK signalling appeared to mediate LOX mRNA 
transcriptional levels by IL-4 and IL-1α, once again attesting to the anti-
inflammatory nature of this pathway at the ovarian cell surface. In essence, it is 
intriguing that NF-κB signalling pathways are not involved in IL-1α-stimulated LOX 
mRNA expression. This is consistent with previous studies proposing that the tumour 
suppressive effects of LOX are mediated through inhibition of the NF-κB pathway 
and associated pro-inflammatory responses (Jeay et al. 2003, Wu et al. 2007). 
Moreover, this is also consistent with our speculation that IL-4 antagonises IL-1α 
pro-inflammatory responses through inhibition of NF-κB and activation of p38 
MAPK pathway (see Chapter 5). Surprisingly, besides the p38 MAPK signalling 
pathway, IL-4-induced LOX mRNA appears to be also mediated by the PI-3K 
pathway, as demonstrated with inhibition of the latter with LY294002. This pathway 
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universally leads to the activation of Akt mitogenic sequence. As such, the present 
data are inconsistent with previously documented reports showing that LOX triggers 
its anti-tumour effects through abrogation of Akt in human lung and pancreatic 
cancer cells (Wu et al. 2007). Nonetheless, whether or not this effect is cell type 
dependent is not known at this time but it should be noted that functional Akt has 
been demonstrated in primary, immortalised and neoplastic epithelial ovarian cells 
with increased expression in EOC (Wong et al. 2001). A negative feedback loop 
mechanism also cannot be excluded. On the other hand, PI-3K involvement has been 
also shown in IL-4-stimulated 3β-HSD1 and 3β-HSD2 mRNA expression in primary 
hOSE cells (see Chapter 5) as well as in IL-4-induced 3β-HSD activity of breast 
cancer cells (Gingras et al. 2000), attesting that participation of this pathway in anti-
inflammatory activities is possible. 
 The caveat regarding LOX studies is that we have only assessed 
transcriptional mRNA regulation of LOX without investigating the effects of 
cytokines on LOX protein. This is very fundamental given the post-transcriptional 
and post-translational modifications that LOX undergoes (Ricard-Blum et al. 2002, 
Trackman et al. 1992, Uzel et al. 2001). For instance, in the osteoblastic MC3T3-E1 
cells, it has been established that LOX activity does not correlate with LOX mRNA 
levels (Feres-Filho et al. 1995). 
 In summary, our data further support the anti-inflammatory nature of IL-4 in 
the ovarian cell surface. Besides its effects on steroid biosynthesis during post-
ovulatory healing, IL-4 also appears to control integral deposition of the ECM 
through attenuation of IL-1α-induced COX-2 mRNA and also elevation of LOX 
mRNA in hOSE. Concomitant IL-4-induced progesterone biosynthesis could further 
contribute in suppression of IL-1α-increased COX-2 mRNA, attesting to a positive 
feedback loop mechanism. IL-1α- and IL-4-mediated LOX mRNA levels appear to 
be mediated by a p38 MAPK pathway. In the case of IL-4, an involvement of the PI-
3K pathway was also shown. A schematic illustration of the proposed model is given 
in Fig. 7.5. 






Figure 7.5: Role of IL-4 in tissue remodelling of hOSE. This figure illustrates 
schematically the effects of IL-4 on COX-2 and LOX mRNA levels in the presence or 
absence of IL-1α. Similarly to progesterone, IL-4 attenuates IL-1α-induced COX-2 mRNA. 
Concomitant IL-4-stimulated progesterone biosynthesis might further enhance this inhibitory 
effect, suggestive of a positive feedback loop mechanism. IL-4-stimulated LOX mRNA 
further supports its fundamental role in connective tissue deposition during post-ovulatory 
repair of hOSE. IL-1α and IL-4-mediated LOX mRNA appears to be mediated by p38 
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8.1 Introduction 
 Ovarian cancer is the most frequent lethal gynaecologic cancer in Europe and 
North America. It is the 5th most common cause of death after breast, colorectum, 
lung and endometrial cancer with post-menopausal women at greater risk (Parkin et 
al. 2005). The lifetime risk to develop ovarian cancer is 1 in 70 and only around 30% 
of the sufferers surviving beyond 5 years (Murdoch & McDonnel 2002, Petricoin et 
al. 2002, Riman et al. 2004).  The main reason for the high mortality is the 
asymptomatic progression of the disease along with the absence of efficient 
screening tests. Also, the lack of proper research models hampers advances in the 
development of effective prognostic and diagnostic techniques.  
As rediscussed in Chapter 1 (Section 1.3), ovarian cancer is classified as a 
surface epithelial-stromal tumour or EOC when it arises from the OSE, a sex cord-
stromal ovarian tumour when it is of mesonephric or mesenchyme origin (granulosa, 
theca, stromal cells) and a germ cell tumour when it derives from primordial germ 
cells. The major focus of this Chapter will be on EOC which represents more than 
85% of ovarian cancers (Chen et al. 2003). Despite the current dogma that EOC 
arises from the hOSE, novel suggestions regarding the peritoneum surface epithelium 
and tubal surface epithelium as candidate origins of EOC should not be 
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8.1.1 Classification of epithelial ovarian cancers  
As mentioned in Chapter 1, the hOSE is a plastic mesothelium responding to 
environmental alterations with no commitment to its embryonic origin, the coelomic 
epithelium (Fig. 8.1A). On the other hand, in neoplastic transformation, cancer cells 
have a strictly epithelial appearance resembling the Müllerian duct epithelial 
derivatives (Fig. 8.1B-F).  
8.1.1.1 Histological classification of EOC 
Based on the World Health Organisation (WHO) classification of ovarian 
tumours (1973) that was reviewed by the International Agency for Research on 
Cancer (IARC) in 1998, there are five groups of EOC according to their histological 
features: serous, mucinous, endometrioid, clear cell and transitional cell or Brenner 
ovarian tumours. If the tumour does not fall in any of these subtypes, it is 
characterised as undifferentiated, whereas it is considered as adenocarcinoma not 
specified (NOS) when it does not have a particular histological morphology (Parkin 
et al. 1998, Scully 1987).  
Serous ovarian carcinomas are classified as tumours that resemble the 
epithelium of the oviduct or fallopian tube (Fig. 8.1B). They usually have multiple 
cystic chambers with papillary projections to extend out of the surface of the tumour. 
The diagnosis of these tumours usually occurs at the sixth decade of a woman’s life. 
The serous tumour subtype encompasses almost 50% of the overall ovarian 
neoplasms. 
Mucinous ovarian cancers have features of the uterine cervical or intestinal 
epithelium (Fig. 8.1C). They contain papillary outgrowths within the cystic chambers 
with some large solid areas as well. They also display necrotic and haemorrhagic 
regions. They are also frequent at the sixth decade of life and reflect around 7% of all 
ovarian tumours. 
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Endometrioid ovarian tumours feature the glandular epithelium of the 
endometrium (Fig. 8.1D). They are sometimes associated with endometriosis or 
endometrial hyperplasia. Although they are quite common among ovarian cancers, 
they are considered to have a better prognosis than serous or mucinous tumours. 
They are more usual in sixth decade of life.  
Clear cell ovarian neoplasias are characterised by solid, papillary or glandular 
tumours consisting of cells with clear cytoplasm that contains high levels of 
glycogen (Fig. 8.1E). They may also appear as cystic masses with polypoids 
projections. They usually appear in the fifth decade of life more commonly in 
women who never gave birth. They represent around 6% of all ovarian neoplasms.  
Transitional or Brenner cell tumours consist of cells that morphologically 
look like epithelial cells of the urinary bladder (Fig. 8.1F). They are extremely rare 
tumours usually diagnosed at an advanced stage. They contain cystic and solid areas 
with polypoid masses. 
EOCs that consist of cells with malignant features such as pleomorphic nuclei 
and undifferentiated cytoplasms are classified as undifferentiated carcinomas. Such 
EOC reflect approximately 5% of all ovarian neoplasms and they are commonly 












Figure 8.1: Epithelial ovarian cancer histological subtypes. Ovarian epithelial tumours 
that arise from hOSE (A) are histologically classified in serous (B), mucinous (C), 
endometrioid (D), clear cell (E) and transitional cell (F) ovarian neoplasms. Adapted from 
http://www.lmp.ualberta.ca/resources/pathoimages/Images-P/000p0519.jpg (2008) and 
Nunez et al. (2005). 
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8.1.1.2 Staging and grading of ovarian cancer 
Staging of ovarian cancer is conducted through the TNM parametric system 
(T stands for extent of primary tumour, N stands for degree of spread to lymph nodes 
and M stands for metastasis). This system was established by the American Joint 
Committee of Cancer (AJCC) and the International Federation of Obstetrics and 
Gynaecology (FIGO) (Flemming et al. 1997, Kosary 1988). The EOC staging 
protocol is illustrated in Table 8.1. 
The grade (G) of ovarian cancer represents the degree to which the tumour 
bears a resemblance to the healthy tissue. The grading of the ovarian tumour is of 
prognostic importance and might prove useful for therapeutic strategies that might 
benefit the patient. G1 refers to tumours that are well-differentiated, G2 to 
moderately-differentiated tumours and G3 to poorly-differentiated tumours (Chen et 
al. 2003).  
Table 8.1 Staging of ovarian cancer according to AJCC and FIGO 
    
Adapted from Chen et al. (2003) 
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8.1.2 Hypotheses for the development of EOC and aim of the Chapter 
  As discussed in Chapter 1, physiological reproductive events are considered 
to contribute in the development of epithelial ovarian cancer. Ovulation-associated 
inflammation coupled with production of reproductive hormones including 
gonadotrophins and steroids pre- and post-ovulatory could contribute in the 
emergence of an oncogenic phenotype (Cramer & Welch 1983, Fathalla 1971, Ness 
et al. 2000b, Risch 1998). In Chapters 3, 4 and 6 it was shown that functional 3β-
HSD activity is possibly a critical event in the maintenance of hOSE homeostasis, 
intracrinally generating progesterone that activates its cognate PR that in turn exerts 
its apoptotic (Bu et al. 1997) and anti-inflammatory (Rae et al. 2004a) effects. 
Moreover, it was shown that IL-4 sustains local progesterone pre-receptor 
metabolism and downstream signalling such that integral restoration of the stigma is 
secured during post-ovulatory healing. This agrees with previous studies illustrating 
that expression of progesterone-related genes i.e. StAR, 3β-HSD and PR in ovarian 
cancers are related with good prognosis of the disease (Abd-Elaziz et al. 2005). On 
the other hand, elevated levels of androgen-related genes such as AR  and AR co-
activators are commonly encountered in ovarian cancers (Cardillo et al. 1998, 
Laughlin et al. 2000, Shaw et al. 2001).  
 Therefore, given the proposed importance of the functionality of 3β-HSD 
along with the demonstrated altered expression of the enzyme during injury and 
repair of hOSE, the objective of this Chapter is to evaluate if the 3β-HSD pathway is 
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8.2 Subjects and Methods 
 In order to evaluate 3β-HSD protein expression in EOC, 3β-HSD 
immunohistochemistry (IHC) of primary ovarian solid tumours as well as freshly 
isolated ascites from women who were diagnosed with EOC was carried out. 
Transcriptional mRNA expression levels were also measured for 3β-HSD1 and 3β-
HSD2 mRNAs as well as IL-4R and IL-1R1 mRNAs in cultured ascites cells and 
compared with those of normal cultured hOSE cells. Finally, we performed 
functional studies where treatments of primary ascites with IL-1α and IL-4 took 
place followed by Taqman qPCR to determine effects of these proxies on 3β-HSD1 
and 3β-HSD2 mRNA species. The basic clinical profile of patients who were used to 
complete these studies is given in Tables 8.2 and 8.3. 
 
Table 8.2 Clinical profile of patients whose hOSE were used for comparison 
studies with ovarian cancer cells 
 
TAH: total abdominal hysterectomy, TAHBSO: total abdominal hysterectomy and bilateral 
salpingo-oophorectomy, HMB: heavy menstruation bleeding, DiagLapar: diagnostic 
laparoscopy, n/s: not specified due to irregular cycle, follicular/luteal phases for menstrual 




Code LREC No Age 
(yrs) 





10 5536 04/S1103/36 23 DiagLapar HMB/pain n/s qPCR 
11 5537 04/S1103/36 24 DiagLapar Dysmenorrhoiea (28) Luteal qPCR 
12 7383 04/S1103/36 43 TAHBSO Fibroids n/s qPCR 
13 7384 04/S1103/36 42 TAH HMB (23) Luteal qPCR 
20 7423 04/S1103/36 49 TAH Fibroids (18) Luteal qPCR 
37 7414 04/S1103/36 22 TAHBSO Fibroids n/s qPCR 
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Table 8.3 Pathology of ovarian cancer patients 




Ascites 1 88 Post-menopausal Serous/endometrioid 202 IIIB 2 
Ascites 2 73 Post-menopausal Serous  447 IV 3 
Ascites 3  66 Post-menopausal Endometrioid 3101 IV 3 
       
Solid tumor 
1 
61 Post-menopausal Papillary serous with 
minor mixed 
components 
21480 IIIC 3 
Solid tumor 
2  
43 Pre-menopausal Mucinous/serous/ 
endometrioid 
17912 IIC 3 
Solid tumor 
3 
41 Pre-menopausal Metastasis from 
breast 
46 * 3 
Solid tumor 
4 
59 Post-menopausal Poorly differentiated 
serous 
1387 IIIC 3 
Solid tumor 
5 
59 Post-menopausal Poorly differentiated 
serous papillary 
3067 IV 3 
       
hOSE vs 
ascites 
      
Ascites 4 55 Post-menopausal Papillary serous 2647 IIIC 3 
Ascites 5 74 Post-menopausal Poorly differentiated 
serous/endometrioid 
305 IIIC 3 
Ascites 6 
 (as tumor 3) 
41 Pre-menopausal Metastasis from 
breast 
46 * 3 
Ascites 7 67 Post-menopausal Serous 353 IIIC 3 
Ascites 1 88 Post-menopausal Serous/endometrioid 202 IIIB 2 
Ascites 2 73 Post-menopausal Serous 447 IV 3 
       
IL-1α 
treatment 
      
Ascites 7 67 Post-menopausal Serous 353 IIIC 3 
Ascites 1 88 Post-menopausal Serous/endometrioid 202 IIIB 2 
Ascites 2 73 Post-menopausal Serous 447 IV 3 
       
IL-4 
treatment 
      
Ascites 6 41 Pre-menopausal Metastasis from 
breast 
46 * 3 
Ascites 8 53 Post-menopausal Serous 447  3 
Ascites 2 73 Post-menopausal Serous  270  3 
IHC: immunohistochemistry. Pathological assessment was conducted by Professor Alistair 
Williams Royal Infirmary of Edinburgh Pathology department. LREC project number: 
04/S1103/44. 
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8.3 Results 
8.3.1 Immunolocalisation of 3β-HSD protein in ovarian cancer 
8.3.1.1 Immunolocalisation of 3β-HSD protein in solid ovarian tumours 
 Colourimetric immunohistochemistry was conducted on paraffin-embedded 
sections (3μm) of ovarian solid tumours from 5 patients (Table 8.3). In all 5 patients, 
3β-HSD protein was immunodetected in the ovarian tumours. Cytokeratin 7 (CK 7) 
staining revealed that 3β-HSD was mainly present in epithelial cells. A 
representative block is illustrated in Fig. 8.2. Characterisation of this tumour is given 




Figure 8.2: Immunodetection of 3β-HSD protein in a representative solid ovarian 
tumour. Colourimetric immunohistochemistry with the 3β-HSD antibody (1:4000 dilution) 
showed expression of 3β-HSD protein (left panel) in cytokeratin 7 (CK 7) positive epithelial 
cells (right panel). Insets represent negative controls for 3β-HSD (left panel) and CK 7 (right 
panel). Slides were visualised with an Olympus Provis microscope and pictures were 
captured with a digital 30D Canon camera in 40X magnification. Scale bars represent 50μm. 
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8.3.1.2 Immunolocalisation of 3β-HSD protein in ascites cells from ovarian cancer 
patients 
 Colourimetric immunohistochemistry of freshly isolated ascites for 3β-HSD 
(1:4000 dilution) and CK 7 (1:1000 dilution) showed similar localisation patterns of 
the two proteins. A representative section is illustrated in Fig. 8.3A (Table 8.3, 
ascites 3). In order to separate epithelial cells of cancer origin from active 
mesothelial or immune cells, double immunofluorescence for cytokeratin 7 and 3β-
HSD was applied (Fig. 8.3B). Both CK 7 (green) and 3β-HSD (red) were 
immunolocalised in the cytoplasm of ascitic clumps (Fig. 8.3B b and 8.3B c, 
respectively). Also, 3β-HSD was expressed exclusively in epithelial-positive cells 
and not in other contaminating cells (Fig. 8.3B e, white arrows). Counterstaining was 
achieved with Dapi staining (1:1000 dilution; blue). The malignant phenotype of 
ascites cells was confirmed with haematoxylin and eosin staining (H+E). Cells were 














Figure 8.3: Expression of 3β-HSD in freshly isolated ascites. A) Representative slide of 
colourimetric IHC for 3β-HSD (1:4000 dilution) and CK 7 (1:1000 dilution) in freshly 
isolated ascites. Insets represent negative controls. Slides were visualised with an Olympus 
Provis microscope and photomicrographs were captured with a digital 30D Canon camera in 
4X magnification. Scale bars represent 200μm. B) Double immunofluorescence for a) Dapi 
stained nuclei (blue, 1:1000 dilution), b) CK 7 (green, 1:300 dilution, c) 3β-HSD (red, 1:400 
dilution), d) merged. Note that 3β-HSD was expressed only in CK 7-positive cells (e). 
Pictures were captured with a Zeiss LSM 510 meta-confocal microscope in 40X 
magnification (20μm scale bars). H+E staining of ascites to confirm malignant phenotype of 
cells (f) (40X magnification, scale bar 50μm). 
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8.3.2 The expression pattern of 3β-HSD1 and 3β-HSD2 mRNA in ascites from 
ovarian cancer patients  
  Because the 3β-HSD antibody immunoreacts with both the 3β-HSD1 and 3β-
HSD2 isoforms, we further investigated the isoform expression pattern by qPCR 
using isoform-specific sets of primers/probes as described in Chapter 2. An 
assessment of 3β-HSD1 and 3β-HSD2 mRNA species in RNA samples of cultured 
ascites from 6 patients who were diagnosed with EOC revealed the presence of both 
transcripts. The mean dCt value for 3β-HSD1 was 21.7, whilst for that of 3β-HSD2 
was 24.3. However, increased 3β-HSD1 mRNA levels relative to ones of 3β-HSD2 
mRNA were only a trend and did not reach statistical significance (Fig. 8.4). 
 
 
Figure 8.4: Isoform expression pattern in malignant ovarian cells. Taqman qPCR for 3β-
HSD1 and 3β-HD2 mRNA in 6 separate primary ascites cell cultures was conducted as 
described in Chapter 2, section 2.3.4. Measurable transcripts were observed for both 
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8.3.3 The relative expression of target genes in primary cultured EOC cells and 
hOSE cells 
8.3.3.1 Relative expression mRNA levels of 3β-HSD1 and 3β-HSD2 mRNA in 
primary hOSE and EOC cells 
 After establishment of the presence of 3β-HSD protein and mRNA transcripts 
in EOC, we determined whether there was any difference in 3β-HSD1 and 3β-HSD2 
mRNA species in 6 independent primary hOSE and 6 independent EOC cell 
monolayers. Taqman qPCR showed that average 3β-HSD1 mRNA levels in hOSE 
cell samples were 42 times higher than those of EOC cell samples (Fig. 8.5, upper 
panel, b=p<0.05). On the other hand, 3β-HSD2 mRNA levels in EOC were not 
statistically different from hOSE cells, although a trend towards down-regulated 3β-
HSD2 in EOC was observed (Fig. 8.5, lower panel, p=0.06).  
 
Figure 8.5: Relative 3β-HSD1 
and 3β-HSD2 mRNA levels in 
hOSE and EOC cells. 
Combined data of 6 separate 
hOSE and 6 further EOC 
samples. Taqman qPCR was 
performed to assess differences 
in 3β-HSD1 and 3β-HSD2 
transcriptional levels between 
normal hOSE and EOC cells. 
Mean dCt of 3β-HSD1 mRNA 
and 3β-HSD2 mRNA in hOSE 
was 16.3 and 21.6, respectively. 
In EOC, mean dCt of 3β-HSD1 
mRNA was 21.7 and of 3β-
HSD2 mRNA was 24.3 (n=6, 
p=b<0.05).
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8.3.3.2 Relative levels of IL-1R1 and IL-4R mRNA in primary hOSE and EOC cells 
 Prior to functional studies after IL-1α and IL-4 treatments of cultured EOC 
cells we compared transcriptional levels of the cognate cytokine receptors i.e. IL-1R1 
and IL-4R mRNA in hOSE and ascites cells. Taqman qPCR in the two groups, each 
consisting of 6 samples did not show any difference in basal transcriptional levels of 
either IL-1R1 or IL-4R (Fig. 8.6, upper and lower panels, respectively). 
 
Figure 8.6: Relative IL-1R1 and IL-4R mRNA levels in hOSE and EOC cells. Combined 
data of 6 separate hOSE and 6 further separate EOC samples. Taqman qPCR was performed 
to assess differences in IL-1R1 (upper panel) and IL-4R (lower panel) transcriptional levels 
between normal hOSE and EOC cells. Mean dCt of IL-1R1 mRNA was 13.2 in hOSE and 
13.3 in EOC. Mean dCt of IL-4R mRNA was 14.0 and 14.8 in hOSE and EOC, respectively. 
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8.3.4 Effect of IL-1α on 3β-HSD1 and 3β-HSD2 mRNA levels in primary EOC 
cells 
 Primary cultures of ascites collected from 3 patients who were diagnosed 
with EOC were treated with increasing doses of IL-1α (0.02-1.0ng/mL) for 48h. The 
cells were then harvested in RNA lysis buffer and after RNA extraction and 
quantity/quality assay, Taqman qPCR was performed to determine any potential 
differences in 3β-HSD1 mRNA and 3β-HSD2 mRNA levels between treated and 
untreated samples. A trend towards an IL-1α down-regulation of 3β-HSD1 mRNA 
was observed at all doses tested; however, this effect did not reach statistical 
significance (Fig. 8.7, upper panel, n=3, p=0.058). Regarding 3β-HSD2, there was 
variability among different patients such that no significant difference was observed 
between treated and untreated samples although an apparent up-regulatory trend was 
noted (Fig. 8.7, lower panel, n=3). 
 
Figure 8.7: Effect of IL-
1α on 3β-HSD1 and 3β-
HSD2 mRNA in primary 
EOC cells. Combined data 
of 3 separate EOC samples. 
Cells were treated with 
increasing doses of IL-1α 
(0.02-1.0ng/mL) for 48h. 
Taqman qPCR was 
performed to assess 
differences in 3β-HSD1 
mRNA (upper panel) and 
3β-HSD2 mRNA levels 
(lower panel) between 
treated and untreated 
control samples. 
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8.3.5 Effect of IL-4 on 3β-HSD1 and 3β-HSD2 mRNA levels in primary EOC 
cells 
Primary cultures of ascites collected from 3 patients who were diagnosed 
with EOC were treated with increasing doses of IL-4 (0.02-1.0ng/mL) for 48h. The 
cells were then harvested, RNA extracted and quantity/quality assays carried out, 
Taqman qPCR was performed to determine potential differences in 3β-HSD1 mRNA 
and 3β-HSD2 mRNA levels between treated and untreated samples. IL-4 
substantially increased 3β-HSD1 and 3β-HSD2 mRNA levels when 0.1, 0.5 or 
1.0ng/mL IL-4 were added with no statistical difference between different doses (Fig. 
8.8, b=p<0.05). The average increase of 3β-HSD1 mRNA was approximately 100-
fold when 1.0ng/mL IL-4 was added (Fig. 8.8, upper panel), whilst 3β-HSD2 mRNA 
was increased approximately 80 times by 0.5ng/mL IL-4 (Fig. 8.8, lower panel). 
 
Figure 8.8: Effect of IL-4 
on 3β-HSD1 and 3β-HSD2 
mRNA levels in primary 
EOC cells. Combined data 
of 3 separate EOC samples. 
Cells were treated with 
increasing doses of IL-4 
(0.02-1.0ng/mL) for 48h. 
Taqman qPCR was 
performed to assess 
differences in 3β-HSD1 
mRNA (upper panel) and 
3β-HSD2 mRNA levels 
(lower panel) between 
treated and untreated control 
samples (n=3, b=p<0.05). 
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8.3.6 Summary of data accumulated with primary EOC cells 
Table 8.4 Comparison studies in primary hOSE and EOC cells 




Expression in EOC 
relative to hOSE 
3β-HSD1 
mRNA 
16.3 21.6 ↓ 
3β-HSD2 
mRNA 
21.7 24.3 n/s (p=0.06) 
IL-1R1 
mRNA 
13.2 13.3 n/s 
IL-4R 
mRNA 
14 14.8 n/s 
↓: down-regulation, n/s: not significant; mean dCT represents PCR cycle when target gene 
started to accumulate relative to internal 18S. Differences in dCT between different samples 
are presented at the logarithmic level 
 
Table 8.5 Effects of IL-1α and IL-4 on 3β-HSD1 mRNA and 3β-HSD2 mRNA in 
primary EOC cells 
Treatment 3β-HSD1 mRNA 3β-HSD2 mRNA 
IL-1α n/s (p=0.058) n/s 
IL-4 ↑ ↑ 
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8.4 Discussion 
 We have demonstrated 3β-HSD gene expression and enzymatic activity in 
EOC, suggestive of an intracrine role for 3β-HSD activity in determining functional 
cellular responses mediated by AR and PR in ovarian cancer.  We also have 
established that both 3β-HSD1 and 3β-HSD2 mRNAs are expressed in EOC. 
However, we found that ovarian cancer cells have much lower levels of overall 3β-
HSD gene expression, but importantly that this can be restored by exposure to IL-4.  
 The finding that 3β-HSD is expressed in solid ovarian tumours and epithelial 
cells of malignant origin implies that ovarian tumours have the capacity locally to 
generate active progestogens and androgens. Importantly, in double 
immunofluorescence studies of ascites samples, it was shown that only epithelial 
cytokeratin 7-immunopositive cells expressed 3β-HSD. This suggests that our 3β-
HSD data for primary ascitic cell cultures most likely reflect malignant epithelial 
cells rather than other cellular components of the cultures such as activating 
mesothelial cells. Notwithstanding this potential limitation, comparisons of ascites 
with normal hOSE cells established that 3β-HSD mRNA expression is substantially 
reduced in ovarian cancer cells. Collectively, these data are suggestive of attenuated 
pre-receptor metabolism in cancer cells relative to normal hOSE, which might be a 
feature of neoplastic transformation.   
 A caveat to our comparison of normal hOSE and ovarian cancer cells is that 
we have compared pre-menopausal normal hOSE with post-menopausal cancer cells, 
instead of post-menopausal normal hOSE with cancer. Indeed, the differences in 3β-
HSD expression levels observed herein might reflect a feature of the post-
menopausal ovary in general rather than a feature of oncogenesis, although the study 
of a single pre-menopausal cancer patient did not show any difference in 3β-HSD 
expression levels relative to post-menopausal cancers (Table 8.3, ascites 6). However, 
this finding remains important because attenuation of progesterone biosynthesis post-
menopausally could lead to defects of apoptotic molecular mechanisms that underlie 
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progesterone signalling. This, in turn, could result in tumourigenesis (Bu et al. 1997, 
Murdoch et al. 2001). On the other hand, 3β-HSD attenuation in post-menopausal 
and ovarian cancer women might be considered beneficial since minimisation of 
local androgen synthesis could suppress cell growth and survival (Edmondson et al. 
2002). Nevertheless, this is likely not the case since it is well established that the 
post-menopausal ovary retains the steroidogenic capacity to produce androgens 
(Havelock et al. 2006, Laughlin et al. 2000), suggesting alternative pathways rather 
than 3β-HSD for local androgen production.  Previous studies have consistently 
shown increased AR protein (Cardillo et al. 1998, Kühnel et al. 1988) and co-
activators (Shaw et al. 2001) in ovarian cancer, whilst greatly decreased PR mRNA 
and protein in a significant percentage of ovarian cancers has also been reported 
(Cardillo et al. 1998, Chadha et al. 1993, Lau et al. 1999). Importantly, the 
expression of PR in ovarian tumours has been positively associated with an increased 
survival rate (Abd-Elaziz et al. 2005, Hempling et al. 1998).  Jointly, the shift from a 
progestogenic to an androgenic-dominant ovarian environment peri- and post-
menopausally is probably the consequence of diminished 3β-HSD at this stage of life 
and could be reflective of the promotion of ovarian cancer. 
Because the 3β-HSD antibody cross-reacts with both isoforms, semi-
quantitative and quantitative RT-PCR were performed to further elucidate the 
expression pattern of HSD3B gene products (i.e. 3β-HSD mRNA). Similarly to 
hOSE, both mRNA species were present in cultured ascites cells of malignant origin, 
attesting that both 3β-HSD isoforms likely contribute to overall 3β-HSD enzymatic 
activity. However, unlike in hOSE cells, there was no statistical difference between 
3β-HSD1 mRNA and 3β-HSD2 mRNA levels, although a trend towards increased 
3β-HSD1 mRNA was apparent. This was probably reflective of the disparity existing 
among individual ovarian cancers coupled with a relatively small group of samples.   
In Chapters 4 and 5, we distinguished the relative functional importance of 
3β-HSD1 and 3β-HSD2 mRNA species in primary hOSE cells. We showed that 
exposure of hOSE to the pro-inflammatory IL-1α attenuated 3β-HSD1 mRNA 
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expression, whereas IL-1α stimulated 3β-HSD2 mRNA levels. We also showed that 
these effects are mediated through differential signalling pathways. In primary cancer 
cells, 3β-HSD1 mRNA was attenuated by IL-1α treatment (p=0.058), whilst 3β-
HSD2 mRNA levels were unaltered by this proxy, suggesting that IL-1α responses to 
ovarian cancer are altered relative to normal hOSE cells. Nonetheless, there was not 
any difference in IL-1R1 mRNA expression levels between the two cell populations. 
Jointly, these findings indicate that altered actions of IL-1α on 3β-HSD gene 
regulation are not a consequence of lack of IL-1R1 but of changes in downstream 
signalling molecules. Importantly, a lack of IL-1α to up-regulate 3β-HSD2 mRNA 
probably represents aberrant local anti-inflammatory steroid action in ovarian cancer. 
This is consistent with a previous study, demonstrating differences in inflammatory 
responses between primary hOSE cells and EOC cell lines (Gubbay et al. 2005). 
The low levels of 3β-HSD expression in ovarian cancer cells and the striking 
restoration of 3β-HSD1 and 3β-HSD2 mRNA levels after IL-4 treatment of cells of 
malignant origin, is consistent with an anti-tumourigenic role for this cytokine in 
ovarian cancer.  We note that an anti-tumour role of IL-4 in breast cancer has been 
also demonstrated (Gingras et al. 1999, Nagai & Toi 2000). IL-4 has been reported to 
attenuate expression of TNF-α- and IL-1α-related pro-inflammatory effects in TNF-α 
transgenic mice (Bessis et al. 1998).  Like hOSE cells, cancer cells do not secrete IL-
4 de novo but they do express the IL-4 receptor (Burke et al. 1996). Importantly, we 
did not observe any differences in IL-4R mRNA expression levels between cancer 
and hOSE cells, suggesting that it is the absence of the ligand and not the receptor 
that is associated with tumourigenesis. Consistently, serum IL-4 levels have been 
shown to be reduced in post-menopausal women (Kumru et al. 2004), a stage of life 
where EOC is commonly encountered. It is very possible therefore, that IL-4-
increased 3β-HSD that favours local progesterone signalling in hOSE is lost after the 
menopause. This could have profound implications for the development of post-
menopausal ovarian cancer and deserves further investigation. Moreover, it has been 
reported that oestrogens can increase interferon-γ levels (Th-1 response), resulting in 
a lack of an increase in serum IL-4 levels (Th-2 response) (Kumru et al. 2004). It is 
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therefore of interest that a positive correlation exists between oestrogen levels and 
ovarian cancer (Choi et al. 2001b, Mukherjee et al. 2005).  
In summary, we have demonstrated attenuated expression and functionality 
of 3β-HSDs in EOC cells relative to normal hOSE. However, IL-4 can stimulate 3β-
HSD expression levels, potentially triggering steroid production in the ovarian milieu. 
IL-4-increased 3β-HSD could therefore be a critical determinant of progesterone 
bioavailability and anti-tumourigenic signalling via PR with the potential application 
to the treatment of ovarian cancer. A schematic illustration of our findings is 




Figure 8.9: Effects of cytokines in EOC. Basally decreased levels of 3β-HSD1 mRNA in 
EOC is further attenuated in response to IL-1α. However, restoration can be achieved in the 
presence of IL-4. Also, 3β-HSD2 mRNA can be substantially increased by IL-4 treatment. 
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9.1 Synopsis and General Discussion 
 This thesis explored the steroid mechanisms that physiologically occur in the 
human ovarian surface epithelium (hOSE), a poorly understood compartment of the 
biology of the ovary. The main focus was the regulation of pre-receptor metabolism 
of cytoproliferative androgens and apoptotic and anti-inflammatory progestogens, 
through investigation of 3β-HSD gene and protein function, during injury and repair 
of the post-ovulatory hOSE. Some preliminary work on cognate steroid androgen 
(AR) and progesterone (PR) receptors was also performed. Furthermore, as 
dysfunction of hOSE is also relevant to the development of epithelial ovarian cancer 
(EOC), preliminary approaches on the 3β-HSD pathway in EOC was also performed.    
 The study has established that 3β-HSD is localised in the ovarian cell surface, 
indicating that this ovarian compartment can actively participate in steroid 
biosynthesis not only of the surface epithelium but also of the whole ovarian tissue at 
least up to the progesterone level. It was also demonstrated that 3β-HSD is 
differentially regulated during the post-ovulatory injury and repair of the hOSE, 
attesting to its significance in tissue homeostasis. Ovulation-associated injury was 
mimicked with pro-inflammatory cytokines, namely IL-1α, TNF-α, IL-6, IL-18 and 
GM-CSF, whereas T lymphocyte-associated cytokines, namely IL-4 and IL-10 were 
used to induce post-ovulatory healing.  
 In post-ovulatory wounding, the two 3β-HSD isoforms, 3β-HSD1 and 3β-
HSD2, were shown to be differentially regulated by IL-1α but little or no effect on 
total 3β-HSD protein and activity was noticed, within the time window applied, 
revealing that a balance in steroid biosynthesis is essential for restriction of tissue 
damage that might arise from ovulation-associated inflammation. Importantly, our 
studies demonstrated that opposing effects of IL-1α on 3β-HSD1 and 3β-HSD2 
mRNA species are a result of activation of different signalling networks; 
inflammatory NF-κB pathway appears to regulate the IL-1α attenuation of 3β-HSD1 
mRNA, whilst a cross-talk among NF-κB, PI-3K and p38 MAPK pathways appears 
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to involve IL-1α-stimulated 3β-HSD2 mRNA. Moreover, IL-1α did not alter AR or 
PR mRNA expression levels, further supporting a balance in steroid actions via 
nuclear receptors during ovulation.  
 A substantial increase of 3β-HSD1, 3β-HSD2 mRNA and total 3β-HSD 
protein and activity was established after in vitro treatment of hOSE cells with IL-4. 
Importantly, IL-4-induced 3β-HSD1 and 3β-HSD2 mRNA required activated PI-3K 
and STAT-6 pathways. Moreover, IL-4 induction of 3β-HSD2 mRNA was 
suppressed when the SB203580 p38 MAPK pathway inhibitor was added. IL-4 
treatment also attenuated AR mRNA and protein without any alteration of PR 
mRNA expression levels. Intriguingly, this effect involved p38 MAPK signalling 
pathway. Collectively, it was shown that IL-4 sustains apoptotic and anti-
inflammatory progesterone pre-receptor metabolism and signalling via cognate PR, 
implying an anti-inflammatory role of this cytokine in post-ovulatory healing. To 
further confirm that IL-4 plays a role in hOSE post-ovulatory repair, we also tested 
two genes that play a key role in extracellular matrix (ECM) integrity, a process 
fundamental for proper hOSE regeneration; namely, the pro-inflammatory COX-2 
that is responsible for prostaglandin synthesis and thus ECM degradation and LOX 
that is responsible for ECM deposition. The T lymphocyte-associated cytokine IL-4 
was demonstrated to suppress IL-1α-induced COX-2 mRNA and also to stimulate 
LOX mRNA, thereby implying that this cytokine is essential not only for controlled 
proliferation of hOSE (through increase of 3β-HSD and thus intracrine generation of 
progesterone) but also for deposition of ECM. Remarkably, IL-4-induced LOX was 
abrogated when inhibitors for p38 MAPK and PI-3K pathways were added. 
p38 MAPK was clearly shown to be involved in the anti-inflammatory effects 
of IL-4 and also in the anti-inflammatory effects of IL-1α such as 3β-HSD2 
induction. However, as shown by numerous studies that were acknowledged in this 
thesis, an IL-1-induced p38 MAPK pathway is involved in the regulation of pro-
inflammatory-associated processes such as IL-6, IL-8 and prostaglandin synthesis. 
This raises the question of how p38 MAPK could be targeted pharmacologically to 
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alleviate rather than trigger inflammatory environments of inflammation-associated 
diseases such as ovarian cancer. This is more difficult, however, at the case of IL-1α, 
as this stimulus appears to utilise this pathway for both inflammatory and anti-
inflammatory-associated mechanisms; on the one hand, it down-regulates 3β-HSD1 
mRNA (pro-inflammatory effect), whereas on the other hand it up-regulates 3β-
HSD2 and 11β-HSD1 mRNA, thereby favouring in hOSE anti-inflammatory 
progesterone and glucocorticoid generation, respectively. On the other hand, IL-4 
appears to positively regulate anti-inflammatory genes (3β-HSD1, 3β-HSD2, LOX) 
and negatively regulate genes that are involved in cytoproliferation (AR) and 
inflammation (IL-1α-induced COX-2). Intriguingly, all of these genes appeared to be 
targets of p38 MAPK signalling cascades, at least at the mRNA 
transcriptional/stabilisation level, suggesting that targeting this pathway through IL-4 
rather than IL-1α could be an efficient pharmaceutical strategy in ovarian disorders 
such as cancer.  
Preliminary studies showed attenuated 3β-HSD gene expression in EOC. In 
primary EOC cell monolayers, it was demonstrated that 3β-HSD1 mRNA was 
expressed 42 times lower than that of primary hOSE cells. Moreover, a mean 6-fold 
decrease of 3β-HSD2 mRNA was observed to primary EOC compared to primary 
hOSE, although this effect did not reach significance (p=0.06). Importantly, IL-4 
treatment restored attenuated 3β-HSD1 and 3β-HSD2 mRNA and this could be of 
therapeutic advantage.    
  
9.2 Advantages, Caveats and Future Directions  
 A primary advantage of our studies was that all experimental sets were 
performed with primary cells collected from various patients, thereby taking into 
consideration variability among individual subjects. Therefore, data collected and 
conclusions drawn could reflect in part in vivo conditions. However, restrictions in 
the availability and numbers of primary cells did not allow us to design extended 
experiments, thereby many times excluding important parameters such as incubation 
time- and dose-points of target agents. Moreover, most of the data obtained were 
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limited at mRNA levels, making our studies one-dimensional. Though, this could be 
overcome by the use of proper controls, sufficient replicates and a reasonable amount 
of accumulating data.  
 Therefore, in order to further take forwrad speculations and conclusions 
developed in the present thesis, a series of additional studies are essential. Regarding 
intracellular signalling pathways, it is important to document phosphorylation of 
target proteins, namely p38 MAPK, NF-κB, PI-3K and STAT-6 by IL-1α and/or IL-4. 
Also, to further confirm whether IL-1α and IL-4 actions are antagonistic or 
independent, co-treatment experiments should be pursued in order to evaluate their 
combined effects on NF-κB and p38 MAPK signalling pathways. Importantly, it 
should also be ascertained that the pathway inhibitors tested specifically block 
phosphorylation of those proteins. Moreover, it would be quite conclusive to 
investigate which of the pathway inhibitors affect protein levels besides their impact 
on transcription/mRNA stabilisation of target genes. Also, given the importance of 
pre-receptor generation of progesterone in hOSE, it is fundamental to identify 
additional agents that positively or negatively regulate its generation. This could also 
contribute to the development of efficient strategies to diagnose or treat ovarian 
disorders such as cancer. 
 Preliminary studies in primary EOC cells demonstrated that 3β-HSD gene 
expression was decreaseed in the malignant ovary but this attenuation could be 
counteracted by treatment with IL-4. Attenuation in overall 3β-HSD protein and 
activity in EOC relative to hOSE followed by restoration thereof by IL-4 should be 
also shown to fundamentally establish this observation. It would be also of value to 
investigate if these effects are suppressed by addition of pathway inhibitors as shown 
in primary hOSE cells.   
 It is apparent that limitations in primary tissue availability and cell numbers 
yielded from one specimen hampers extended exploration of the human ovarian cell 
surface along with its role in the development of EOC. It is therefore clearly 
necessary to identify proper animal and human cell line models that could be used to 
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advance more consistently the biology of the human ovarian surface epithelium and 
also of human ovarian cancer.  
9.3 General Conclusion 
 In the present thesis, we demonstrated a functional 3β-HSD pathway in the 
ovarian cell surface that is differentially regulated during injury and repair of post-
ovulatory hOSE. Importantly, we showed attenuated expression and functionality of 
3β-HSDs in EOC cells relative to normal hOSE, probably reflecting an acquired 
feature of neoplastic transformation of hOSE. However, IL-4 could stimulate 3β-
HSD expression levels, potentially triggering steroid production in the ovarian 
milieu. IL-4-increased 3β-HSD could therefore be a critical determinant of 
progesterone bioavailability and anti-tumourigenic signalling via PR during 
ovulatory menstrual cycles with potential application to the treatment of ovarian 
cancer. We also identified p38 MAPK signalling pathway as a fundamental regulator 
of these processes with prospective use of this pathway to target inflammation-
associated disorders of the ovary including epithelial ovarian cancer.
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During the whole procedure, centrifugations were run for 15sec at 5000 x g, followed 
by discard of the flow-through, unless otherwise indicated.  Homogenised lysates 
were incubated at 37oC for 20min. 0.35mL of 70% ethanol was added to each cell 
homogenate and the resultant 0.7mL volumes were transferred to RNeasy mini 
columns placed on collection tubes. Then, DNase digestion was conducted using the 
Qiagen RNase-Free DNase set. Briefly, 0.35mL RW1 (washing buffer) was added 
followed by centrifugation. Then, 0.08mL DNase I mix, containing 0.01mL DNase I 
enzyme diluted in 0.07mL buffer RDD, was added to each column and lysates were 
centrifuged after incubation for 15min at room temperature. Finally, columns were 
washed with RW1 and centrifuged. For the RNA isolation, mini columns were 
washed with 0.5mL of RPE buffer twice (washing buffer). Two centrifugation steps 
followed. The second centrifugation lasted 2min in order to dry the silica-gel 
membranes. Then, mini columns were centrifuged for 1min at full speed. For the 
elution of the RNA, 0.03mL RNase-free water was added to each column placed on a 
new 1.5mL collection eppendorf, and the RNA was eluted after centrifugation for 
1min. To increase the RNA concentration, the eluate RNA was pipetted directly onto 
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POSTER PRESENTATIONS 
• 15-18 June 2008, San Frasisco, CA: 90th Annual Meeting of Endocrine 
Society  
Steroid signalling in human ovarian surface epithelium wound-healing (Trainee 
poster competition winner in Steroid hormone biosynthesis and metabolism).   
• 7-8 March 2008, London, UK: 1st International Meeting of Ovarian 
Cancer Action 
Evidence for the attenuation of progesterone biosyntheis in primary cultures of 
epithelial ovarian    cancer. Could IL-4 have a therapeutic role?  
• 11-12 September, 2007, Edinburgh, UK: MRC Inflammation Showcase 
3β-Hydroxysteroid dehydrogenase type1 and type 2 in the human ovarian 
surface epithelium:   Differential regulation and transduction of the two isoforms 
by cytokines 
• 2-5 June, 2007, Toronto,Canada: The Endocrine’s Society 89th Annual 
Meeting 
3β-Hydroxysteroid dehydrogenase type1 and type 2 in the human ovarian 
surface epithelium:   Differential regulation and transduction of the two isoforms 
by cytokines (Awarded to attend ENDO trainee day). 
• 13-16 September, 2006, Athens, Greece: 12th International Congress on  
Hormonal Steroids and Hormones & Cancer 
3β-Hydroxysteroid dehydrogenase type1 in the human ovarian surface 
epithelium: Down-regulation by pro-inflammatory cytokines (Top 10 poster 
prize for young investigators). 
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ORAL PRESENTATIONS 
• 13th November 2007, CRB Research Day 
Regulation of 3β-hydroxysteroid dehydrogenases (3β-HSDs) by cytokines 
• 8-9 September, 2007, Cambridge, UK: 9th National Ovarian Workshop 
3β-Hydroxysteroid dehydrogenase type 1 and type 2 in the human ovarian 
surface epithelium:   Differential regulation and transduction of the two isoforms 
by cytokines 
 
• 11th May, 2007, Aberdeen, UK: Scottish Society of Experimental 
Medicine 
Altered expression of 3β-hydroxysteroid dehydrogenase type 1 and type 2 
among the human ovarian surface epithelium (hOSE) cells, pre-neoplastic and 
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Ovulation-associated inflammation with accompanied cytokines and reproductive hormones impact
upon the human ovarian surface epithelium (hOSE) and probably have a role in the aetiology of ovar-
ian cancer. Progesterone and progestin-related events, i.e. pregnancy and oral contraception, protect from
the disease. We have investigated the pre-receptor metabolism of progesterone in primary hOSE cells






dehydrogenase (3-HSD) by inflammatory, anti-inflammatory and apoptotic factors. In hOSE cells, we
show that anti-inflammatory effects of IL-1 and IL-4 on 3-HSD2 mRNA involve a p38 MAPK signalling
pathway, whereas pro-inflammatory response of IL-1 to 3-HSD1 mRNA involves a NF-B inflamma-
tory pathway. In OSE-C2 cells, retinoic acid and transforming growth factor-1 massively induce 3-HSD1
mRNA levels. In conclusion, we elaborate several mechanisms for intracrine formation of progesterone















pithelial ovarian cancer ovarian cancer.
. Introduction
The human ovarian surface epithelium (hOSE) is a squamous-
o-cuboidal cellular monolayer of mesodermal origin that covers
he ovary (Gillett et al., 1991). It was only lately that it has been
ealised that the human surface epithelium is probably the origin
f at least 85% of ovarian cancers, the so-called epithelial ovarian
ancer (EOC), with stromal-sex cord and germ cell ovarian tumours
nly representing sparse cases (Parkin et al., 2005). At least three
ypotheses have been reported to explain the development of EOC
hat are interrelated and not mutually exclusive. Ovulation, accom-
anied inflammation and associated reproductive hormones (i.e.
onadotrophins, oestrogens, androgens, progesterone) prior to and
ost-ovulation are believed to have a role in the aetiology of EOC
Cramer and Welch, 1983; Espey, 1994; Fathalla, 1971; Ness andPlease cite this article in press as: Papacleovoulou, G., et al., 3-Hydroxy
human ovarian surface epithelium. Mol. Cell. Endocrinol. (2008), doi:10.10
ottreau, 1999; Risch, 1998). In essence, the ovarian cell surface
ndergoes injury and repair cycles after each ovulation and factors
uch as gonadotrophins, steroid hormones and immune media-
ors that are released at this time are primary candidates for the
∗ Corresponding author. Tel.: +44 131 242 6442; fax: +44 131 242 6441.
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rogression of or protection from the disease. A series of studies
ocusing on anti-inflammatory steroid signalling on hOSE led to
he concept that identification of anti-inflammatory steroid mech-
nisms that essentially control integrity of the ovarian cell surface
fter ovulation-associated wounding could undoubtedly lead to the
evelopment of efficient strategies to diagnose and/or treat EOC
Rae and Hillier, 2005; Rae et al., 2004b).
From a recent screening of steroid-related markers in hOSE,
t was shown that 3-hydroxysteroid dehydrogenase type 1
3-HSD1) mRNA is suppressed by interleukin-1 (IL-1), an
vulation-associated pro-inflammatory proxy (Rae et al., 2004b).
-HSD1 and 3-HSD2 are two separate isoforms of the same
nzyme (they arise from different genes) that control the intracrine
ormation of progesterone. Progesterone has been reported to be
poptotic and anti-inflammatory in hOSE and EOC cells and links
f pregnancy, oral contraception (especially progestin-only con-
raception) and reduced risk of emergence of the disease have
een demonstrated (Bu et al., 1997; Murdoch and Van Kirk, 2002;
ae et al., 2004a; Risch et al., 1994; Rodriguez et al., 1998). 3-steroid dehydrogenases and pre-receptor steroid metabolism in the
16/j.mce.2008.08.010
SD1 is mainly expressed in trophoblast, mammary and skin,
hilst 3-HSD2 is principally expressed in steroidogenic organs
uch as gonads and adrenal (Lorence et al., 1990; Rheaume et al.,
991; Thomas et al., 1988, 1989). Therefore, although the relevant






















































































































(v/v) (PBST; Sigma), sequential incubations with anti-rabbit biotinylated IgG1 (Vec-
tor) and RTU ready-to-use ABC kit (avidin–biotin complex; horse radish peroxidase
(HRP)-conjugated; Vector) for 1 h each were performed. Washing steps with PBSTARTICLECE-6942; No. of Pages 9
G. Papacleovoulou et al. / Molecular an
redicted, total 3-HSD activity essentially controls the bioavail-
bility of progesterone and its access to progesterone receptor
PR) in a tissue. Therefore, it is of great importance to elucidate
he mechanisms that are involved in progesterone pre-receptor
etabolism in hOSE. In support of this, characterisation of inflam-
atory, anti-inflammatory and apoptotic mediators that could
otentially mediate progesterone pre-receptor metabolism should
e a priority. For example, IL-1 is a prototypic cytokine that
s secreted during ovulation and induces changes in a series of
nflammatory-associated genes (Rae et al., 2004a,b). Additionally,
L-4 is a T-lymphocyte cytokine that is mainly secreted at the peri-
vulatory follicle, corpus luteum and corpus luteum of pregnancy
all characterised by elevated progestogens) (Hashii et al., 1998).
nother candidate could be transforming growth factor-1 (TGF-
1) that has been demonstrated to have a role in ovarian tissue
emodelling and more importantly has been established to exert
nti-proliferative and apoptotic effects on hOSE and EOC (Berchuck
t al., 1992; Choi et al., 2001; Harlow et al., 2003). Finally, retinoic
cid (RA), a derivative of vitamin A, is considered to be chemo-
reventive and anti-carcinogenic and has been shown to exert
poptotic effects in EOC cell lines (Bu et al., 1997; Formelli and
leris, 1993). Remarkably, aldehyde dehydrogenases (ALDH), the
nzymes that are involved in oxidation/reduction of retinol and
etinal as well as retinoic acid receptors (RAR) are present in hOSE
ells, suggesting functional signalling by retinoic acid in hOSE phys-
ology (Rae et al., 2004b).
Limitations in primary tissue availability do not allow sustained
nvestigation of hOSE physiology, a restriction that literally har-
esses good prognosis of EOC. As such, identification of models
o study hOSE biology appears essential for prevention and/or
iagnosis of the disease. OSE-C2 cell line has been established by
mmortalisation of hOSE cells obtained from a pre-menopausal
oman undergoing surgery for non-malignant gynaecological con-
itions (Davies et al., 2003). The advantage of this cell line is that
t maintains its the epithelial-specific cytokeratin staining pattern
Davies et al., 2003), characteristic of primary hOSE cells in tissue
ulture (Auersperg et al., 2001; Dyck et al., 1996; Rae et al., 2004b).
inally, the OSE-C2 cell line is not considered cancerous, because it
oes not express E-cadherin, a cell–cell adhesion molecule that has
een reported to be highly expressed in advanced epithelial ovar-
an carcinomas (Ong et al., 2000) and failed to form xenografts in
ice (Davies et al., 2003).
Therefore, in the present study we have investigated the iso-
orm expression pattern of 3-HSD1 and 3-HSD2 in hOSE both
n vivo and in vitro and their transcriptional regulation by the
ro-inflammatory cytokine IL-1 as well as the anti-inflammatory
ytokine IL-4. Moreover, we have tested whether OSE-C2 cells
espond similarly to primary hOSE cells. Due to limitations in pri-
ary tissue, we have used OSE-C2 cell line to examine further the
ole of the apoptotic agents, TGF-1 and RA, in the regulation of
-HSD mRNA levels.
. Subjects and methods
.1. Subjects
hOSE cells for in vitro experimentation or normal ovarian tissue for histological
tudies were collected from pre-menopausal women (mean age 36 yrs) who under-
ent surgery for non-malignant, benign gynaecological disorders, such as fibroids,
eavy menstruation and pelvic pain. Written consent to obtain tissue was provided
y all patients and the Lothian Research Ethical Committee (LREC) approved the
roject (project number 05/S1103/14).Please cite this article in press as: Papacleovoulou, G., et al., 3-Hydroxy
human ovarian surface epithelium. Mol. Cell. Endocrinol. (2008), doi:10.10
.1.1. OSE-C2 cells
The OSE-C2 cell line immortalised from a primary hOSE cell culture collected
rom a pre-menopausal woman, has been previously described (Davies et al., 2003).
riefly, cells were immortalised with the catalytic subunit of telomerase (hTERT)








lar Endocrinology xxx (2008) xxx–xxx
2 cells were maintained and tested at the permissive temperature of 33 ◦C (Davies
t al., 2003).
.2. Cell culture of primary hOSE cells
Ovarian surface epithelial cells were cultured as previously reported (Hillier et
l., 1998; Kruk et al., 1990). Primary hOSE cells were retrieved by brushing of the
varian surface, then placed in 75 cm2 donor-calf serum pre-coated flasks (Corning
nc. Glass Works; Corning NY) and cultured in a humidified tissue culture incubator
assed with 95% air–5% CO2 at 37 ◦C until confluence (between 2 and 4 weeks). The
ulture medium contained MCDB 105:M199 (1:1, v/v) culture media, supplemented
ith 15% (v/v) of fetal bovine serum (FBS), 2 mmol/L l-glutamine, 50 g/mL strepto-
ycin and 50 IU/mL penicillin (Invitrogen Life Technologies, Inc.; Renfrewshire, UK
nd Sigma Chemical Co.; Poole, UK). Purity of epithelial cultures was verified with
hase-contrast microscopy. Cytokeratin staining (5, 6, 8 and 17) was performed in
elective cases with a commercial mouse monoclonal antibody (not shown) (Dako,
ly; Cambridgeshire, UK).
.3. Cell culture of OSE-C2 cells
OSE-C2 cells were cultured as primary hOSE cells with minor modifications.
riefly, cells were grown at 33 ◦C in T165 flasks (Corning) in MCDB 105:M199 culture
edia (1:1, v/v) containing 2 mmol/L of l-glutamine and 10% of FBS. Culture medium
id not contain antibiotics. Medium was changed every 3 days and confluence was
chieved in around 5 days. An epithelial phenotype of OSE-C2 cells was ascertained
sing a mouse monoclonal antibody that immunoreacts with cytokeratins 5, 6, 8
nd 17.
.4. Experimental treatments of primary hOSE and OSE-C2 cells
Once confluent, cells were enzymatically digested with 0.05% trypsin (w/v)
nd 0.5 mM EDTA (Sigma) at 37 ◦C for 5 min. Cell suspensions were then washed
ith Dulbecco’s phosphate buffer saline (DPBS) (Sigma) and centrifuged twice
rior to reconstitution of resultant cell pellets in 1 mL of pre-warmed culture
edium. After cell viability assessment with a haemocytometer and trypan blue
taining exclusion (viability ranged between 80 and 95%), 3.5 × 105 of viable cells
n a total of 2 mL of culture medium were distributed in 6-well plastic culture
lates (Corning). Cell attachment was allowed for 24 h before serum-starvation
or another 24 h in culture medium that contained 0.01% BSA (Sigma) instead of
BS, followed by experimental treatments with serial doses of IL-1, IL-4 (R&D
ystems; Abingdon Science Park, UK), RA (Sigma) and TGF-1 (Preprotech; Lon-
on, UK). In order to investigate the potential involvement of the inflammatory
uclear factor-B (NF-B) and mitogenic p38 MAPK signalling transduction path-
ays in IL-1 and IL-4 responses, 1 M BAY117082 (Merck; Beeston, Nottingham,
K), a selective inhibitor of the IB (an intermediate mediator of NF-B path-
ays) and SB203580 (Merck), a selective inhibitor of p38 MAPK, were included in
he culture media in the presence or absence of IL-1 or IL-4. Doses of inhibitors
ere selected per manufacturers’ guidance. All other reagents were obtained from
igma.
.5. Immunohistochemistry
Ovarian sections from three separate ovaries that were embedded in paraffin
locks were cut with a microtome and subjected to immunostaining for 3-HSD.
he 3-HSD polyclonal rabbit antibody was raised against human recombinant 3-
SD2 and immunoreacts with both human isoforms (Thomas et al., 2002). Slides
ere deparaffinised in xylene, serial dilutions of ethanol (100–50%), PBS (Sigma)
nd distilled H2O. Following permeabilisation using a microwave heating step in
.01 M of sodium citrate buffer (Sigma) for 15 min and cooling down for another
0 min under running tap water, sequential blocking steps of endogenous peroxi-
ase (3% H2O2 in H2O (v/v); Sigma) and avidin, biotin (Vector; Peterbourough, UK)
ere performed. Each step was followed by PBS washes for 5 min. Slides were then
ubmitted to a non-immunised blocking step for 20 min and overnight incubation
ith the 3-HSD antibody at 4 ◦C. The antibody was diluted in 1:6000 in normal
oat serum (NGS) (1:5 in PBS (v/v) supplemented with 5% BSA (w/v)). Negative
lides incubated with mock rabbit IgG1 antibody were run routinely at matched
oncentrations. Following washes with PBS supplemented with 0.05% Tween 20steroid dehydrogenases and pre-receptor steroid metabolism in the
16/j.mce.2008.08.010
ere performed between each step for 5 min thrice. Finally, slides were submit-
ed to staining with HRP-conjugated diaminobenzidine (DAB; Vector) chromagen
or 5 min followed by haematoxylin staining and dehydration with serial doses of
thanol (50–100%) and xylene. Slides were mounted with coverslips using pertex
Sigma). Visualisation and capture of pictures was achieved with an Olympus Provis
icroscope (Olympus Optical, London, UK).
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ell type 3-HSD1 mean dCt 3-HSD2 mean dCt
OSE cells 14.03 18.12
SE-C2 cell line 20 28.2
ean dCt reflects Ct of target gene relative to Ct of 18S as the internal reference.
.6. RNA extraction and quantity measurement
Following in vitro treatments, cells were harvested and homogenised in lysis
uffer (RLT buffer, Qiagen, West Sussex, UK) before RNA extraction with the RNeasy
ini-kit (Qiagen) per manufacturer’s guidance. Exclusion of genomic DNA was
chieved with DNase treatment of samples, on-column, with the RNase free DNase
et (Qiagen) according to supplier’s protocol. Purification and quantification were
ssessed using a Nanodrop spectrophotometer (ND-1000, Nanodrop Technologies
nc, Wilmington, DE, USA).
.7. Quantitative measurement of 3ˇ-HSD1 and 3ˇ-HSD2 mRNA
Quantitative Taqman Real-Time PCR was performed to measure relative expres-
ion levels of 3-HSD1 and 3-HSD2 mRNA in response to treatments. Briefly, pure
NA (200 ng) was reversed transcribed to cDNA using the RT-Reagent kit (Applied
iosystems, Applera, Warrington, UK) per supplier’s instructions in a final reaction
f 10 L. Then, Real-Time PCR was performed using commercial Applied Biosystems
eagents. Briefly, 2 L cDNA was used as a template mixed with 1× universal Taqman
aster cocktail (Applied Biosystems) and the specific set of 1× primer/probe mix-
ure. Both 3-HSD1 and 3-HSD2 primer/probe sets were purchased pre-validated
Assay-on-Demand Systems, Applied Biosystems). A ribosomal 18S primer/probe set
as also included and served as an internal reference control. Mean values reflecting
he PCR cycle when the target transcript started to be accumulated relative to 18S
mean dCt in a 40 cycle PCR reaction) are illustrated in Table 1. Values more than 36
ut of 40 PCR cycles were assessed as beyond the limit of robust detection; however
hey were included in analysis for comparison reasons. Each reaction was carried
ut in duplicate. Samples were evaluated in 96-well plates using an ABI Prism 7900
equence Detector (Applied Biosystems).
.8. Statistical analysis
Data sets are presented as means and standard errors of at least three indepen-
ent sets of replicates. Basic statistical analysis was run using the GraphPad Prism
.00 software (GraphPad Software Inc., San Diego, USA). Multiple comparisons were
erformed with one-way ANOVA and Neuman–Keuls post hoc tests, whilst single
omparisons were achieved with paired Student’s t-tests. Statistical significant were
onsidered at p-values ≤ 0.05. All values given in Section 3 and figure legends reflect
tatistical difference relative to untreated control cells, unless otherwise specified.
. ResultsPlease cite this article in press as: Papacleovoulou, G., et al., 3-Hydroxy
human ovarian surface epithelium. Mol. Cell. Endocrinol. (2008), doi:10.10
.1. Expression of 3ˇ-HSD protein in the human ovarian surface
pithelium
Staining with the 3-HSD antibody in a representative ovary is





ig. 1. Expression of 3-HSD in hOSE. (A) Immunolocalisation of 3-HSD in the hOSE lay
ells of the ovarian cell surface is noticed. The inset represents a negative control. (B) Im
embrana granulosa and theca interna. The inset reflects a negative slide. Scale bars repr PRESS
lar Endocrinology xxx (2008) xxx–xxx 3
varian surface epithelium of the pre-menopausal human ovary
s revealed with immunohistochemistry with a polyclonal rabbit
-HSD antibody (block arrow, Fig. 1A). Intriguingly, expression
evels varied among different cells of the ovarian surface. Specificity
f the antibody was tested by using an antral follicle as positive
ontrol. As illustrated in Fig. 1B, follicular cells and particularly
embrana granulosa and theca interna were immunostained for
-HSD (block arrow). Incubation with unconjugated IgG1 rabbit
ntibody was used for negative control (insets in Fig. 1A and B).
.2. Expression pattern of 3ˇ-HSD1 and 3ˇ-HSD2 mRNA in
rimary hOSE cells and OSE-C2 cell line
Because the 3-HSD antibody used in immunolocalisa-
ion studies reflected total 3-HSD protein (3-HSD1 and/or
-HSD2 proteins), relative isoform expression was investi-
ated with quantitative Real-Time PCR using isoform-specific
rimer/probe sets. Primary hOSE cells obtained from 7 indi-
idual patients were positive for both 3-HSD1 and 3-HSD2
RNA with a mean 12-fold increase of 3-HSD1 mRNA
s opposed to 3-HSD2 mRNA (n = 7, b = p < 0.05; Fig. 2,
pper panel). On the other hand OSE-C2 cells displayed only
-HSD1 mRNA, 3-HSD2 mRNA being immeasurable (n = 3,
= p < 0.001; Fig. 2B, lower panel). Raw dCt values are listed in
able 1.
.3. Regulation of 3ˇ-HSD1 and 3ˇ-HSD2 mRNA by IL-1˛ in
rimary hOSE cells and OSE-C2 cell line
Stimulation of primary hOSE cells with IL-1 in a dose–response
anner for 48 h as a proxy to mimic ovulation-associated inflam-
ation resulted in a 3-fold suppression of 3-HSD1 mRNA as
ssessed by quantitative Real-Time PCR (Taqman). This effect
as dose-dependent (0.02 and 0.5 ng/mL) with a maximal down-
egulation when IL-1 (0.5 ng/mL) was added (n = 4, b = p < 0.05;
ig. 3, upper panel). At the same time, 3-HSD2 mRNA was
p-regulated in response to IL-1 in a dose-dependent manner.
he maximal fold-change (4-fold-change) was observed with 0.1steroid dehydrogenases and pre-receptor steroid metabolism in the
16/j.mce.2008.08.010
anel).
In OSE-C2 cells, no effect on 3-HSD1 mRNA by IL-1 was
emonstrable, probably due to very low basal expression lev-
ls (data not shown). Moreover, loss of 3-HSD2 mRNA was not
estored by IL-1 treatment (data not shown).
er of a representative human ovary. Disparity of staining intensity among different
munostaining of an antral follicle for 3-HSD. Immunopositivity is observed in
esent 50 m.
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ig. 2. The pattern of mRNA expression of 3-HSD isoforms in primary hOSE and
SE-C2 cells. Upper panel: The hOSE cells were separately collected from seven
atients (n = 7, b = p < 0.05; upper panel). Lower panel: In OSE-C2 cells, only 3-HSD1
RNA was detectable (n = 3, c = p < 0.001; lower panel).
.4. Regulation of 3ˇ-HSD1 and 3ˇ-HSD2 mRNA by IL-4 in
rimary hOSE cells and OSE-C2 cell line
Following IL-1 treatment, primary hOSE and OSE-C2 cells were
reated with the ‘anti-inflammatory’ cytokine IL-4 for 48 h and
uantification of 3-HSD1 and 3-HSD2 mRNA levels was per-
ormed. In primary hOSE cells obtained from 4 separate patients,
L-4 had a substantial stimulatory dose-dependent effect on
oth 3-HSD1 and 3-HSD2 mRNAs (15-fold-change and 70-fold
ncrease, respectively, n = 4, b = p < 0.05, c = p < 0.001 Fig. 4A). Treat-
ent of OSE-C2 cells with IL-4 in a time- and dose-dependent
anner resulted in a substantial increase of 3-HSD1 mRNA (n = 3,
= p < 0.001, Fig. 4B, upper panel). Combined data from 3 indepen-
ent replicates showed that 3-HSD2 mRNA levels did not alter
ith extended IL-4 treatment times (data not shown). In con-
rast, 8 h treatment with serial doses of IL-4 dose-dependently
ncreased 3-HSD1 mRNA with a maximal effect when 0.25 ng/mL
f IL-4 was added (n = 3, b = p < 0.05, c, d = p < 0.001, Fig. 4B, lower
anel).Please cite this article in press as: Papacleovoulou, G., et al., 3-Hydroxy
human ovarian surface epithelium. Mol. Cell. Endocrinol. (2008), doi:10.10
.5. Involvement of NF-B inflammatory signalling pathway in
L-1˛- and IL-4-mediated 3ˇ-HSD mRNAs in primary hOSE cells
In order to investigate if the inflammatory pathway NF-B was




ig. 3. The effect of IL-1 on 3-HSD mRNA levels in primary hOSE cells. Combined
ata of four independent replicates of primary hOSE cells treated with the indicated
oses of IL-1 for 48 h. Upper panel: 3-HSD1 (b = p < 0.05); lower panel: 3-HSD2
b = p < 0.05, c = p < 0.01).
ion of 3-HSD1 and 3-HSD2 mRNA, we treated primary hOSE
ells with 1 M BAY117082, a selective inhibitor of IB, in the pres-
nce or absence of 0.5 ng/mL of IL-1 or 0.5 ng/mL of IL-4 for 48 h
Fig. 5). BAY117082 reversed IL-1-suppressed 3-HSD1 mRNA lev-
ls, whereas it did not affect the IL-4 response (n = 4, b = p < 0.05,
= p < 0.001; Fig. 5, upper panel). Regarding 3-HSD2 mRNA regu-
ation, the IL-1 effect was also blocked with no effect with respect
o IL-4 stimulation (Fig. 5, lower panel).
.6. Involvement of p38 MAPK signalling pathway in IL-1˛- and
L-4-mediated 3ˇ-HSD mRNA expression in primary hOSE cells
We also addressed whether the p38 MAPK signalling pathway
articipated in the transduction of 3-HSD mRNA transcriptional
egulation. Primary hOSE cells were treated with 10 M SB203580,
selective pathway inhibitor. Intriguingly, this inhibitor alone
own-regulated 3-HSD1 mRNA levels, although it did not further
ffect responses observed with cytokines alone (n = 3, b = p < 0.05;
ig. 6, upper panel). On the other hand, stimulatory effects of
.5 ng/mL IL-1 and IL-4 on 3-HSD2 mRNA levels were com-
letely blocked in the presence of the inhibitor (n = 3, b = p < 0.05,
= p < 0.001; Fig. 6, lower panel).
.7. Regulation of 3ˇ-HSD1 mRNA by TGF-ˇ1 and all-transsteroid dehydrogenases and pre-receptor steroid metabolism in the
16/j.mce.2008.08.010
etinoic acid (RA) using OSE-C2 cell line as a model of hOSE
Because of restricted primary tissue availability and given that
SE-C2 cells respond to cytokines similarly to primary hOSE cells,
e further investigated progesterone pre-receptor metabolism
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arious doses of IL-4 for 48 h—3-HSD1 (upper panel) and 3-HSD2 (lower panel) m
f 3-HSD1 mRNA levels in OSE-C2 cells treated with IL-4 (0.5 ng/mL) for the indica
= 0.001, lower panel).
sing this cell line as a model. OSE-C2 cells were treated with
poptotic factors RA and TGF-1 at various different doses and
ime-points (Fig. 7). Then, 3-HSD1 mRNA expression levels in
esponse to these factors were measured. Treatment with RA
esulted in a dose-dependent stimulation of 3-HSD1 mRNA with
n average 18-fold increase obtained with 1 M RA treatment for
8 h. This effect was not significantly altered at the two differ-
nt time-points tested (n = 4, b = p < 0.05, c = p < 0.01; Fig. 7, upper
anel). Culture of OSE-C2 cells in the presence of TGF-1 resulted
n induction of 3-HSD1 mRNA at both doses tested. Notably, the
ffect was maximal at the 8 h time-point (35-fold-change) with
oderate but significant reduction after 48 h of treatment (n = 4,
= p < 0.05, c = p < 0.01; Fig. 7, lower panel).
We next tested if there was a synergistic effect between these
wo components on 3-HSD1 mRNA levels. Remarkably, the com-
ination of both RA and TGF-1 for 8 h and 48 h in four independent
eplicates increased 3-HSD1 mRNA expression levels at least 100-
old (n = 4, b = p < 0.05, c = p < 0.01, d = p < 0.001; Fig. 8).
. Discussion
Herein, we demonstrate both 3-HSD1 and 3-HSD2 mRNA
unctionality in the ovarian cell surface. For the first time, we show
ultiple mechanisms of pre-receptor progesterone intracrine for-
ation at the ovarian cell surface with profound implications in the
evelopment of novel pharmaceutical strategies for ovarian disor-Please cite this article in press as: Papacleovoulou, G., et al., 3-Hydroxy
human ovarian surface epithelium. Mol. Cell. Endocrinol. (2008), doi:10.10
ers such as EOC. We confirmed previous reports for abrogation
f 3-HSD1 mRNA by IL-1 (Rae et al., 2004b). We also ascer-
ained expression of 3-HSD2 mRNA that was remarkably induced
n response to IL-1 treatment as well as stimulation of both iso-






(b = p < 0.05; c, d = p < 0.001). (B) Combined data of three independent experiments
mes (upper panel; c = p < 0.05) or treated with various doses of IL-4 for 8 h (b < 0.05,
38 MAPK signalling pathway may play a major role in the anti-
nflammatory responses of IL-1 and IL-4 and also that a NF-B
athway is involved in inflammatory-mediated changes that IL-1
xerts in the transcriptional regulation of 3-HSD1 and 3-HSD2.
lso novel is the finding that 3-HSD1 mRNA levels in OSE-C2
ells are profoundly induced by the apoptotic and anti-proliferative
actors TGF-1 and RA, with an even more substantial transcript
ccumulation when both agents are combined.
Localisation of 3-HSD in the human ovarian surface epithe-
ium is suggestive of a capacity of this ovarian compartment to
ontrol local bioavailability of progesterone in situ for binding to
he cognate progesterone receptor (PR). Remarkably, we noticed
ifferences in the intensity of 3-HSD staining among different
ells of the surface suggestive of disparity in steroidogenic pro-
le within the same compartment. Attenuated 3-HSD expression
ight well represent a defining feature of (pre)-neoplastic transfor-
ation and this demands further investigation. In support of this,
he presence of steroidogenic acute regulatory (StAR) protein, 3-
SD and PR has previously been demonstrated in ovarian cancers,
ll involved in progesterone formation and action, and linked with
good prognosis of the disease (Abd-Elaziz et al., 2005).
Because the 3-HSD antibody reacts with both isoforms, we
urther assessed the isoform expression pattern with quantita-
ive Real-Time PCR using isoform-specific primer/probe sets. To
ssess this, we used primary hOSE cell cultures as well as the
mmortalised cell line, OSE-C2. Notably in primary hOSE cells bothsteroid dehydrogenases and pre-receptor steroid metabolism in the
16/j.mce.2008.08.010
ranscripts were present with 3-HSD1 mRNA expressed at higher
evels compared to 3-HSD2 mRNA. This predominance was fur-
her confirmed in OSE-C2 cells, where 3-HSD2 mRNA was not
etectable. This expression pattern is different from what has been
eported for the rest of the ovary where 3-HSD2 predominates,
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Fig. 6. The effect of SB203580, a selective p38 MAPK kinase pathway inhibitor,
























ransduction of 3-HSD mRNAs in primary hOSE cells. hOSE cells from four indepen-
ent patients were variously treated with IL-1 (0.5 ng/mL), IL-4 (0.5 ng/mL) and/or
AY117082 (1 M) for 48 h prior to isolation of RNA for qRT-PCR analysis (upper
anel) 3-HSD1 mRNA and (lower panel) 3-HSD2 mRNA (b = p < 0.05, c = p < 0.001).
ith emergence of low levels of 3-HSD1 only in the corpus luteum
Rheaume et al., 1991). The relevance of 3-HSD1 preponderance
n this compartment could be related to the low capacity of these
ells to produce de novo steroids from cholesterol at least in vitro
Rae et al., 2004b; Rembiszewska and Brynczak, 1985).
As previously demonstrated, IL-1 treatment of primary hOSE
ells had an inhibitory effect on 3-HSD1 mRNA expression,
mplicating that, physiologically at the peri-ovulatory period, the
teroidogenic capacity of hOSE is minimised and this may prob-
bly be a key event for the initiation of ovulation (Rae et al.,
004b). On the other hand, concomitant IL-1-induced 3-HSD2
RNA expression indicates an efficient mechanism of hOSE cells to
aintain basic steroid formation, at least of progesterone. Another
echanism to restore intracrine formation in hOSE is via IL-4 treat-
ent. IL-4 in vivo is secreted by peripheral mononuclear blood
ells that infiltrate the ovary and starts to accumulate at the peri-
vulatory period with peak production at the luteal phase of the
enstrual cycle when progesterone secretion is also at its peak
Hashii et al., 1998). Collectively, progesterone accumulation and
ownstream signalling peri-/post-ovulatory highlight an efficientPlease cite this article in press as: Papacleovoulou, G., et al., 3-Hydroxy
human ovarian surface epithelium. Mol. Cell. Endocrinol. (2008), doi:10.10
echanism of hOSE to minimise genetic instability and protect
lonal expansion of any transformed cell that could lead to EOC
Murdoch and Van Kirk, 2002). Fundamentally, progesterone has
een proven anti-inflammatory, anti-proliferative and apoptotic






OSE cells. Cells from three separate patients were treated with IL-1 (0.5 ng/mL),
L-4 (0.5 ng/mL) and/or SB203580 (10 M) for 48 h, after which RNA was isolated
nd qRT-PCR performed (upper panel: n = 3, b = p < 0.05, c = p < 0.001; lower panel:
= p < 0.05, c = p < 0.001).
riggers apoptosis to attenuate potential genetic damage of the
ost-ovulatory ovarian surface. In sheep, progesterone treatment
esulted in a decline of 8-oxoguanine adducts through induction
f polymerase- and poly(ADP-ribose) polymerase, both involved
n DNA repair. Moreover, reports suggest that progesterone exerts
ts apoptotic and anti-proliferative effects through up-regulation
f the tumour suppressor p53 protein (Murdoch and Van Kirk,
002b). The latter has been also seen in human ovarian can-
er cell lines, where progesterone exerted anti-proliferative and
poptotic effects through arrest of cells at G1 phase of the cell
ycle and concomitant stimulation of the p53 mRNA (Bu et al.,
997). Also, progesterone has been demonstrated to have a role in
esolution of ovulation-associated inflammation as it reversed IL-
-induced inflammatory cyclooxygenase-2 (COX-2) mRNA (Rae et
l., 2004a).
We were unable to demonstrate an IL-1 pro-inflammatory
ffect on 3-HSD1 mRNA levels in OSE-C2 cells. This limitation was
robably due to the fact that basal 3-HSD1 mRNA levels in this
ell type were already much lower than those of hOSE cells (data
ot shown) and therefore it was not feasible practically to demon-steroid dehydrogenases and pre-receptor steroid metabolism in the
16/j.mce.2008.08.010
trate down-regulation of the transcript in response to this proxy.
lso, absence of 3-HSD2 mRNA was not reversed with IL-1 treat-
ent (data not shown). Collectively, the attenuation of 3-HSD1
nd 3-HSD2 mRNA could be a defining feature of (pre)-neoplastic
ransformation and this will be the subject of further investiga-
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evels of OSE-C2 cells. Upper panel: Four independent cultures of OSE-C2 cells were
reated with serial doses of RA (1 M) for 8 and 48 h (n = 4, b = p < 0.05, c = p < 0.01).
ower panel: Four separate cultures of OSE-C2 cells treated with TGF-1 (2 doses)
or 8 and 48 h (n = 4, b = p < 0.05, c = p < 0.01, lower panel).Please cite this article in press as: Papacleovoulou, G., et al., 3-Hydroxy
human ovarian surface epithelium. Mol. Cell. Endocrinol. (2008), doi:10.10
ion using primary cancer cells (Papacleovoulou et al., unpublished
ata). On the other hand, IL-4 substantially up-regulated 3-
SD1 mRNA, consistent with the IL-4 effect on primary hOSE
ells, establishing this cell line as an appropriate model to study
ig. 8. Synergistic effect of all-trans-retinoic acid (RA) and TGF-1 on 3-HSD1
RNA transcript levels in OSE-C2 cells. In four independent experiments, OSE-C2
ells were treated for 8 or 48 h with RA (1 M) or TGF-1 (5 ng/mL) or in combination
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hysiology and pre-neoplastic transformation of the ovarian cell
urface.
Identification of mechanisms that drive IL-1 and IL-4 pro-
nflammatory and anti-inflammatory responses to regulation of
-HSD1 and 3-HSD2 could be potentially proved essential for
revention or treatment of ovarian disorders. We are the first
o show that a pro-inflammatory NF-B pathway is involved in
ransduction of 3-HSD1 and 3-HSD2 mRNA by cytokines at
east in hOSE cells as revealed by blockage of IL-1-mediated 3-
SD mRNAs after treatment with a selective pathway inhibitor.
reviously, it has been proposed that NF-B and PR mutually sup-
ress each other’s activity (van der Burg and van der Saag, 1996).
recisely, it has been demonstrated that progesterone’s immuno-
uppressive and anti-inflammatory action is subject to its ability
o harness the initiation of inflammatory processes such as ovu-
ation through inhibition of NF-B signalling. Vice versa, NF-B
ctivation abrogates PR-associated action (Kalkhoven et al., 1996).
ur data suggest that these effects might well be mediated by 3-
SD regulation that essentially controls local bioavailability of the
ctive ligand and access to PR, a crucial event for trans-activation of
ownstream progesterone signalling. Remarkably, the p38 MAPK
athway appears to have a role in that, since its abrogation sup-
ressed basal 3-HSD1 and 3-HSD2 mRNA levels, establishing
he anti-inflammatory nature of this gene. Also, inhibition of
38 MAPK action completely blocked anti-inflammatory responses
f IL-4 and IL-1 with regard to 3-HSD2 mRNA, attesting a
ole of this transduction signalling pathway in anti-inflammatory
teroid mechanisms within hOSE. It remains to be established
f IL-4 exerts its anti-inflammatory action through inhibition of
F-B-associated pro-inflammatory responses and if concurrent
ctivation of the p38 MAPK signalling transduction pathway is a
re-requisite for this effect.
Because of a very restricted availability of primary tissue, we
sed OSE-C2 cells to demonstrate that retinoic acid can enhance
-HSD1 mRNA, indicating that a mechanism through which it
ay exert its chemopreventive and pro-apoptotic effects is by
egulation of 3-HSD1 and thereby promotion of progesterone for-
ation. Retinoic acid and its derivatives have been considered as
herapeutic targets of several cancers such as leukaemia, breast can-
er, cervical cancer and pancreatic adenocarcinoma (Altucci and
ronemeyer, 2001; Behbakht et al., 1996; El-Metwally et al., 2006).
n ovarian cancer, retinoids have been shown to increase the sur-
ival time of mice treated with a human ovarian cancer cell line
enograft and also enhanced anti-tumour activity of cispaltin in
wo human EOC cell lines (Formelli and Cleris, 1993). Additionally,
n human ovarian cancer cell lines, retinoid treatment resulted in
ncreased apoptosis (Bu et al., 1997).
We also established that TGF-1 can markedly promote
ntracrine formation of progesterone. Because we used OSE-C2
ells to test that assumption, only data regarding the major 3-
SD transcript (3-HSD1) is available. Once again, these data
uggest that pro-apoptotic and anti-proliferative effects of TGF-
1 might well be exerted through enhancement of progesterone
re-receptor signalling. It has been previously demonstrated that
GF-1 supplementation in pre-neoplastic and tumour ovarian
ells attenuated cell proliferation, promoted DNA fragmentation
nd reduced anti-apoptotic bcl-2 protein (Berchuck et al., 1992;
hoi et al., 2001). Intriguingly, it has been also shown that TGF-
1 up-regulated 3-HSD2 activity in human lutein-granulosa cells
nd 3-HSD2 mRNA in human adrenal cells (Lebrethon et al., 1994;steroid dehydrogenases and pre-receptor steroid metabolism in the
16/j.mce.2008.08.010
cAllister et al., 1994). It is therefore interesting to investigate if this
s reproducible in 3-HSD2 of hOSE cells.
Finally, we treated OSE-C2 cells with TGF-1 in the pres-
nce of retinoic acid. Expectedly, up-regulation of 3-HSD1 mRNA
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han that achieved with RA or TGF-1 alone, implying a syn-
rgistic action of these two agents. A proposed mechanism for
nti-proliferative action of RA in human pancreatic cancer and rat
rostatic epithelial cells is through induction of TGF-1 secretion
Danielpour, 1996; Singh et al., 2007). As such, co-treatment of
oth factors in OSE-C2 cells could result in a parallel autocrine
nd paracrine signalling of TGF-1 thereby driving progesterone
ormation. Furthermore, in mice, it has been demonstrated that
etinoic acid participates in TGF-1 differential immune-associated
ignalling by promoting TGF-1 anti-inflammatory responses
Mucida et al., 2007).
In summary, we have presented major immune and growth
actors that are involved in enhancement of pre-receptor proges-
erone metabolism with profound implications in the development
f therapeutic strategies for ovarian disorders and more impor-
antly EOC. We have elucidated that p38 MAPK signalling pathway
as an indispensable role at this process. Moreover, combination
f TGF-1 with retinoic acid could be proved beneficial for driving
rogesterone signalling in the human ovary.
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